instead O
, O
the O
dry O
and O
powdered O
leaf O
be O
burn O
as O
incense B-Plant
in O
japan O
. O

akris O
, O
a O
locust B-Plant
and O
carpos O
, O
a O
fruit O
, O
allude O
to O
the O
winged O
fruit O
) O
be O
a O
genus O
of O
plant O
in O
family O
malpighiaceae O
. O

acridocarpus B-Plant
monodii I-Plant
arènes I-Plant
& I-Plant
p.jaeger I-Plant
ex I-Plant
birnbaum I-Plant
& I-Plant
j.florence I-Plant
pluchea O
be O
a O
genus O
of O
flower O
plant O
in O
the O
stinkwort B-Plant
tribe O
within O
the O
sunflower O
family O
. O

member O
of O
this O
genus O
may O
be O
know O
as O
camphorweed B-Plant
, O
pluchea B-Plant
, O
or O
less O
uniquely O
fleabane B-Plant
. O

some O
, O
such O
as O
p. B-Plant
carolinensis I-Plant
and O
p. B-Plant
odorata I-Plant
, O
be O
call O
sourbush O
. O

pluchea B-Plant
laxiflora I-Plant
hook O
. O

baccharis B-Plant
decussata I-Plant
( O
klatt O
) O
hieron O
. O

( O
as O
p. B-Plant
decussata I-Plant
klatt O
) O
cratystylis B-Plant
conocephala I-Plant
( O
f.muell O
. O

) O
s.moore O
( O
as O
p. B-Plant
conocephala I-Plant
( O
f.muell O
. O

) O
neurolaena B-Plant
lobata I-Plant
( O
l. O
) O
cass B-Plant
. O

( O
as O
p. B-Plant
symphytifolia I-Plant
( O
mill O
. O

) O
streptoglossa B-Plant
liatroide I-Plant
( O
turcz O
. O

) O
dunlop O
( O
as O
p. B-Plant
ligulata I-Plant
f.muell O
. O

) O
streptoglossa B-Plant
macrocephala I-Plant
( O
f.muell O
. O

) O
dunlop O
( O
as O
p. B-Plant
macrocephala I-Plant
f.muell O
. O

) O
streptoglossa B-Plant
odora I-Plant
( O
f.muell O
. O

) O
dunlop O
( O
as O
p. B-Plant
odora I-Plant
f.muell O
. O

) O
thespidium B-Plant
basiflorum I-Plant
( O
f.muell O
. O

) O
( O
as O
p. B-Plant
basiflora I-Plant
f.muell O
. O

) O
nothotsuga O
contain O
only O
one O
specie O
, O
nothotsuga B-Plant
longibracteata I-Plant
, O
commonly O
know O
as O
the O
bristlecone B-Plant
hemlock I-Plant
, O
which O
be O
find O
in O
southeastern O
china O
, O
in O
southern O
fujian O
, O
northern O
guangdong O
, O
northeast O
guangxi O
, O
northeast O
guizhou O
, O
and O
southwest O
hunan O
. O

artemisia B-Plant
chamaemelifolia I-Plant
be O
a O
european O
and O
middle O
eastern O
specie O
of O
plant O
in O
the O
daisy O
family O
. O

ponthieva O
( O
commonly O
call O
shadow B-Plant
witch I-Plant
) O
be O
a O
genus O
form O
the O
orchid O
family O
( O
orchidaceae O
) O
. O

platanus B-Plant
orientalis I-Plant
, O
the O
old O
world O
sycamore B-Plant
, O
or O
oriental B-Plant
plane I-Plant
, O
be O
a O
large O
, O
deciduous O
tree O
of O
the O
platanaceae O
family O
, O
grow O
to O
30 O
m O
( O
98 O
ft O
) O
or O
more O
, O
and O
know O
for O
-PRON- O
longevity O
and O
spread O
crown O
. O

several O
of O
the O
specie O
have O
yellow O
heartwood O
, O
to O
which O
generic O
name O
allude O
. O

the O
fruit O
of O
several O
specie O
be O
use O
to O
make O
the O
spice O
sichuan B-Plant
pepper I-Plant
. O

common O
name O
include O
prickly B-Plant
ash I-Plant
and O
hercule B-Plant
club I-Plant
. O

acineta B-Plant
chrysantha I-Plant
be O
a O
species O
of O
orchid B-Plant
find O
in O
the O
forest O
of O
guatemala O
, O
el O
salvador O
, O
costa O
rica O
and O
panama O
. O

the O
specie O
be O
first O
collect O
by O
humboldt O
and O
bonpland O
on O
the O
outskirt O
of O
mina O
de O
morán O
in O
the O
sierra B-Plant
de O
pachuca O
of O
the O
modern O
- O
day O
mexican O
state O
of O
hidalgo O
on O
-PRON- O
latin O
american O
expedition O
of O
1799–1804 O
. O

p. B-Plant
moranensis I-Plant
remain O
the O
most O
common O
and O
most O
widely O
distribute O
member O
of O
the O
section O
orcheosanthus O
. O

have O
long O
be O
cultivate O
for O
carnivorous O
nature O
and O
attractive O
flower O
, O
and O
be O
one O
of O
the O
most O
common O
butterwort B-Plant
in O
cultivation O
. O

octomeria B-Plant
tricolor I-Plant
be O
a O
species O
of O
orchid B-Plant
endemic O
to O
southeastern O
brazil O
. O

bulbophyllum B-Plant
resupinatum I-Plant
be O
a O
species O
of O
orchid B-Plant
in O
the O
genus O
bulbophyllum O
. O

haptanthus O
be O
a O
monotypic O
genus O
contain O
the O
sole O
specie O
haptanthus B-Plant
hazlettii I-Plant
, O
a O
shrub O
or O
small O
tree O
know O
only O
from O
the O
locality O
of O
matarras O
in O
the O
arizona O
municipality O
in O
honduras O
. O

the O
common O
name O
for O
this O
genus O
be O
rushfoil O
and O
croton O
, O
but O
the O
latter O
also O
refer O
to O
codiaeum B-Plant
variegatum I-Plant
. O

siraitia B-Plant
grosvenorii I-Plant
( O
luo O
han O
guo O
, O
monk B-Plant
's I-Plant
fruit I-Plant
) O
, O
from O
china O
and O
thailand O
siraitia B-Plant
taiwaniana I-Plant
, O
from O
taiwan O
, O
see O
sinobaijiania B-Plant
taiwaniana I-Plant
lathyrus B-Plant
tuberosus I-Plant
, O
also O
know O
as O
the O
tuberous B-Plant
pea I-Plant
, O
tuberous B-Plant
vetchling I-Plant
, O
earthnut B-Plant
pea I-Plant
, O
aardaker B-Plant
or O
tine B-Plant
- I-Plant
tare I-Plant
, O
be O
a O
small O
, O
climb O
perennial O
plant O
, O
native O
in O
moist O
temperate O
part O
of O
europe O
and O
western O
asia O
. O

the O
plant O
be O
a O
trailer O
or O
weak O
climber B-Plant
, O
support O
by O
tendril O
, O
grow O
to O
1.2 O
m O
tall O
. O

aralia B-Plant
racemosa I-Plant
, O
with O
common O
name O
american B-Plant
spikenard I-Plant
, O
small B-Plant
spikenard I-Plant
, O
indian B-Plant
root I-Plant
, O
spice B-Plant
berry I-Plant
, O
spignet B-Plant
, O
life B-Plant
- I-Plant
of I-Plant
- I-Plant
man I-Plant
, O
petty B-Plant
morel I-Plant
, O
be O
an O
ornamental O
plant O
in O
the O
araliaceae O
family O
native O
to O
the O
united O
states O
and O
canada O
. O

ampelodesmo B-Plant
mauritanicus I-Plant
be O
a O
large O
clumping O
perennial O
bunchgrass B-Plant
, O
which O
be O
native O
to O
the O
mediterranean O
region O
. O

in O
native O
area O
be O
use O
as O
a O
fiber O
for O
make O
mat O
, O
broom O
, O
and O
twine O
. O

the O
genus O
name O
come O
from O
the O
greek O
ampelo O
, O
vine B-Plant
, O
and O
desmo O
, O
bond O
, O
from O
former O
use O
as O
a O
string O
to O
tie O
up O
grapevine O
. O

euphorbia B-Plant
pachypodioid I-Plant
be O
a O
species O
of O
plant O
in O
the O
euphorbiaceae O
family O
. O

also O
have O
the O
binomial O
synonym O
euphorbia B-Plant
antankara I-Plant
( O
leandri O
, O
1946 O
) O
. O

crowea O
be O
a O
genus O
of O
small O
evergreen O
shrub O
in O
the O
plant O
family O
rutaceae O
sometimes O
know O
as O
waxflowers B-Plant
. O

helianthella B-Plant
quinquenervi I-Plant
, O
fivenerve B-Plant
helianthella I-Plant
, O
be O
a O
north O
american O
plant O
specie O
in O
the O
sunflower O
family O
. O

this O
include O
the O
rockies O
, O
the O
black O
hills O
, O
the O
range O
of O
the O
great O
basin O
, O
and O
the O
northern O
sierra B-Plant
madre O
, O
from O
montana O
, O
oregon O
, O
and O
south O
dakota O
south O
as O
far O
as O
western O
chihuahua O
and O
coahuila O
. O

helianthella B-Plant
quinquenervis I-Plant
be O
a O
herbaceous O
plant O
up O
to O
150 O
cm O
( O
4.9 O
ft O
) O
tall O
. O

lepismium B-Plant
houlletianum I-Plant
be O
a O
species O
of O
plant O
in O
the O
family O
cactaceae O
. O

chaetonema O
be O
a O
genus O
of O
green O
algae B-Plant
in O
the O
family O
aphanochaetaceae O
. O

notable O
culprit O
be O
c. B-Plant
fragran I-Plant
( O
inch B-Plant
plant I-Plant
) O
and O
c. B-Plant
repen I-Plant
( O
turtle B-Plant
vine I-Plant
) O
. O

selenicereus O
, O
or O
moonlight O
cacti B-Plant
, O
be O
an O
epiphytic O
, O
lithophytic O
, O
and O
terrestrial O
cactus B-Plant
genus O
find O
in O
central O
america O
, O
the O
caribbean O
and O
northern O
south O
america O
. O

grevillea B-Plant
preissii I-Plant
be O
a O
small O
shrub O
which O
be O
endemic O
to O
western O
australia O
. O

alkali B-Plant
grass I-Plant
redirect O
here O
. O

this O
name O
be O
also O
use O
for O
the O
mountain B-Plant
deathcama I-Plant
( O
anticlea B-Plant
elegan I-Plant
) O
which O
be O
not O
a O
grass O
. O

puccinellia O
be O
a O
genus O
of O
plant O
in O
the O
grass O
family O
, O
know O
as O
alkali B-Plant
grass I-Plant
or O
salt B-Plant
grass I-Plant
. O

scyphiphora B-Plant
hydrophyllacea I-Plant
, O
which O
have O
a O
large O
distribution O
range O
from O
madagascar O
, O
to O
tropical O
asia O
and O
the O
western O
pacific O
. O

-PRON- O
be O
a O
shrub O
of O
about O
3 O
m O
( O
10 O
ft O
) O
and O
be O
often O
find O
in O
mangrove B-Plant
forest O
or O
sandy O
beach O
. O

engelmannia O
( O
engelmann B-Plant
's B-Plant
daisy I-Plant
) O
be O
a O
genus O
of O
north O
american O
flower O
plant O
in O
the O
daisy O
family O
. O

pinus B-Plant
heldreichii I-Plant
( O
synonym O
p. B-Plant
leucodermis I-Plant
family O
pinaceae O
) O
, O
the O
heldreich O
’s O
pine B-Plant
or O
bosnian B-Plant
pine I-Plant
, O
be O
a O
species O
of O
pine B-Plant
native O
to O
mountainous O
area O
of O
the O
balkans O
and O
southern O
italy O
. O

be O
a O
member O
of O
the O
hard B-Plant
pine I-Plant
group O
, O
pinus O
subgenus O
pinus O
, O
with O
leaf O
( O
' O
needle O
' O
) O
in O
fascicle O
( O
bundle O
) O
of O
two O
, O
with O
a O
persistent O
sheath O
. O

the O
best O
- O
know O
member O
of O
the O
genus O
be O
the O
avocado B-Plant
, O
p. B-Plant
americana I-Plant
, O
widely O
cultivate O
in O
subtropical O
region O
for O
-PRON- O
large O
, O
edible O
fruit O
. O

ilex B-Plant
canariensis I-Plant
, O
the O
small B-Plant
- I-Plant
leave I-Plant
holly O
, O
be O
an O
endemic O
specie O
of O
holly O
native O
to O
macaronesian O
island O
. O

goldenseal B-Plant
( O
hydrastis B-Plant
canadensis I-Plant
) O
, O
also O
call O
orangeroot B-Plant
or O
yellow B-Plant
puccoon I-Plant
, O
be O
a O
perennial O
herb O
in O
the O
buttercup O
family O
ranunculaceae O
, O
native O
to O
southeastern O
canada O
and O
the O
eastern O
united O
states O
. O

goldenseal B-Plant
mostly O
reproduce O
clonally O
through O
the O
rhizome O
. O

in O
summer O
, O
bear O
a O
single O
berry O
the O
size O
of O
a O
large O
raspberry B-Plant
with O
10–30 O
seed O
. O

in O
herbal O
medicine O
, O
goldenseal B-Plant
's O
root O
and O
rhizome O
be O
harvest O
and O
use O
as O
a O
multi O
- O
purpose O
remedy O
because O
of O
high O
concentration O
of O
berberine O
and O
hydrastine O
. O

however O
, O
there O
be O
little O
scientific O
evidence O
that O
goldenseal B-Plant
be O
effective O
. O

goldenseal B-Plant
be O
use O
to O
control O
muscle O
spasm O
, O
treat O
cancer O
, O
stimulate O
the O
heart O
and O
increase O
blood O
pressure O
, O
treat O
gastrointestinal O
disorder O
, O
treat O
conjunctivitis O
, O
manage O
painful O
and O
heavy O
menstruation O
, O
treat O
infection O
topically O
, O
reduce O
swell O
and O
alleviate O
edema O
. O

goldenseal B-Plant
may O
be O
purchase O
in O
salve O
, O
tablet O
, O
tincture O
form O
or O
as O
a O
bulk O
powder O
. O

a O
second O
specie O
from O
japan O
, O
previously O
list O
as O
hydrastis O
palmatum O
, O
be O
sufficiently O
distinct O
that O
be O
now O
usually O
treat O
in O
a O
separate O
genus O
, O
as O
glaucidium B-Plant
palmatum I-Plant
. O

piper B-Plant
auritum I-Plant
( O
hoja B-Plant
santa I-Plant
) O
be O
an O
aromatic O
herb O
with O
a O
heart O
- O
shape O
, O
velvety O
leaf O
which O
grow O
in O
tropic O
mesoamerica O
. O

the O
name O
hoja B-Plant
santa I-Plant
mean O
sacred O
leaf O
in O
spanish O
. O

be O
also O
know O
as O
yerba B-Plant
santa I-Plant
, O
hierba B-Plant
santa I-Plant
, O
mexican B-Plant
pepperleaf I-Plant
, O
acuyo O
, O
tlanepa O
, O
anisillo B-Plant
, O
root B-Plant
beer I-Plant
plant I-Plant
, O
vera B-Plant
cruz I-Plant
pepper I-Plant
and O
sacred B-Plant
pepper I-Plant
. O

melaleuca B-Plant
pulchella I-Plant
, O
commonly O
know O
as O
claw B-Plant
flower I-Plant
and O
claw B-Plant
honey I-Plant
- I-Plant
myrtle I-Plant
, O
be O
a O
plant O
in O
the O
myrtle O
family O
, O
myrtaceae O
and O
be O
endemic O
to O
the O
south O
of O
western O
australia O
. O

( O
the O
other O
be O
melaleuca B-Plant
violacea I-Plant
) O
. O

the O
outer O
stamen O
be O
long O
and O
curve O
, O
give O
the O
appearance O
of O
a O
claw B-Plant
to O
the O
flower O
. O

amentotaxus O
be O
a O
genus O
of O
conifer B-Plant
( O
catkin B-Plant
- I-Plant
yew I-Plant
) O
comprise O
five O
specie O
, O
treat O
in O
either O
the O
cephalotaxaceae O
, O
or O
in O
the O
taxaceae O
when O
that O
family O
be O
consider O
in O
a O
broad O
sense O
. O

-PRON- O
differ O
from O
the O
related O
genus O
cephalotaxus O
in O
the O
broad O
leaf O
, O
and O
from O
torreya B-Plant
by O
the O
blunt O
, O
not O
spine O
- O
tip O
leaf O
. O

banksia B-Plant
serratuloide I-Plant
be O
a O
shrub O
endemic O
to O
western O
australia O
. O

be O
know O
as O
dryandra B-Plant
serratuloide I-Plant
until O
2007 O
, O
when O
all O
dryandra O
specie O
be O
transfer O
to O
banksia O
by O
austin O
mast O
and O
kevin O
thiele O
. O

one O
specie O
, O
t. B-Plant
minuta I-Plant
, O
be O
consider O
a O
noxious O
invasive O
plant O
in O
some O
area O
. O

calothamnus B-Plant
quadrifidus I-Plant
, O
commonly O
know O
as O
one B-Plant
- I-Plant
sided I-Plant
bottlebrush I-Plant
, O
be O
a O
plant O
in O
the O
myrtle O
family O
, O
myrtaceae O
and O
be O
endemic O
to O
the O
south O
- O
west O
of O
western O
australia O
. O

-PRON- O
be O
a O
shrub O
with O
grey O
- O
green O
, O
pine B-Plant
- O
like O
foliage O
cover O
with O
soft O
hair O
and O
red O
, O
four O
- O
part O
flower O
in O
spring O
. O

( O
in O
2014 O
craven O
, O
edwards O
and O
cowley O
propose O
that O
the O
specie O
be O
rename O
melaleuca B-Plant
quadrifida I-Plant
. O

) O
cistus B-Plant
salviifolius I-Plant
, O
common O
name O
sage B-Plant
- I-Plant
leave I-Plant
rock I-Plant
- I-Plant
rise I-Plant
, O
salvia B-Plant
cistus I-Plant
or O
gallipoli B-Plant
rise I-Plant
, O
be O
a O
perennial O
ligneous O
plant O
of O
the O
family O
cistaceae O
. O

volkameria B-Plant
aculeata I-Plant
and O
volkameria B-Plant
glabra I-Plant
be O
grow O
as O
ornamental O
in O
the O
tropic O
. O

volkameria B-Plant
heterophylla I-Plant
be O
also O
know O
in O
cultivation O
. O

volkameria B-Plant
inermis I-Plant
be O
plant O
as O
a O
sand O
binder O
. O

bulbophyllum B-Plant
dalatense I-Plant
be O
a O
species O
of O
orchid B-Plant
in O
the O
genus O
bulbophyllum O
. O

aechmea B-Plant
distichantha I-Plant
( O
brazilian O
vaseplant O
, O
vase O
plant O
) O
be O
a O
bromeliad B-Plant
typical O
of O
cerrado O
vegetation O
in O
brazil O
, O
which O
be O
also O
native O
to O
northern O
argentina O
, O
bolivia O
, O
paraguay O
, O
and O
uruguay O
. O

both O
characteristic O
have O
allow O
some O
specie O
to O
become O
weedy O
in O
temperate O
area O
outside O
native O
range O
, O
notably O
pinellia B-Plant
ternata I-Plant
in O
eastern O
north O
america O
. O

amelanchier B-Plant
sanguinea I-Plant
, O
know O
as O
red B-Plant
- I-Plant
twigged I-Plant
shadbush I-Plant
or O
roundleaf B-Plant
serviceberry I-Plant
, O
be O
a O
shrub O
native O
to O
eastern O
and O
central O
north O
america O
. O

be O
most O
common O
in O
eastern O
canada O
, O
the O
northeastern O
united O
states O
, O
and O
the O
great O
lakes O
region O
. O

amelanchier B-Plant
sanguinea I-Plant
be O
a O
shrub O
that O
can O
grow O
up O
to O
3 O
metre O
( O
9.8 O
ft O
) O
tall O
, O
and O
have O
edible O
sweet O
- O
flavor O
fruit O
that O
be O
red O
when O
young O
and O
become O
purple O
or O
dark O
- O
blue O
when O
ripen O
. O

atractophora O
be O
a O
genus O
of O
red O
algae B-Plant
of O
the O
family O
naccariaceae O
. O

darmera B-Plant
peltata I-Plant
( O
indian B-Plant
rhubarb I-Plant
or O
umbrella B-Plant
plant I-Plant
) O
be O
a O
flower O
plant O
, O
the O
only O
specie O
within O
the O
genus O
darmera O
in O
the O
family O
saxifragaceae O
. O

in O
garden O
, O
darmera B-Plant
peltata I-Plant
flourish O
in O
pond O
margin O
and O
bog O
garden O
, O
where O
form O
an O
impose O
umbrella O
- O
like O
clump O
. O

be O
suit O
to O
small O
garden O
where O
there O
be O
no O
room O
for O
gunnera B-Plant
manicata I-Plant
or O
gunnera B-Plant
tinctoria I-Plant
, O
unrelated O
plant O
that O
be O
somewhat O
similar O
in O
appearance O
, O
but O
much O
large O
. O

darmera B-Plant
peltata I-Plant
have O
gain O
the O
royal O
horticultural O
society O
's O
award O
of O
garden O
merit O
. O

though O
somewhat O
reminiscent O
of O
willow B-Plant
( O
salix O
) O
in O
habitus O
, O
be O
not O
particularly O
close O
relative O
of O
these O
. O

selliguea O
be O
a O
fern B-Plant
genus O
in O
the O
family O
polypodiaceae O
. O

the O
type O
species O
be O
selliguea B-Plant
feei I-Plant
. O

plant O
of O
the O
genus O
may O
be O
know O
generally O
as O
joyweed B-Plant
, O
or O
joseph B-Plant
's I-Plant
coat I-Plant
. O

senna B-Plant
( O
from O
arabic O
sanā O
) O
, O
the O
senna B-Plant
, O
be O
a O
large O
genus O
of O
flower O
plant O
in O
the O
legume O
family O
fabaceae O
, O
and O
the O
subfamily O
caesalpinioideae O
and O
the O
tribe O
cassieae O
. O

the O
type O
specie O
for O
the O
genus O
be O
senna B-Plant
alexandrina I-Plant
. O

about O
50 O
species O
of O
senna B-Plant
be O
know O
in O
cultivation O
. O

orthotrichum O
be O
a O
genus O
of O
moss B-Plant
in O
family O
orthotrichaceae O
. O

rhynchostylis B-Plant
retusa I-Plant
( O
also O
call O
foxtail B-Plant
orchid I-Plant
) O
be O
an O
exotic O
blooming O
orchid B-Plant
, O
belong O
to O
the O
vanda B-Plant
alliance O
. O

eucomis B-Plant
comosa I-Plant
( O
pineapple B-Plant
flower O
, O
pineapple B-Plant
lily I-Plant
, O
wine O
eucomis O
) O
be O
a O
species O
of O
flower O
plant O
in O
the O
asparagus O
family O
asparagaceae O
( O
subfamily O
scilloideae O
) O
. O

from O
a O
basal O
rosette O
of O
leave O
produce O
a O
flower O
spike B-Plant
clothe O
in O
small O
starry O
flower O
on O
a O
stout O
purple O
spine O
. O

the O
overall O
effect O
be O
of O
a O
miniature O
pineapple B-Plant
plant O
( O
ananas B-Plant
comosus I-Plant
) O
, O
though O
in O
fact O
the O
two O
specie O
be O
not O
closely O
related O
. O

cadmium O
uptake O
and O
sequestration O
kinetic O
in O
individual O
leaf O
cell O
protoplast O
of O
the O
cd O
/ O
zn O
hyperaccumulator O
thlaspi B-Plant
caerulescen I-Plant
. O

for O
investigate O
cadmium O
uptake O
, O
incubate O
protoplast O
obtain O
from O
leaf O
of O
thlaspi B-Plant
caerulescen I-Plant
( O
ganges O
ecotype O
) O
with O
a O
cd O
- O
specific O
fluorescent O
dye O
. O

soluble O
phosphoru O
( O
p O
) O
compound O
and O
intracellular O
ph O
be O
analyse O
each O
2.5 O
min O
interval O
in O
heterotrophic O
sycamore B-Plant
( O
acer B-Plant
pseudoplatanus I-Plant
) O
cell O
use O
in O
vivo O
phosphorus O
nuclear O
magnetic O
resonance O
( O
( O
31)p O
- O
nmr O
) O
. O

examine O
the O
hydraulic O
connectivity O
of O
module O
comprise O
juvenile O
and O
adult O
of O
the O
aridland O
chamaephyte O
cryptantha B-Plant
flava I-Plant
( O
boraginaceae B-Plant
) O
, O
motivate O
by O
the O
observation O
that O
rosette O
mortality O
be O
spatially O
aggregate O
in O
adult O
, O
but O
not O
in O
juvenile O
. O

expression O
of O
a O
brassica B-Plant
napus I-Plant
heme O
oxygenase O
confer O
plant O
tolerance O
to O
mercury O
toxicity O
. O

to O
elucidate O
the O
mechanism O
by O
which O
hos O
regulate O
plant O
adaptation O
to O
heavy O
metal O
exposure O
, O
three O
novel O
hos O
gene O
be O
isolate O
from O
rapeseed B-Plant
( O
brassica B-Plant
napus I-Plant
) O
and O
expression O
pattern O
be O
analyse O
. O

to O
investigate O
whether O
the O
bnho O
regulate O
plant O
tolerance O
to O
hg O
toxicity O
, O
construct O
b. B-Plant
napus I-Plant
transgenic O
plant O
overexpress O
bnho-1 O
. O

clone O
the O
promoter O
sequence O
of O
bnho-1 O
from O
b. B-Plant
napus I-Plant
. O

transient O
expression O
in O
tobacco B-Plant
leaf O
show O
differential O
response O
to O
heavy O
metal O
( O
zn O
, O
cu O
, O
pb O
, O
hg O
and O
cd O
) O
. O

osran2 O
, O
essential O
for O
mitosis O
, O
enhance O
cold O
tolerance O
in O
rice B-Plant
by O
promote O
export O
of O
intranuclear O
tubulin O
and O
maintain O
cell O
division O
under O
cold O
stress O
. O

with O
global O
climate O
change O
, O
abnormally O
low O
temperature O
have O
affect O
the O
world O
's O
rice B-Plant
production O
. O

many O
gene O
have O
be O
show O
to O
be O
essential O
for O
molecular O
improvement O
of O
rice B-Plant
cold O
- O
tolerance O
trait O
. O

here O
, O
investigate O
osran2 O
involve O
in O
regulation O
of O
cell O
division O
during O
cold O
stress O
in O
rice B-Plant
. O

knockdown O
transgenic O
rice B-Plant
line O
show O
an O
aberrant O
organization O
of O
spindle O
during O
mitosis O
and O
stunt O
growth O
during O
development O
. O

overexpression O
of O
osran2 O
enhance O
cold O
tolerance O
in O
rice B-Plant
. O

the O
transgenic O
rice B-Plant
overexpressing O
osran2 O
show O
maintained O
cell O
division O
, O
decrease O
proportion O
of O
cell O
with O
intranuclear O
tubulin O
and O
formation O
of O
a O
normal O
nuclear O
envelope O
under O
the O
cold O
condition O
. O

study O
suggest O
a O
mechanism O
for O
osran2 O
in O
regulate O
cold O
resistance O
in O
rice B-Plant
by O
maintain O
cell O
division O
through O
promote O
the O
normal O
export O
of O
intranuclear O
tubulin O
at O
the O
end O
of O
mitosis O
. O

this O
insight O
could O
help O
improve O
the O
cold O
- O
tolerance O
trait O
in O
rice B-Plant
. O

gene O
expression O
analysis O
of O
wound O
- O
induce O
root O
- O
to O
- O
shoot O
communication O
in O
arabidopsis B-Plant
thaliana I-Plant
. O

in O
this O
study O
, O
establish O
a O
model O
system O
for O
root O
- O
to O
- O
shoot O
signalling O
to O
observe O
global O
gene O
expression O
in O
arabidopsis B-Plant
thaliana I-Plant
. O

the O
effect O
of O
competition O
from O
neighbour O
on O
stomatal O
conductance O
in O
lettuce B-Plant
and O
tomato B-Plant
plant O
. O

competition O
decrease O
transpiration O
from O
young O
lettuce B-Plant
plant O
after O
2 O
day O
, O
before O
any O
reduction O
in O
leaf O
area O
become O
apparent O
, O
and O
stomatal O
conductance O
( O
g(s O
) O
) O
of O
lettuce B-Plant
and O
tomato B-Plant
plant O
be O
also O
reduce O
. O

competition O
- O
induce O
stomatal O
closure O
be O
absent O
in O
an O
abscisic O
acid O
( O
aba)-deficient O
tomato B-Plant
mutant O
, O
flacca O
, O
indicate O
a O
fundamental O
involvement O
of O
aba O
. O

although O
tomato B-Plant
xylem O
sap O
aba O
concentration O
be O
unaffected O
by O
the O
presence O
of O
neighbour O
, O
aba O
/ O
ph O
- O
base O
stomatal O
modulation O
be O
still O
likely O
to O
underlie O
the O
response O
to O
competition O
, O
as O
soil O
and O
xylem O
sap O
alkalization O
be O
observe O
in O
compete O
plant O
. O

competition O
also O
modulate O
leaf O
ethylene O
production O
, O
and O
treatment O
of O
lettuce B-Plant
plant O
with O
an O
ethylene O
perception O
inhibitor O
( O
1-methylcyclopropene O
) O
diminish O
the O
difference O
in O
g(s O
) O
between O
single O
and O
compete O
plant O
grow O
in O
a O
control O
environment O
room O
, O
but O
increase O
in O
plant O
grow O
in O
the O
greenhouse O
: O
ethylene O
alter O
the O
extent O
of O
the O
stomatal O
response O
to O
competition O
. O

in  O
1917 O
and O
1918 O
with O
herbert O
carr O
, O
r O
a O
frazer O
, O
i O
a O
richards O
( O
and O
his O
spaniel O
sancho O
panza O
) O
, O
c O
f O
holland O
and O
others O
, O
she O
explored O
tryfan O
, O
lliwedd O
, O
the O
devil O
's O
kitchen O
, O
cwm O
idwal O
151 O
and O
was O
one O
of O
the O
first O
party O
up O
holly B-Plant
tree I-Plant
wall O
. O

the O
trees O
were O
the O
real O
enemy O
, O
old O
trees O
, O
young O
trees O
, O
rotten O
and O
burnt O
trees O
, O
douglas B-Plant
firs I-Plant
, O
jack O
pines B-Plant
, O
spruce B-Plant
, O
poplar B-Plant
and O
birch B-Plant
; O
the O
lower O
slopes O
between O
2700 O
and O
3000 O
metres O
are O
dominated O
by O
the O
yunnan B-Plant
pine I-Plant
pinus B-Plant
yunnanensis I-Plant
which O
is O
interspersed O
with O
hardwood O
trees O
such O
as O
poplar B-Plant
and O
lime B-Plant
as O
well O
as O
a O
very O
wide O
range O
of O
interesting O
shrubs O
. O

above O
the O
deciduous O
tree O
- O
line O
, O
pine B-Plant
forests O
compete O
with O
swashes O
of O
yellow B-Plant
azalea I-Plant
giving O
way O
to O
meadows O
bejewelled O
with O
alpine O
flowers O
swept O
by O
wave O
- O
tossed O
tracts O
of O
the O
white O
blossomed O
rhododendron B-Plant
caucasicum I-Plant
. O

wild B-Plant
jasmine I-Plant
( O
jasminum B-Plant
fruticans I-Plant
) O
and O
bar B-Plant
- I-Plant
berry I-Plant
( O
berberis B-Plant
vulgaris I-Plant
) O
bloom O
amidst O
the O
glossy O
evergreen O
foliage O
of O
straw B-Plant
- I-Plant
berry I-Plant
trees O
( O
arbutus O
unedd O
) O
and O
spanish B-Plant
laurel I-Plant
( O
laurus B-Plant
nobilis I-Plant
) O
, O
whilst O
the O
turpentine B-Plant
tree I-Plant
( O
pistacia B-Plant
terebinthus I-Plant
) O
, O
a O
close O
relative O
of O
the O
pistachio B-Plant
, O
spreads O
its O
leaves O
in O
the O
sunniest O
spots O
together O
with O
wild O
figs B-Plant
( O
ficus B-Plant
carica I-Plant
) O
, O
walnuts B-Plant
( O
juglans B-Plant
regia I-Plant
) O
and O
olives B-Plant
( O
olea B-Plant
europaea I-Plant
ssp. I-Plant
sylvestris I-Plant
) O
. O

its O
abun O
- O
dant O
forests O
, O
exploited O
by O
seafaring O
nations O
from O
the O
romans O
onwards O
, O
combine O
chestnut B-Plant
, O
oak B-Plant
, O
beech B-Plant
and O
, O
above O
all O
, O
the O
transcendental O
corsican B-Plant
pine I-Plant
, O
a O
monarch O
of O
european O
trees O
, O
which O
attains O
700 O
years O
of O
age O
and O
over O
50 O
m O
in O
height O
. O

from O
a O
distance O
the O
tree O
silhouettes O
could O
have O
been O
scots O
pines B-Plant
, O
but O
were O
actually O
evergreen O
beech B-Plant
nothofagus B-Plant
betuloides I-Plant
, O
intermingled O
with O
the O
autumn O
crimson O
and O
gold O
of O
deciduous O
southern B-Plant
beech I-Plant
nothofaguspumilla O
and O
antarctica O
. O

up O
in O
the O
fragile O
alpine O
zone O
, O
where O
even O
a O
small O
two O
- O
foot O
- O
diameter O
conifer B-Plant
( O
deodar B-Plant
or O
pine B-Plant
) O
will O
be O
some O
200 O
years O
old O
, O
we O
watched O
in O
horror O
as O
many O
of O
these O
trees O
were O
cut O
down O
merely O
to O
melt O
tar O
to O
put O
on O
the O
road O
. O

and O
, O
by O
the O
sacred O
lake O
of O
mabartsho O
, O
yellow O
tree O
paeonies O
, O
a O
variety O
of O
paeonia B-Plant
lutea I-Plant
. O

and O
on O
the O
walk O
- O
out O
next O
day O
there O
were O
fine O
tree B-Plant
ferns I-Plant
and O
bright O
blue O
iris B-Plant
decora I-Plant
. O

he O
pointed O
out O
a O
bequartodendron O
tree O
, O
enmeshed O
in O
a O
strangler O
fig B-Plant
which O
he O
had O
watched O
grow O
since O
he O
first O
came O
here O
in O
1962 O
. O

a O
pleasant O
scramble O
zigzags O
through O
boulders O
, O
prickly O
euphorbia O
and O
the O
surreal O
, O
fleshy O
kokerboom O
or O
' O
quiver O
' O
trees O
, O
whose O
pith B-Plant
was O
made O
into O
arrow O
quivers O
by O
the O
bushmen O
. O

13 O
we O
found O
a O
small O
group O
of O
mountain B-Plant
cabbage I-Plant
trees O
( O
cordyline B-Plant
indivisa I-Plant
) O
growing O
on O
the O
ridge O
above O
the O
tree O
line O
. O

not O
a O
sturdy O
english B-Plant
oak I-Plant
or O
anything O
of O
the O
kind O
, O
but O
a O
tree O
, O
a O
bush O
of O
a O
tree O
, O
of O
sorts O
. O

thick O
tangles O
of O
nothofagus B-Plant
antarctica I-Plant
had O
to O
be O
fought O
through O
, O
but O
on O
crossing O
the O
lapataia O
river O
we O
found O
guanaco O
trails O
, O
speeding O
progress O
through O
the O
forest O
and O
low O
tree O
scrub O
. O

run O
by O
mr O
conrad O
pinches O
, O
this O
school O
occupied O
one O
of O
the O
large O
terraced O
houses O
on O
the O
west O
side O
of O
the O
road O
running O
south O
from O
walnut B-Plant
tree O
walk O
. O

vol O
99 O
of O
the O
, O
4/(1994)contains O
an O
article O
by O
rosemary B-Plant
setting O
out O
the O
relationships O
and O
climbing O
achievements O
of O
her O
convoluted O
quaker O
family O
, O
together O
with O
a O
family O
tree O
. O

there O
was O
a O
small O
pink O
- O
headed O
onion B-Plant
here O
also O
( O
allium B-Plant
carolinianum I-Plant
) O
, O
collected O
by O
the O
kirghiz O
for O
food O
, O
as O
well O
as O
numerous O
aromatic O
herbs O
whose O
fragrance O
drifted O
across O
the O
slopes O
. O

herbs O
such O
as O
the O
beautiful O
george O
forrest O
's O
primrose B-Plant
primula B-Plant
forrestii I-Plant
with O
flowers O
of O
rich O
golden O
- O
yellow O
also O
flourish O
at O
this O
altitude O
, O
as O
does O
the O
rare O
and O
bizarre O
- O
looking O
slipper B-Plant
orchid I-Plant
cypripedium B-Plant
margaritaceum I-Plant
. O

the O
list O
of O
herbs O
which O
grow O
within O
this O
rich O
area O
of O
temperate O
forest O
is O
truly O
encyclopaedic O
, O
for O
here O
are O
to O
be O
found O
such O
treasures O
as O
primula B-Plant
bella I-Plant
, O
iris B-Plant
chrysographes I-Plant
, O
arisaema B-Plant
wilsonii I-Plant
and O
the O
yellow O
slipper B-Plant
orchid I-Plant
cypripedium B-Plant
flavum I-Plant
. O

until O
further O
work O
is O
done O
with O
the O
existing O
herbarium O
material O
it O
is O
doubtful O
whether O
we O
shall O
hear O
anything O
further O
of O
gentiana B-Plant
tilmanii I-Plant
. O

fruit O
and O
herbs O
that O
grew O
naturally O
in O
borrowdale O
rounded O
off O
an O
austere O
but O
healthy O
diet O
prepared O
over O
an O
open O
fire O
, O
a O
woodbine B-Plant
clasped O
between O
his O
toes B-Plant
to O
prevent O
ash O
falling O
into O
his O
food O
. O

and O
for O
its O
associations O
with O
the O
high O
places O
, O
the O
highland O
heather B-Plant
, O
so O
disagreeable O
to O
captain O
bun O
, O
was O
crowned O
by O
ruskin O
, O
with O
the O
blue O
gentian B-Plant
and O
the O
alpine B-Plant
rose I-Plant
, O
in O
uncontested O
queenliness O
, O
flowers O
wholly O
without O
similitude O
. O

even O
alpine O
flowers O
are O
at O
home O
here O
especially O
the O
' O
k'fcchenschelle O
' O
, O
the O
pasque B-Plant
flower I-Plant
( O
anemone O
pulsatilla O
) O
. O

a O
yellow O
starry O
- O
flowered O
clematis O
( O
c. B-Plant

hilariae I-Plant
) O
formed O
tumbled O
entanglements O
along O
field O
boundaries O
. O

along O
the O
rivers O
and O
streams O
there O
are O
the O
usual O
sedge B-Plant
pastures O
mixed O
with O
a O
few O
grasses O
but O
in O
the O
wet O
places O
, O
large O
drifts O
of O
deep O
blue O
primroses O
( O
primula B-Plant
macrophylla I-Plant
) O
and O
a O
small O
bright O
yellow O
buttercup B-Plant
( O
ranunculus B-Plant
pulchellus I-Plant
) O
were O
almost O
past O
flowering O
. O

most O
memorable O
was O
the O
carpet O
of O
crocus O
sieberi O
that O
grew O
so O
thick O
amidst O
the O
tussock B-Plant
grass I-Plant
of O
the O
upper O
pastures O
that O
it O
was O
impossible O
to O
avoid O
treading O
its O
flowers O
underfoot O
. O

in O
june O
the O
meadows O
at O
this O
altitude O
are O
alight O
with O
the O
colour O
of O
flowers O
- O
rhododendron B-Plant
adenogynutn I-Plant
occurs O
in O
flowing O
masses O
of O
pale O
pink O
, O
the O
yellow B-Plant
bells I-Plant
of O
lilium O
lopophorum O
stud O
the O
slopes O
in O
association O
with O
the O
purple O
lloydia B-Plant
tibetica I-Plant
var. I-Plant
purpurescens I-Plant
( O
an O
asian O
counterpart O
of O
the O
snowdon O
lily B-Plant
) O
and O
the O
golden O
meconopsis B-Plant
integrifolia I-Plant
. O

on O
the O
cliffs O
cling O
cushions O
of O
androsace B-Plant
delavayi I-Plant
and O
the O
almost O
impossibly O
- O
named O
solmslaubachia B-Plant
pulcherrima I-Plant
, O
one O
of O
forrest O
's O
favourite O
alpines O
with O
cress B-Plant
- O
like O
ice O
- O
blue O
flowers O
. O

best O
of O
all O
is O
the O
exquisite O
dwarf O
alpine O
' O
blue B-Plant
poppy I-Plant
' O
meconopsis B-Plant
delavayi I-Plant
which O
kingdon O
- O
ward O
described O
as O
' O
a O
shimmering O
bluish O
- O
violet B-Plant
flower O
with O
the O
texture O
of O
japanese O
silk O
' O
. O

higher O
still O
in O
the O
north O
- O
facing O
base O
- O
rich O
wetter O
flushes O
the O
seemingly O
uncultivatable O
primula B-Plant
dryadifolia I-Plant
shows O
its O
mauve O
- O
pink O
flowers O
against O
broad O
prostrate O
mats O
of O
foliage O
( O
25 O
cm O
across O
) O
, O
accompanied O
by O
three O
' O
sisters O
' O
of O
the O
same O
genus O
, O
primula B-Plant
pinnatifida I-Plant
, O
p O
secundiflora O
and O
p O
pseudo O
- O
sikkimensis O
. O

while O
we O
were O
on O
rajrambha O
the O
tiny O
blades O
of O
iris B-Plant
kumaonensis I-Plant
had O
suddenly O
sprouted O
purple O
flowers O
, O
streaked O
and O
mottled O
like O
the O
skin O
of O
exotic O
reptiles O
. O

) O
, O
towering O
white O
asphodels O
( O
asphodelus B-Plant
albus I-Plant
) O
( O
plate O
63 O
) O
and O
pyrenean B-Plant
lilies I-Plant
( O
lilium B-Plant
pyrenaicum I-Plant
) O
decorate O
these O
meadows O
, O
whilst O
the O
montane O
grasslands O
are O
renowned O
for O
their O
pasque B-Plant
- I-Plant
flowers I-Plant
( O
pulsatilla B-Plant
rubra I-Plant
, O
p. B-Plant
alpina I-Plant
( O
plate O
66 O
) O
and O
p. B-Plant
vernalis I-Plant
) O
, O
anemones B-Plant
( O
anemone B-Plant
pavoniana I-Plant
) O
, O
dog B-Plant
's I-Plant
violets I-Plant
( O
erythronium O
dens O
- O
can O
is O
) O
and O
pyrenean B-Plant
fritillaries I-Plant
( O
fritillaria B-Plant
pyrenaica I-Plant
) O
. O

we O
studied O
a O
thiamine O
- O
dependent O
enzyme O
, O
transketolase O
, O
from O
fibroblasts O
of O
a O
diabetic B-Disease
patient O
who O
developed O
wernicke B-Disease
' I-Disease
s I-Disease
encephalopathy I-Disease
when O
treated O
with O
tolazamide O
, O
in O
order O
to O
delineate O
if O
this O
patient O
also O
had O
transketolase O
abnormality O
[ O
high O
km O
for O
thiamine O
pyrophosphate O
( O
tpp O
) O
] O
, O
as O
previously O
reported O
in O
postalcoholic O
wernicke B-Disease
- I-Disease
korsakoff I-Disease
syndrome I-Disease
. O

in O
addition O
to O
this O
patient O
, O
we O
also O
studied O
this O
enzyme O
from O
three O
diabetic B-Disease
kindreds O
without O
any O
history O
of O
wernicke B-Disease
' I-Disease
s I-Disease
encephalopathy I-Disease
and O
from O
four O
normal O
controls O
. O

we O
found O
that O
the O
above O
- O
mentioned O
patient O
and O
one O
of O
the O
diabetic B-Disease
kindreds O
with O
no O
history O
of O
wernicke B-Disease
' I-Disease
s I-Disease
encephalopathy I-Disease
had O
abnormal O
transketolase O
as O
determined O
by O
its O
km O
for O
tpp O
. O

these O
data O
suggest O
a O
similarity O
between O
postalcoholic O
wernicke B-Disease
- I-Disease
korsakoff I-Disease
syndrome I-Disease
and O
the O
patient O
with O
tolazamide O
- O
induced O
wernicke B-Disease
' I-Disease
s I-Disease
encephalopathy I-Disease
from O
the O
standpoint O
of O
transketolase O
abnormality O
. O

bradycardia B-Disease
due O
to O
trihexyphenidyl O
hydrochloride O
. O

a O
chronic O
schizophrenic B-Disease
patient O
was O
treated O
with O
an O
anticholinergic O
drug O
, O
trihexyphenidyl O
hydrochloride O
. O

the O
patient O
developed O
, O
paradoxically O
, O
sinus O
bradycardia B-Disease
. O

this O
antidyskinetic O
drug O
is O
widely O
used O
in O
clinical O
psychiatric B-Disease
practice O
and O
physicians O
should O
be O
aware O
of O
this O
side O
effect O
. O

post O
- O
operative O
rigidity B-Disease
after O
fentanyl O
administration O
. O

a O
case O
of O
thoraco O
- O
abdominal O
rigidity B-Disease
leading O
to O
respiratory B-Disease
failure I-Disease
is O
described O
in O
the O
post O
- O
operative O
period O
in O
an O
elderly O
patient O
who O
received O
a O
moderate O
dose O
of O
fentanyl O
. O

anti O
- O
carcinogenic B-Disease
action O
of O
phenobarbital O
given O
simultaneously O
with O
diethylnitrosamine O
in O
the O
rat O
. O

the O
present O
work O
has O
been O
planned O
in O
order O
to O
elucidate O
the O
effect O
of O
phenobarbital O
( O
pb O
: O
15 O
mg O
per O
rat O
of O
ingested O
dose O
) O
on O
carcinogenesis B-Disease
when O
it O
is O
administered O
simultaneously O
with O
diethylnitrosamine O
( O
den O
: O
10 O
mg O
/ O
kg O
/ O
day O
) O
. O

wistar O
rats O
( O
180 O
g O
) O
were O
treated O
by O
den O
alone O
or O
by O
den O
+ O
pb O
during O
2 O
, O
4 O
and O
6 O
weeks O
according O
to O
our O
schedule O
for O
hepatocarcinogenesis B-Disease
. O

after O
the O
end O
of O
the O
treatment O
, O
the O
number O
and O
the O
size O
of O
induced O
pas O
positive O
preneoplastic B-Disease
foci I-Disease
was O
significantly O
reduced O
when O
pb O
was O
given O
simultaneously O
with O
den O
for O
4 O
and O
6 O
weeks O
. O

in O
den O
+ O
pb O
treated O
rats O
, O
the O
survival O
was O
prolonged O
and O
the O
tumor B-Disease
incidence O
decreased O
as O
compared O
with O
the O
results O
obtained O
by O
den O
alone O
. O

it O
is O
concluded O
that O
pb O
, O
which O
promotes O
carcinogenesis B-Disease
when O
administered O
after O
the O
den O
treatment O
, O
reduces O
the O
carcinogen O
effect O
when O
given O
simultaneously O
with O
den O
. O

this O
' O
anti O
- O
carcinogen O
' O
effect O
acts O
on O
the O
initiation O
as O
well O
as O
on O
the O
promotion O
of O
the O
precancerous B-Disease
lesions I-Disease
. O

bilateral B-Disease
optic I-Disease
neuropathy I-Disease
due O
to O
combined O
ethambutol O
and O
isoniazid O
treatment O
. O

a O
bilateral B-Disease
retrobulbar I-Disease
neuropathy I-Disease
with O
an O
unusual O
central O
bitemporal O
hemianopic O
scotoma B-Disease
was O
found O
. O

the O
hazards O
of O
optic O
nerve O
toxicity B-Disease
due O
to O
ethambutol O
are O
known O
. O

vancomycin O
was O
curative O
in O
95 O
% O
of O
43 O
patients O
with O
proven O
infection B-Disease
. O

reactions O
included O
thrombophlebitis B-Disease
( O
20 O
of O
54 O
patients O
) O
, O
rash B-Disease
( O
4 O
of O
54 O
) O
, O
nephrotoxicity B-Disease
( O
4 O
of O
50 O
) O
, O
proteinuria B-Disease
( O
1 O
of O
50 O
) O
and O
ototoxicity B-Disease
( O
1 O
of O
11 O
patients O
tested O
by O
audiometry O
) O
. O

thrombophlebitis B-Disease
occurred O
only O
with O
infusion O
through O
peripheral O
cannulae O
; O
nephrotoxicity B-Disease
and O
ototoxicity B-Disease
were O
confined O
to O
patients O
receiving O
an O
aminoglycoside O
plus O
vancomycin O
. O

we O
conclude O
that O
vancomycin O
, O
administered O
appropriately O
, O
constitutes O
safe O
, O
effective O
therapy O
for O
infections B-Disease
caused O
by O
susceptible O
bacteria O
. O

factors O
associated O
with O
nephrotoxicity B-Disease
and O
clinical O
outcome O
in O
patients O
receiving O
amikacin O
. O

data O
from O
60 O
patients O
treated O
with O
amikacin O
were O
analyzed O
for O
factors O
associated O
with O
nephrotoxicity B-Disease
. O

when O
the O
parameters O
were O
examined O
individually O
, O
duration O
of O
therapy O
and O
total O
auc O
correlated O
significantly O
( O
p O
less O
than O
. O

5 O
) O
with O
nephrotoxicity B-Disease
. O

based O
on O
this O
model O
and O
on O
bayes O
' O
theorem O
, O
the O
predictive O
accuracy O
of O
identifying O
nan O
nephrotoxic B-Disease
nan O
patients O
increased O
from O
0 O
. O

17 O
to O
0 O
. O

39 O
. O

cardiac B-Disease
toxicity I-Disease
of O
5 O
- O
fluorouracil O
. O

report O
of O
a O
case O
of O
spontaneous O
angina B-Disease
. O

we O
report O
a O
case O
of O
a O
patient O
with O
colon B-Disease
carcinoma I-Disease
and O
liver O
metastasis B-Disease
who O
presented O
chest B-Disease
pain I-Disease
after O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
administration O
. O

clinical O
electrocardiographic O
evolution O
was O
similar O
to O
that O
observed O
in O
prinzmetal B-Disease
' I-Disease
s I-Disease
angina I-Disease
, O
and O
chest B-Disease
pain I-Disease
promptly O
resolved O
with O
nifedipine O
. O

these O
data O
suggest O
that O
coronary B-Disease
spasm I-Disease
may O
be O
the O
cause O
of O
cardiotoxicity B-Disease
due O
to O
5 O
- O
fu O
, O
and O
that O
calcium O
antagonists O
may O
probably O
be O
used O
in O
the O
prevention O
or O
treatment O
of O
5 O
- O
fu O
cardiotoxicity B-Disease
. O

dose O
- O
related O
beneficial O
and O
adverse O
effects O
of O
dietary O
corticosterone O
on O
organophosphorus O
- O
induced O
delayed O
neuropathy B-Disease
in O
chickens O
. O

supplemented O
diets O
were O
continued O
until O
clinical O
signs O
and O
lesions O
of O
delayed O
neuropathy B-Disease
appeared O
. O

although O
low O
concentrations O
( O
less O
than O
or O
equal O
to O
50 O
ppm O
) O
of O
corticosterone O
had O
beneficial O
effects O
on O
totp O
- O
induced O
neuropathy B-Disease
, O
greater O
than O
or O
equal O
to O
200 O
ppm O
exacerbated O
clinical O
signs O
in O
chickens O
given O
either O
totp O
or O
dfp O
. O

neurotoxic B-Disease
esterase O
activities O
24 O
hr O
after O
totp O
or O
dfp O
were O
less O
than O
20 O
% O
of O
values O
measured O
in O
chickens O
not O
given O
organophosphorous O
compounds O
. O

degenerating B-Disease
myelinated I-Disease
fibers I-Disease
were O
also O
evident O
in O
distal O
levels O
of O
the O
peripheral O
nerves O
of O
chickens O
given O
totp O
or O
dfp O
. O

hepatotoxicity B-Disease
of O
amiodarone O
. O

amiodarone O
has O
proved O
very O
effective O
in O
the O
treatment O
of O
otherwise O
resistant O
cardiac O
tachyarrhythmias B-Disease
. O

a O
patient O
with O
cholestatic B-Disease
hepatitis I-Disease
due O
to O
amiodarone O
treatment O
is O
presented O
below O
and O
a O
review O
of O
the O
hepatotoxicity B-Disease
of O
amiodarone O
is O
given O
. O

it O
is O
concluded O
that O
solid O
evidence O
exists O
of O
hepatic B-Disease
injury I-Disease
due O
to O
amiodarone O
treatment O
, O
including O
steatosis B-Disease
, O
alterations O
resembling O
alcoholic B-Disease
hepatitis I-Disease
, O
cholestatic B-Disease
hepatitis I-Disease
and O
micronodular O
cirrhosis B-Disease
of I-Disease
the I-Disease
liver I-Disease
. O

therapy O
should O
be O
discontinued O
on O
the O
suspicion O
of O
cholestatic B-Disease
injury I-Disease
or O
hepatomegaly B-Disease
. O

promotional O
effects O
of O
testosterone O
and O
dietary O
fat O
on O
prostate O
carcinogenesis B-Disease
in O
genetically O
susceptible O
rats O
. O

germfree O
( O
gf O
) O
lobund O
strain O
wistar O
( O
lw O
) O
rats O
, O
fed O
vegetable O
diet O
l O
- O
485 O
, O
have O
developed O
prostate B-Disease
adenocarcinomas I-Disease
spontaneously O
( O
10 O
% O
incidence O
) O
at O
average O
age O
34 O
months O
. O

conventional O
lw O
rats O
, O
implanted O
with O
testosterone O
at O
age O
4 O
months O
, O
developed O
a O
higher O
incidence O
of O
prostate B-Disease
cancer I-Disease
after O
an O
average O
interval O
of O
14 O
months O
: O
24 O
% O
had O
developed O
gross O
tumors B-Disease
, O
and O
40 O
% O
when O
it O
included O
microscopic O
tumors B-Disease
. O

preliminary O
results O
indicate O
that O
testosterone O
- O
treated O
lw O
rats O
that O
were O
fed O
the O
same O
diet O
, O
which O
was O
supplemented O
with O
corn O
oil O
up O
to O
20 O
% O
fat O
, O
developed O
prostate B-Disease
cancer I-Disease
after O
intervals O
of O
6 O
- O
12 O
months O
. O

aged O
gf O
sprague O
- O
dawley O
( O
sd O
) O
rats O
have O
not O
developed O
prostate B-Disease
cancer I-Disease
spontaneously O
. O

conventional O
sd O
rats O
fed O
diet O
l O
- O
485 O
and O
treated O
with O
testosterone O
developed O
only O
prostatitis B-Disease
. O

experimental O
designs O
should O
consider O
genetic O
susceptibility O
as O
a O
basic O
prerequisite O
for O
studies O
on O
experimental O
prostate B-Disease
cancer I-Disease
. O

significant O
qtc B-Disease
prolongation I-Disease
occurred O
in O
30 O
seconds O
to O
one O
minute O
in O
association O
with O
marked O
hypotension B-Disease
and O
elevation O
of O
cardiac O
output O
. O

muscle B-Disease
degeneration I-Disease
is O
followed O
by O
regeneration O
of O
the O
damaged O
muscle O
fibers O
. O

in O
addition O
to O
muscle B-Disease
damage I-Disease
, O
severe O
damage O
was O
also O
seen O
in O
harderian O
glands O
, O
especially O
after O
exposure O
to O
mepivacaine O
and O
lidocaine O
plus O
epinephrine O
. O

with O
these O
findings O
in O
rats O
, O
it O
is O
hypothesized O
that O
the O
temporary O
diplopia B-Disease
sometimes O
seen O
in O
patients O
after O
ophthalmic O
surgery O
might O
be O
due O
to O
anesthetic O
- O
induced O
damage O
to O
the O
extraocular O
muscles O
. O

gentamicin O
nephropathy B-Disease
in O
a O
neonate O
. O

the O
clinical O
and O
autopsy O
findings O
in O
a O
premature O
baby O
who O
died O
of O
acute B-Disease
renal I-Disease
failure I-Disease
after O
therapy O
with O
gentamicin O
( O
5 O
mg O
/ O
kg O
/ O
day O
) O
and O
penicillin O
are O
presented O
. O

the O
serum O
gentamicin O
concentration O
had O
reached O
toxic O
levels O
when O
anuria B-Disease
developed O
. O

induction O
by O
paracetamol O
of O
bladder B-Disease
and I-Disease
liver I-Disease
tumours I-Disease
in O
the O
rat O
. O

papillomas B-Disease
of O
the O
transitional O
epithelium O
of O
the O
bladder O
developed O
in O
all O
paracetamol O
- O
treated O
groups O
, O
and O
three O
rats O
bore O
bladder B-Disease
carcinomas I-Disease
. O

however O
, O
significant O
yields O
of O
bladder B-Disease
tumours I-Disease
were O
only O
obtained O
from O
low O
dosage O
females O
and O
high O
dosage O
males O
. O

additionally O
, O
20 O
to O
25 O
% O
of O
paracetamol O
- O
treated O
rats O
developed O
hyperplasia B-Disease
of O
the O
bladder O
epithelium O
, O
which O
was O
not O
coincident O
with O
the O
presence O
of O
bladder B-Disease
calculi I-Disease
. O

a O
low O
yield O
of O
tumours B-Disease
at O
various O
other O
sites O
also O
arose O
following O
paracetamol O
feeding O
. O

an O
electron O
microscope O
study O
of O
the O
livers O
of O
paracetamol O
- O
treated O
rats O
revealed O
ultrastructural O
changes O
in O
the O
hepatocytes O
that O
resemble O
those O
that O
result O
from O
exposure O
to O
a O
variety O
of O
known O
hepatocarcinogens B-Disease
. O

transient O
hemiparesis B-Disease
: O
a O
rare O
manifestation O
of O
diphenylhydantoin O
toxicity B-Disease
. O

among O
the O
common O
side O
effects O
of O
diphenylhydantoin O
( O
dph O
) O
overdose B-Disease
, O
the O
most O
frequently O
encountered O
neurological O
signs O
are O
those O
of O
cerebellar B-Disease
dysfunction I-Disease
. O

two O
patients O
are O
presented O
who O
suffered O
progressive O
hemiparesis B-Disease
due O
to O
dph O
overdose B-Disease
. O

it O
is O
assumed O
that O
patients O
with O
some O
cerebral B-Disease
damage I-Disease
are O
liable O
to O
manifest O
dph O
toxicity B-Disease
as O
focal O
neurological O
signs O
. O

tiapride O
in O
levodopa O
- O
induced O
involuntary B-Disease
movements I-Disease
. O

tiapride O
, O
a O
substituted O
benzamide O
derivative O
closely O
related O
to O
metoclopramide O
, O
reduced O
levodopa O
- O
induced O
peak O
dose O
involuntary B-Disease
movements I-Disease
in O
16 O
patients O
with O
idiopathic B-Disease
parkinson I-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

however O
, O
an O
unacceptable O
increase O
in O
disability O
from O
parkinsonism B-Disease
with O
aggravation O
of O
end O
- O
of O
- O
dose O
akinesia B-Disease
led O
to O
its O
cessation O
in O
14 O
patients O
. O

tiapride O
had O
no O
effect O
on O
levodopa O
- O
induced O
early O
morning O
of O
nan O
off O
- O
period O
nan O
segmental O
dystonia B-Disease
. O

these O
results O
fail O
to O
support O
the O
notion O
that O
levodopa O
- O
induced O
dyskinesias B-Disease
are O
caused O
by O
overstimulation O
of O
a O
separate O
group O
of O
dopamine O
receptors O
. O

quinidine O
hepatitis B-Disease
. O

liver O
biopsy O
showed O
active O
hepatitis B-Disease
. O

we O
concluded O
that O
this O
patient O
had O
quinidine O
hepatotoxicity B-Disease
and O
believe O
that O
this O
is O
the O
first O
case O
reported O
with O
liver O
biopsy O
documentation O
. O

this O
report O
also O
suggests O
that O
, O
even O
after O
long O
- O
term O
administration O
, O
the O
hepatic B-Disease
toxicity I-Disease
is O
reversible O
. O

arterial O
thromboembolism B-Disease
in O
patients O
receiving O
systemic O
heparin O
therapy O
: O
a O
complication O
associated O
with O
heparin O
- O
induced O
thrombocytopenia B-Disease
. O

arterial O
thromboembolism B-Disease
is O
a O
recognized O
complication O
of O
systemic O
heparin O
therapy O
. O

characteristic O
of O
the O
entity O
is O
arterial B-Disease
occlusion I-Disease
by O
platelet O
- O
fibrin O
thrombi B-Disease
with O
distal O
ischemia B-Disease
occurring O
four O
to O
twenty O
days O
after O
the O
initiation O
of O
heparin O
therapy O
, O
preceded O
by O
profound O
thrombocytopenia B-Disease
with O
platelet O
counts O
in O
the O
range O
of O
30 O
, O
0 O
to O
40 O
, O
0 O
per O
cubic O
millimeter O
. O

the O
clinically O
apparent O
occlusion O
may O
be O
preceded O
by O
gastrointestinal B-Disease
and I-Disease
musculoskeletal I-Disease
symptoms I-Disease
that O
appear O
to O
be O
ischemic B-Disease
in O
origin O
, O
and O
might O
serve O
to O
warn O
the O
clinician O
of O
these O
complications O
. O

the O
common O
factor O
relating O
thromboembolism B-Disease
and O
thrombocytopenia B-Disease
is O
heparin O
- O
induced O
platelet B-Disease
aggregation I-Disease
. O

its O
antiarrhythmic O
effectiveness O
surpasses O
that O
of O
propranolol O
and O
pindolol O
inhibiting O
the O
ouabain O
arrhythmia B-Disease
in O
dogs O
and O
cats O
. O

adverse O
reactions O
to O
bendrofluazide O
and O
propranolol O
for O
the O
treatment O
of O
mild O
hypertension B-Disease
. O

report O
of O
medical O
research O
council O
working O
party O
on O
mild O
to O
moderate O
hypertension B-Disease
. O

participants O
in O
the O
medical O
research O
council O
treatment O
trial O
for O
mild O
hypertension B-Disease
are O
randomly O
allocated O
to O
one O
of O
four O
treatment O
groups O
: O
bendrofluazide O
, O
propranolol O
, O
or O
a O
placebo O
for O
either O
of O
these O
drugs O
. O

the O
results O
show O
an O
association O
between O
bendrofluazide O
treatment O
and O
impotence B-Disease
, O
and O
impotence B-Disease
also O
occurred O
more O
frequently O
in O
patients O
taking O
propranolol O
than O
in O
those O
taking O
placebos O
. O

other O
adverse O
reactions O
significantly O
linked O
with O
active O
drugs O
include O
impaired B-Disease
glucose I-Disease
tolerance I-Disease
in O
men O
and O
women O
and O
gout B-Disease
in O
men O
, O
associated O
with O
bendrofluazide O
treatment O
, O
and O
raynaud B-Disease
' I-Disease
s I-Disease
phenomenon I-Disease
and O
dyspnoea B-Disease
in O
men O
and O
women O
taking O
propranolol O
. O

no O
corneal B-Disease
disease I-Disease
is O
known O
to O
have O
occurred O
in O
the O
propranolol O
group O
. O

serotonergic O
drugs O
, O
benzodiazepines O
and O
baclofen O
block O
muscimol O
- O
induced O
myoclonic B-Disease
jerks I-Disease
in O
a O
strain O
of O
mice O
. O

in O
male O
swiss O
mice O
, O
muscimol O
produced O
myoclonic B-Disease
jerks I-Disease
. O

of O
the O
benzodiazepines O
, O
clonazepam O
( O
0 O
. O

1 O
- O
0 O
. O

3 O
mg O
/ O
kg O
) O
was O
found O
to O
be O
several O
fold O
more O
potent O
than O
diazepam O
( O
0 O
. O

3 O
- O
3 O
mg O
/ O
kg O
) O
in O
blocking O
the O
myoclonic B-Disease
jerks I-Disease
. O

considering O
the O
fact O
that O
5 O
- O
htp O
and O
the O
benzodiazepines O
have O
been O
found O
to O
be O
beneficial O
in O
the O
management O
of O
clinical O
myoclonus B-Disease
, O
the O
muscimol O
- O
induced O
myoclonus B-Disease
seems O
to O
be O
a O
satisfactory O
animal O
model O
that O
may O
prove O
useful O
for O
the O
development O
of O
new O
drug O
treatments O
for O
this O
condition O
. O

our O
present O
study O
indicated O
the O
possible O
value O
of O
mk O
- O
212 O
and O
( O
- O
) O
- O
baclofen O
in O
the O
management O
of O
clinical O
myoclonus B-Disease
. O

three O
patients O
with O
ischaemic B-Disease
heart I-Disease
disease I-Disease
developed O
profound O
cardiac B-Disease
failure I-Disease
, O
hypotension B-Disease
and O
bradycardia B-Disease
during O
combined O
therapy O
with O
verapamil O
and O
beta O
- O
adrenergic O
blocking O
drugs O
. O

nineteen O
patients O
had O
zollinger B-Disease
- I-Disease
ellison I-Disease
syndrome I-Disease
, O
one O
patient O
had O
systemic B-Disease
mastocytosis I-Disease
, O
and O
two O
patients O
had O
idiopathic O
hypersecretion O
. O

sixty O
percent O
of O
the O
males O
developed O
breast O
changes O
or O
impotence B-Disease
while O
taking O
cimetidine O
and O
in O
all O
cases O
these O
changes O
disappeared O
when O
cimetidine O
was O
replaced O
by O
ranitidine O
. O

treatment O
with O
high O
doses O
of O
cimetidine O
( O
one O
to O
60 O
months O
; O
median O
, O
11 O
months O
) O
or O
ranitidine O
( O
two O
to O
31 O
months O
; O
median O
, O
14 O
months O
) O
was O
not O
associated O
with O
hepatic B-Disease
or I-Disease
hematologic I-Disease
toxicity I-Disease
or O
alterations O
of O
serum O
gastrin O
concentrations O
, O
but O
ranitidine O
therapy O
was O
associated O
with O
a O
significantly O
lower O
serum O
creatinine O
level O
than O
seen O
with O
cimetidine O
therapy O
. O

in O
one O
patient O
, O
enflurane O
administered O
during O
a O
donor O
nephrectomy O
resulted O
in O
unexpected O
partial O
motor O
seizures B-Disease
. O

until O
the O
cause O
of O
the O
seizures B-Disease
was O
correctly O
identified O
, O
the O
patient O
was O
inappropriately O
treated O
with O
anticonvulsants O
. O

two O
other O
patients O
suffered O
from O
partial O
, O
complex O
and O
generalized O
seizures B-Disease
uncontrolled O
by O
medication O
. O

epileptic B-Disease
foci O
delineated O
and O
activated O
by O
enflurane O
were O
surgically O
ablated O
and O
the O
patients O
are O
now O
seizure B-Disease
- O
free O
. O

on O
the O
other O
hand O
, O
enflurane O
may O
prove O
to O
be O
a O
safe O
fast O
acting O
activator O
of O
epileptic B-Disease
foci O
during O
corticography O
or O
depth O
electrode O
intraoperative O
recordings O
. O

development O
of O
isoproterenol O
- O
induced O
cardiac B-Disease
hypertrophy I-Disease
. O

the O
development O
of O
cardiac B-Disease
hypertrophy I-Disease
was O
studied O
in O
adult O
female O
wistar O
rats O
following O
daily O
subcutaneous O
injections O
of O
isoproterenol O
( O
iso O
) O
( O
0 O
. O

3 O
mg O
/ O
kg O
body O
weight O
) O
. O

ventricular O
dna O
content O
was O
unchanged O
during O
the O
early O
stage O
( O
1 O
- O
4 O
days O
) O
of O
hypertrophic B-Disease
growth O
but O
increased O
to O
a O
new O
steady O
- O
state O
level O
19 O
% O
above O
the O
controls O
after O
8 O
days O
of O
treatment O
. O

intraventricular O
pressures O
and O
coronary O
flow O
measures O
were O
similar O
for O
control O
and O
experimental O
animals O
following O
4 O
days O
of O
developed O
hypertrophy B-Disease
. O

these O
data O
indicate O
that O
the O
adaptive O
response O
to O
iso O
shows O
an O
early O
hypertrophic B-Disease
phase O
( O
1 O
- O
4 O
days O
) O
characterized O
by O
a O
substantial O
increase O
in O
rna O
content O
and O
cardiac O
mass O
in O
the O
absence O
of O
changes O
in O
dna O
. O

however O
, O
prolonged O
stimulation O
( O
8 O
- O
12 O
days O
) O
appears O
to O
represent O
a O
complex O
integration O
of O
both O
cellular O
hypertrophy B-Disease
and O
hyperplasia B-Disease
within O
the O
heart O
. O

multiple O
side O
effects O
of O
penicillamine O
therapy O
in O
one O
patient O
with O
rheumatoid B-Disease
arthritis I-Disease
. O

skin B-Disease
rashes I-Disease
, O
proteinuria B-Disease
, O
systemic B-Disease
lupus I-Disease
erythematosus I-Disease
, O
polymyositis B-Disease
and O
myasthenia B-Disease
gravis I-Disease
have O
all O
been O
recorded O
as O
complications O
of O
penicillamine O
therapy O
in O
patients O
with O
rheumatoid B-Disease
arthritis I-Disease
. O

the O
skin B-Disease
lesion I-Disease
resembled O
elastosis B-Disease
perforans I-Disease
serpiginosa I-Disease
, O
which O
has O
been O
reported O
as O
a O
rare O
side O
effect O
in O
patients O
with O
wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
but O
not O
in O
patients O
with O
rheumatoid B-Disease
arthritis I-Disease
treated O
with O
penicillamine O
. O

one O
case O
of O
acute O
hypercalcaemia B-Disease
and O
two O
of O
recurrent O
nephrolithiasis B-Disease
are O
reported O
in O
patients O
who O
had O
regularly O
consumed O
large O
amounts O
of O
calcium O
carbon O
- O
ate O
- O
sodium O
bicarbonate O
powders O
for O
more O
than O
20 O
years O
. O

doxorubicin O
cardiomyopathy B-Disease
in O
children O
with O
left O
- O
sided O
wilms B-Disease
tumor I-Disease
. O

two O
children O
with O
wilms B-Disease
tumor I-Disease
of O
the O
left O
kidney O
experienced O
severe O
anthracycline O
cardiomyopathy B-Disease
after O
irradiation O
to O
the O
tumor B-Disease
bed O
and O
conventional O
dosage O
of O
doxorubicin O
. O

the O
cardiomyopathy B-Disease
is O
attributed O
1 O
) O
to O
the O
fact O
that O
radiation O
fields O
for O
left O
wilms B-Disease
tumor I-Disease
include O
the O
lower O
portion O
of O
the O
heart O
and O
2 O
) O
to O
the O
interaction O
of O
doxorubicin O
and O
irradiation O
on O
cardiac O
muscle O
. O

it O
is O
recommended O
that O
doxorubicin O
dosage O
be O
sharply O
restricted O
in O
children O
with O
wilms B-Disease
tumor I-Disease
of O
the O
left O
kidney O
who O
receive O
postoperative O
irradiation O
. O

calcitonin O
injection O
resulted O
in O
a O
potentiation O
of O
haloperidol O
- O
induced O
catalepsy B-Disease
and O
a O
partial O
prevention O
of O
apomorphine O
- O
induced O
hyperactivity B-Disease
. O

pretreatment O
with O
naloxazone O
significantly O
blocked O
morphine O
analgesia B-Disease
, O
catalepsy B-Disease
and O
hypothermia B-Disease
at O
a O
dose O
which O
completely O
eliminated O
high O
- O
affinity O
binding O
in O
brain O
membranes O
. O

moreover O
, O
naloxazone O
significantly O
attenuated O
the O
morphine O
- O
induced O
hypotension B-Disease
and O
respiratory B-Disease
depression I-Disease
, O
whereas O
morphine O
- O
induced O
bradycardia B-Disease
was O
less O
affected O
. O

modification O
of O
drug O
action O
by O
hyperammonemia B-Disease
. O

pretreatment O
with O
ammonium O
acetate O
( O
nh4ac O
) O
( O
6 O
mmol O
/ O
kg O
s O
. O

c O
. O

) O
approximately O
doubled O
the O
time O
morphine O
- O
treated O
mice O
remained O
on O
a O
hot O
surface O
and O
similarly O
increased O
muscular O
incoordination B-Disease
by O
diazepam O
, O
but O
nh4ac O
treatment O
alone O
had O
no O
effect O
. O

thus O
, O
hyperammonemia B-Disease
is O
capable O
of O
altering O
drug O
action O
and O
must O
be O
considered O
along O
with O
impaired O
drug O
metabolism O
in O
enhanced O
drug O
responses O
associated O
with O
liver B-Disease
disease I-Disease
. O

addition O
of O
excess O
calcium O
reversed O
the O
depression B-Disease
in O
both O
tissues O
, O
but O
calcium O
- O
independent O
catecholamine O
release O
by O
acetaldehyde O
was O
not O
blocked O
by O
nh4ac O
. O

both O
verapamil O
( O
10 O
mg O
/ O
kg O
i O
. O

p O
. O

) O
and O
nh4ac O
pretreatment O
enhanced O
morphine O
analgesia B-Disease
- O
and O
diazepam O
- O
induced O
muscular O
incoordination B-Disease
and O
antagonized O
amphetamine O
- O
induced O
motor O
activity O
, O
and O
neither O
verapamil O
nor O
nh4ac O
affected O
the O
convulsant O
action O
of O
metrazol O
. O

the O
data O
suggest O
that O
hyperammonemia B-Disease
exerts O
a O
calcium O
channel O
blocking O
action O
which O
enhances O
the O
effects O
of O
central O
nervous O
system O
depressants O
and O
certain O
opioid O
analgesics O
. O

levodopa O
- O
induced O
dyskinesia B-Disease
and O
thalamotomy O
. O

levodopa O
- O
induced O
dyskinesia B-Disease
of O
the O
limbs O
in O
thirteen O
cases O
of O
parkinsonism B-Disease
, O
which O
was O
choreic O
, O
ballistic O
or O
dystonic B-Disease
in O
type O
, O
was O
alleviated O
almost O
completely O
by O
stereotaxic O
surgery O
using O
a O
microelectrode O
technique O
for O
the O
ventralis O
oralis O
anterior O
and O
posterior O
nuclei O
of O
the O
thalamus O
, O
but O
much O
less O
by O
the O
ventralis O
intermedius O
nucleus O
. O

control O
of O
levodopa O
- O
induced O
dyskinesias B-Disease
by O
thalamic B-Disease
lesions I-Disease
in O
the O
course O
of O
routine O
treatment O
of O
parkinsonism B-Disease
is O
discussed O
. O

treatment O
of O
ifosfamide O
- O
induced O
urothelial B-Disease
toxicity I-Disease
by O
oral O
administration O
of O
sodium O
2 O
- O
mercaptoethane O
sulphonate O
( O
mesna O
) O
to O
patients O
with O
inoperable O
lung B-Disease
cancer I-Disease
. O

the O
protective O
effect O
of O
oral O
administration O
of O
the O
thiol O
compound O
sodium O
2 O
- O
mercaptoethane O
sulphonate O
( O
mesna O
) O
against O
urothelial B-Disease
toxicity I-Disease
induced O
by O
ifosfamide O
( O
if O
) O
was O
tested O
in O
a O
group O
of O
45 O
patients O
with O
inoperable O
lung B-Disease
cancer I-Disease
under O
treatment O
with O
if O
( O
2250 O
mg O
/ O
m2 O
on O
days O
2 O
- O
5 O
) O
as O
part O
of O
a O
polychemotherapy O
regimen O
repeated O
in O
a O
4 O
- O
week O
cycle O
. O

out O
of O
a O
total O
of O
88 O
courses O
of O
this O
treatment O
we O
observed O
10 O
episodes O
of O
asymptomatic O
microscopic O
haematuria B-Disease
and O
no O
episodes O
of O
gross O
haematuria B-Disease
. O

in O
this O
group O
there O
were O
1 O
complete O
and O
5 O
partial O
remissions O
( O
total O
24 O
% O
) O
, O
but O
nearly O
all O
patients O
developed O
either O
gross O
haematuria B-Disease
and O
/ O
or O
symptoms O
of O
bladder B-Disease
irritation I-Disease
( O
cystitis B-Disease
and O
pollakisuria B-Disease
) O
. O

there O
were O
no O
appreciable O
differences O
between O
the O
mesna O
series O
and O
the O
conventional O
prophylaxis O
series O
with O
respect O
to O
either O
haematological O
or O
systemic O
toxicity B-Disease
of O
the O
cytostatic O
treatment O
. O

myoclonic B-Disease
, I-Disease
atonic I-Disease
, I-Disease
and I-Disease
absence I-Disease
seizures I-Disease
following O
institution O
of O
carbamazepine O
therapy O
in O
children O
. O

five O
children O
, O
aged O
3 O
to O
11 O
years O
, O
treated O
with O
carbamazepine O
for O
epilepsy B-Disease
, O
had O
an O
acute O
aberrant O
reaction O
characterized O
by O
the O
onset O
of O
myoclonic B-Disease
, I-Disease
atypical I-Disease
absence I-Disease
and I-Disease
/ I-Disease
or I-Disease
atonic I-Disease
( I-Disease
minor I-Disease
motor I-Disease
) I-Disease
seizures I-Disease
within O
a O
few O
days O
. O

when O
the O
carbamazepine O
was O
discontinued O
, O
two O
of O
the O
children O
returned O
to O
their O
former O
state O
very O
quickly O
, O
two O
had O
the O
minor O
motor O
seizures B-Disease
resolve O
in O
3 O
and O
6 O
months O
, O
and O
one O
had O
the O
seizures B-Disease
persist O
. O

the O
child O
in O
whom O
the O
seizures B-Disease
persisted O
was O
later O
found O
to O
have O
ceroid B-Disease
lipofuscinosis I-Disease
. O

effect O
of O
prostaglandin O
synthetase O
inhibitors O
on O
experimentally O
induced O
convulsions B-Disease
in O
rats O
. O

to O
investigate O
the O
relationship O
of O
prostaglandins O
( O
pgs O
) O
to O
seizure B-Disease
induction O
, O
the O
effects O
of O
six O
pg O
synthetase O
inhibitors O
on O
convulsions B-Disease
induced O
by O
flurothyl O
, O
picrotoxin O
, O
pentetrazol O
( O
ptz O
) O
, O
electroshock O
or O
bicuculline O
were O
evaluated O
. O

these O
results O
suggest O
that O
pgs O
are O
involved O
in O
the O
mechanism O
( O
s O
) O
underlying O
fluorthyl O
- O
and O
ptz O
- O
induced O
convulsions B-Disease
, O
but O
not O
picrotoxin O
- O
, O
electroshock O
- O
, O
or O
bicuculline O
- O
induced O
convulsions B-Disease
. O

valproic O
acid O
( O
vpa O
) O
was O
given O
to O
24 O
epileptic B-Disease
patients O
who O
were O
already O
being O
treated O
with O
other O
antiepileptic O
drugs O
. O

ammonia O
( O
nh3 O
) O
was O
higher O
in O
patients O
who O
, O
during O
continuous O
therapy O
, O
complained O
of O
drowsiness B-Disease
( O
7 O
patients O
) O
than O
in O
those O
who O
were O
symptom O
- O
free O
( O
17 O
patients O
) O
, O
although O
vpa O
plasma O
levels O
were O
similar O
in O
both O
groups O
. O

effect O
of O
captopril O
on O
pre O
- O
existing O
and O
aminonucleoside O
- O
induced O
proteinuria B-Disease
in O
spontaneously O
hypertensive B-Disease
rats O
. O

proteinuria B-Disease
is O
a O
side O
effect O
of O
captopril O
treatment O
in O
hypertensive B-Disease
patients O
. O

the O
possibility O
of O
reproducing O
the O
same O
renal B-Disease
abnormality I-Disease
with O
captopril O
was O
examined O
in O
shr O
. O

oral O
administration O
of O
captopril O
at O
100 O
mg O
/ O
kg O
for O
14 O
days O
failed O
to O
aggravate O
proteinuria B-Disease
pre O
- O
existing O
in O
shr O
. O

also O
, O
captopril O
treatment O
failed O
to O
potentiate O
or O
facilitate O
development O
of O
massive O
proteinuria B-Disease
invoked O
by O
puromycin O
aminonucleoside O
in O
shr O
. O

complete O
heart B-Disease
block I-Disease
following O
a O
single O
dose O
of O
trazodone O
. O

forty O
minutes O
after O
receiving O
a O
single O
starting O
dose O
of O
trazodone O
, O
a O
patient O
developed O
complete O
heart B-Disease
block I-Disease
. O

phenobarbital O
- O
induced O
dyskinesia B-Disease
in O
a O
neurologically B-Disease
- I-Disease
impaired I-Disease
child O
. O

a O
2 O
- O
year O
- O
old O
child O
with O
known O
neurologic B-Disease
impairment I-Disease
developed O
a O
dyskinesia B-Disease
soon O
after O
starting O
phenobarbital O
therapy O
for O
seizures B-Disease
. O

known O
causes O
of O
movement B-Disease
disorders I-Disease
were O
eliminated O
after O
evaluation O
. O

on O
repeat O
challenge O
with O
phenobarbital O
, O
the O
dyskinesia B-Disease
recurred O
. O

phenobarbital O
should O
be O
added O
to O
the O
list O
of O
anticonvulsant O
drugs O
that O
can O
cause O
movement B-Disease
disorders I-Disease
. O

effects O
of O
amine O
pretreatment O
on O
ketamine O
catatonia B-Disease
in O
pinealectomized O
or O
hypophysectomized O
animals O
. O

the O
present O
studies O
were O
designed O
to O
clarify O
the O
role O
of O
catecholamines O
and O
pineal O
idolamines O
on O
ketamine O
- O
induced O
catatonia B-Disease
in O
the O
intact O
, O
pinealectomized O
or O
hypophysectomized O
chick O
and O
rat O
. O

in O
the O
pinealectomized O
chick O
, O
pretreatment O
with O
dopamine O
increased O
the O
duration O
of O
catatonia B-Disease
( O
doc O
) O
after O
ketamine O
, O
but O
pretreatment O
with O
norepinephrine O
did O
not O
. O

furthermore O
, O
dopamine O
appeared O
to O
act O
on O
systems O
more O
closely O
involved O
with O
the O
induction O
of O
ketamine O
catatonia B-Disease
rather O
than O
directly O
on O
the O
pituitary O
. O

heparin O
- O
induced O
thrombocytopenia B-Disease
, O
thrombosis B-Disease
, O
and O
hemorrhage B-Disease
. O

sixty O
- O
two O
patients O
with O
a O
heparin O
- O
induced O
thrombocytopenia B-Disease
are O
reported O
. O

clinical O
manifestations O
of O
this O
disorder O
include O
hemorrhage B-Disease
or O
, O
more O
frequently O
, O
thromboembolic B-Disease
events O
in O
patients O
receiving O
heparin O
. O

laboratory O
testing O
has O
revealed O
a B-Disease
falling I-Disease
platelet I-Disease
count I-Disease
, O
increased O
resistance O
to O
heparin O
, O
and O
aggregation O
of O
platelets O
by O
the O
patient O
' O
s O
plasma O
when O
heparin O
is O
added O
. O

the O
20 O
deaths O
, O
52 O
hemorrhagic B-Disease
and I-Disease
thromboembolic I-Disease
complications I-Disease
, O
and O
21 O
surgical O
procedures O
to O
manage O
the O
complications O
confirm O
the O
seriousness O
of O
the O
disorder O
. O

if O
the O
platelet O
count O
falls O
to O
less O
than O
100 O
, O
0 O
/ O
mm3 O
, O
while O
the O
patient O
is O
receiving O
heparin O
, O
platelet B-Disease
aggregation I-Disease
testing O
, O
using O
the O
patient O
' O
s O
plasma O
, O
is O
indicated O
. O

ventricular B-Disease
fibrillation I-Disease
from O
diatrizoate O
with O
and O
without O
chelating O
agents O
. O

the O
toxicity B-Disease
of O
renografin O
76 O
% O
was O
compared O
with O
that O
of O
hypaque O
76 O
% O
by O
selective O
injection O
of O
each O
into O
the O
right O
coronary O
artery O
of O
dogs O
. O

ventricular B-Disease
fibrillation I-Disease
occurred O
significantly O
more O
often O
with O
renografin O
, O
suggesting O
that O
chelating O
agents O
contribute O
to O
toxicity B-Disease
in O
coronary O
angiography O
. O

long O
- O
term O
efficacy O
and O
toxicity B-Disease
of O
high O
- O
dose O
amiodarone O
therapy O
for O
ventricular B-Disease
tachycardia I-Disease
or O
ventricular B-Disease
fibrillation I-Disease
. O

amiodarone O
was O
administered O
to O
154 O
patients O
who O
had O
sustained O
, O
symptomatic O
ventricular B-Disease
tachycardia I-Disease
( O
vt B-Disease
) O
( O
n O
= O
118 O
) O
or O
a O
cardiac B-Disease
arrest I-Disease
( O
n O
= O
36 O
) O
and O
who O
were O
refractory O
to O
conventional O
antiarrhythmic O
drugs O
. O

sixty O
- O
nine O
percent O
of O
patients O
continued O
treatment O
with O
amiodarone O
and O
had O
no O
recurrence O
of O
symptomatic O
vt B-Disease
or O
ventricular B-Disease
fibrillation I-Disease
( O
vf B-Disease
) O
over O
a O
follow O
- O
up O
of O
6 O
to O
52 O
months O
( O
mean O
+ O
/ O
- O
standard O
deviation O
14 O
. O

2 O
+ O
/ O
- O
8 O
. O

2 O
) O
. O

six O
percent O
of O
the O
patients O
had O
a O
nonfatal O
recurrence O
of O
vt B-Disease
and O
were O
successfully O
managed O
by O
continuing O
amiodarone O
at O
a O
higher O
dose O
or O
by O
the O
addition O
of O
a O
conventional O
antiarrhythmic O
drug O
. O

the O
most O
common O
symptomatic O
adverse O
reactions O
were O
tremor B-Disease
or O
ataxia B-Disease
( O
35 O
% O
) O
, O
nausea B-Disease
and O
anorexia B-Disease
( O
8 O
% O
) O
, O
visual B-Disease
halos I-Disease
or I-Disease
blurring I-Disease
( O
6 O
% O
) O
, O
thyroid B-Disease
function I-Disease
abnormalities I-Disease
( O
6 O
% O
) O
and O
pulmonary B-Disease
interstitial I-Disease
infiltrates I-Disease
( O
5 O
% O
) O
. O

although O
large O
- O
dose O
amiodarone O
is O
highly O
effective O
in O
the O
long O
- O
term O
treatment O
of O
vt B-Disease
or O
vf B-Disease
refractory O
to O
conventional O
antiarrhythmic O
drugs O
, O
it O
causes O
significant O
toxicity B-Disease
in O
approximately O
50 O
% O
of O
patients O
. O

however O
, O
when O
the O
dose O
is O
adjusted O
based O
on O
clinical O
response O
or O
the O
development O
of O
adverse O
effects O
, O
75 O
% O
of O
patients O
with O
vt B-Disease
or O
vf B-Disease
can O
be O
successfully O
managed O
with O
amiodarone O
. O

why O
may O
epsilon O
- O
aminocaproic O
acid O
( O
eaca O
) O
induce O
myopathy B-Disease
in O
man O
? O
a O
case O
of O
necrotizing B-Disease
myopathy I-Disease
due O
to O
a O
short O
epsilon O
- O
aminocaproic O
acid O
( O
eaca O
) O
treatment O
in O
a O
72 O
year O
- O
old O
patient O
with O
subarachnoid B-Disease
haemorrhage I-Disease
( O
sah B-Disease
) O
is O
described O
. O

cerebral B-Disease
hemorrhage I-Disease
associated O
with O
phenylpropanolamine O
in O
combination O
with O
caffeine O
. O

phenylpropanolamine O
( O
ppa O
) O
is O
a O
drug O
that O
has O
been O
associated O
with O
serious O
side O
effects O
including O
stroke B-Disease
. O

in O
order O
to O
determine O
if O
ppa O
/ O
caffeine O
can O
lead O
to O
stroke B-Disease
in O
normotensive O
and O
/ O
or O
hypertensive B-Disease
rats O
, O
we O
administered O
the O
combination O
in O
six O
times O
the O
allowed O
human O
dose O
calculated O
on O
a O
per O
weight O
basis O
for O
the O
rats O
two O
times O
per O
day O
for O
five O
days O
. O

subarachnoid B-Disease
and I-Disease
cerebral I-Disease
hemorrhage I-Disease
was O
noted O
in O
18 O
% O
of O
the O
hypertensive B-Disease
rats O
. O

a O
single O
ppa O
/ O
caffeine O
administration O
( O
same O
dose O
) O
lead O
to O
acute O
hypertension B-Disease
in O
both O
the O
normotensive O
and O
hypertensive B-Disease
animals O
. O

these O
results O
suggest O
that O
ppa O
/ O
caffeine O
can O
lead O
to O
cerebral B-Disease
hemorrhage I-Disease
in O
previously O
hypertensive B-Disease
animals O
when O
administered O
in O
greater O
than O
the O
allowed O
dosage O
. O

renal B-Disease
papillary I-Disease
necrosis I-Disease
due O
to O
naproxen O
. O

a O
31 O
- O
year O
- O
old O
man O
with O
rheumatoid B-Disease
arthritis I-Disease
, O
who O
had O
previously O
been O
treated O
with O
sulindac O
, O
fenoprofen O
calcium O
, O
high O
dose O
salicylates O
and O
gold O
salts O
, O
developed O
renal B-Disease
papillary I-Disease
necrosis I-Disease
( O
rpn B-Disease
) O
4 O
months O
after O
institution O
of O
naproxen O
therapy O
. O

no O
other O
factor O
predisposing O
to O
rpn B-Disease
could O
be O
discovered O
. O

we O
review O
previous O
reports O
linking O
rpn B-Disease
to O
antiinflammatory O
drug O
use O
and O
discuss O
possible O
advantages O
of O
sulindac O
in O
patients O
who O
have O
experienced O
renal B-Disease
toxicity I-Disease
from O
other O
antiinflammatory O
agents O
. O

nephrotoxic B-Disease
effects O
of O
aminoglycoside O
treatment O
on O
renal O
protein O
reabsorption O
and O
accumulation O
. O

thus O
, O
aminoglycosides O
may O
act O
as O
nephrotoxicants O
at O
glomerular O
and O
/ O
or O
tubular O
level O
inducing O
impairment B-Disease
of I-Disease
renal I-Disease
reabsorption I-Disease
and O
accumulation O
of O
proteins O
. O

induction O
of O
the O
obstructive B-Disease
sleep I-Disease
apnea I-Disease
syndrome I-Disease
in O
a O
woman O
by O
exogenous O
androgen O
administration O
. O

we O
documented O
airway O
occlusion O
during O
sleep O
and O
an O
abnormally O
high O
supraglottic O
resistance O
while O
awake O
in O
a O
54 O
- O
yr O
- O
old O
woman O
who O
had O
developed O
physical O
changes O
and O
the O
syndrome B-Disease
of I-Disease
obstructive I-Disease
sleep I-Disease
apnea I-Disease
while O
being O
administered O
exogenous O
androgens O
. O

a O
rechallenge O
with O
androgen O
produced O
symptoms O
of O
obstructive B-Disease
sleep I-Disease
apnea I-Disease
that O
abated O
upon O
withdrawal O
of O
the O
hormone O
. O

previous O
reports O
have O
favored O
a O
role O
of O
androgens O
in O
the O
pathogenesis O
of O
sleep B-Disease
apnea I-Disease
. O

development O
of O
the O
obstructive B-Disease
sleep I-Disease
apnea I-Disease
syndrome I-Disease
must O
be O
considered O
a O
possible O
side O
effect O
of O
androgen O
therapy O
. O

cardiotoxic B-Disease
and O
possible O
leukemogenic O
effects O
of O
adriamycin O
in O
nonhuman O
primates O
. O

8 O
of O
the O
10 O
monkeys O
developed O
congestive B-Disease
heart I-Disease
failure I-Disease
at O
an O
average O
cumulative O
adriamycin O
dose O
( O
310 O
mg O
/ O
m2 O
) O
well O
below O
that O
considered O
the O
safe O
upper O
limit O
( O
550 O
mg O
/ O
m2 O
) O
in O
man O
. O

histologically O
, O
the O
myocardial B-Disease
lesions I-Disease
resembled O
those O
found O
in O
human O
anthracycline O
- O
induced O
cardiomyopathy B-Disease
. O

1 O
of O
the O
10 O
monkeys O
developed O
acute B-Disease
myeloblastic I-Disease
leukemia I-Disease
after O
receiving O
324 O
mg O
/ O
m2 O
of O
adriamycin O
; O
the O
10th O
monkey O
is O
alive O
and O
well O
26 O
months O
after O
the O
last O
dose O
of O
drug O
. O

our O
results O
suggest O
that O
adriamycin O
is O
a O
more O
potent O
cardiotoxin O
in O
monkeys O
than O
in O
man O
, O
and O
that O
leukemia B-Disease
may O
be O
a O
consequence O
of O
prolonged O
treatment O
with O
this O
drug O
. O

tricuspid B-Disease
valve I-Disease
regurgitation I-Disease
and O
lithium O
carbonate O
toxicity B-Disease
in O
a O
newborn O
infant O
. O

a O
newborn O
with O
massive O
tricuspid B-Disease
regurgitation I-Disease
, O
atrial B-Disease
flutter I-Disease
, O
congestive B-Disease
heart I-Disease
failure I-Disease
, O
and O
a O
high O
serum O
lithium O
level O
is O
described O
. O

this O
is O
the O
first O
patient O
to O
initially O
manifest O
tricuspid B-Disease
regurgitation I-Disease
and O
atrial B-Disease
flutter I-Disease
, O
and O
the O
11th O
described O
patient O
with O
cardiac B-Disease
disease I-Disease
among O
infants O
exposed O
to O
lithium O
compounds O
in O
the O
first O
trimester O
of O
pregnancy O
. O

lithium O
carbonate O
may O
be O
a O
factor O
in O
the O
increasing O
incidence O
of O
congenital B-Disease
heart I-Disease
disease I-Disease
when O
taken O
during O
early O
pregnancy O
. O

it O
also O
causes O
neurologic B-Disease
depression I-Disease
, O
cyanosis B-Disease
, O
and O
cardiac B-Disease
arrhythmia I-Disease
when O
consumed O
prior O
to O
delivery O
. O

effects O
of O
the O
novel O
compound O
aniracetam O
( O
ro O
13 O
- O
5057 O
) O
upon O
impaired B-Disease
learning I-Disease
and I-Disease
memory I-Disease
in O
rodents O
. O

the O
effect O
of O
aniracetam O
( O
ro O
13 O
- O
5057 O
, O
1 O
- O
anisoyl O
- O
2 O
- O
pyrrolidinone O
) O
was O
studied O
on O
various O
forms O
of O
experimentally O
impaired B-Disease
cognitive I-Disease
functions I-Disease
( O
learning O
and O
memory O
) O
in O
rodents O
and O
produced O
the O
following O
effects O
: O
( O
1 O
) O
almost O
complete O
prevention O
of O
the O
incapacity O
to O
learn O
a O
discrete O
escape O
response O
in O
rats O
exposed O
to O
sublethal O
hypercapnia B-Disease
immediately O
before O
the O
acquisition O
session O
; O
( O
2 O
) O
partial O
( O
rats O
) O
or O
complete O
( O
mice O
) O
prevention O
of O
the O
scopolamine O
- O
induced O
short O
- O
term O
amnesia B-Disease
for O
a O
passive O
avoidance O
task O
; O
( O
3 O
) O
complete O
protection O
against O
amnesia B-Disease
for O
a O
passive O
avoidance O
task O
in O
rats O
submitted O
to O
electroconvulsive O
shock O
immediately O
after O
avoidance O
acquisition O
; O
( O
4 O
) O
prevention O
of O
the O
long O
- O
term O
retention O
- O
or O
retrieval O
- O
deficit O
for O
a O
passive O
avoidance O
task O
induced O
in O
rats O
and O
mice O
by O
chloramphenicol O
or O
cycloheximide O
administered O
immediately O
after O
acquisition O
; O
( O
5 O
) O
reversal O
, O
when O
administered O
as O
late O
as O
1 O
h O
before O
the O
retention O
test O
, O
of O
the O
deficit O
in O
retention O
or O
retrieval O
of O
a O
passive O
avoidance O
task O
induced O
by O
cycloheximide O
injected O
2 O
days O
previously O
; O
( O
6 O
) O
prevention O
of O
the O
deficit O
in O
the O
retrieval O
of O
an O
active O
avoidance O
task O
induced O
in O
mice O
by O
subconvulsant O
electroshock O
or O
hypercapnia B-Disease
applied O
immediately O
before O
retrieval O
testing O
( O
24 O
h O
after O
acquisition O
) O
. O

these O
improvements O
or O
normalizations O
of O
impaired B-Disease
cognitive I-Disease
functions I-Disease
were O
seen O
at O
oral O
aniracetam O
doses O
of O
10 O
- O
100 O
mg O
/ O
kg O
. O

the O
effect O
of O
calcium O
chloride O
injected O
into O
the O
cerebral O
ventricles O
of O
group O
- O
housed O
unanaesthetized O
cats O
upon O
vocalization O
( O
rage O
, O
hissing O
and O
snarling O
) O
, O
fighting O
( O
attack O
with O
paws O
and O
claws O
, O
defense O
with O
paws O
and O
claws O
and O
biting O
) O
, O
mydriasis B-Disease
, O
tremor B-Disease
and O
clonic B-Disease
- I-Disease
tonic I-Disease
convulsions I-Disease
produced O
by O
carbachol O
and O
eserine O
injected O
similarly O
was O
investigated O
. O

on O
the O
other O
hand O
, O
mydriasis B-Disease
, O
tremor B-Disease
and O
clonic B-Disease
- I-Disease
tonic I-Disease
convulsions I-Disease
evoked O
by O
carbachol O
and O
eserine O
were O
not O
significantly O
changed O
by O
calcium O
chloride O
. O

it O
is O
apparent O
that O
calcium O
chloride O
can O
nan O
dissociate O
nan O
vocalization O
and O
fighting O
from O
autonomic O
and O
motor O
phenomena O
such O
as O
mydriasis B-Disease
, O
tremor B-Disease
and O
clonic B-Disease
- I-Disease
tonic I-Disease
convulsions I-Disease
caused O
by O
carbachol O
and O
eserine O
. O

thiazide O
diuretics O
, O
hypokalemia B-Disease
and O
cardiac B-Disease
arrhythmias I-Disease
. O

hypokalemia B-Disease
is O
a O
commonly O
encountered O
metabolic O
consequence O
of O
chronic O
thiazide O
therapy O
. O

we O
treated O
38 O
patients O
( O
22 O
low O
renin O
, O
16 O
normal O
renin O
) O
with O
moderate O
diastolic B-Disease
hypertension I-Disease
with O
hydrochlorothiazide O
( O
hctc O
) O
administered O
on O
a O
twice O
daily O
schedule O
. O

in O
conclusion O
we O
found O
that O
thiazide O
diuretics O
cause O
hypokalemia B-Disease
and O
depletion O
of O
body O
potassium O
. O

the O
more O
profound O
hypokalemia B-Disease
, O
the O
greater O
the O
propensity O
for O
the O
occurrence O
of O
pvc O
' O
s O
. O

circulating O
lysosomal O
enzymes O
and O
acute B-Disease
hepatic I-Disease
necrosis I-Disease
. O

the O
activities O
of O
the O
lysosomal O
enzymes O
acid O
and O
neutral O
protease O
, O
n O
- O
acetylglucosaminidase O
, O
and O
acid O
phosphatase O
were O
measured O
in O
the O
serum O
of O
patients O
with O
fulminant B-Disease
hepatic I-Disease
failure I-Disease
. O

acid O
protease O
( O
cathepsin O
d O
) O
activity O
was O
increased O
about O
tenfold O
in O
patients O
who O
died O
and O
nearly O
fourfold O
in O
those O
who O
survived O
fulminant B-Disease
hepatic I-Disease
failure I-Disease
after O
paracetamol O
overdose B-Disease
, O
whereas O
activities O
were O
increased O
equally O
in O
patients O
with O
fulminant B-Disease
hepatic I-Disease
failure I-Disease
due O
to O
viral B-Disease
hepatitis I-Disease
whether O
or O
not O
they O
survived O
. O

hepatic B-Disease
veno I-Disease
- I-Disease
occlusive I-Disease
disease I-Disease
caused O
by O
6 O
- O
thioguanine O
. O

clinically O
reversible O
veno B-Disease
- I-Disease
occlusive I-Disease
disease I-Disease
of I-Disease
the I-Disease
liver I-Disease
developed O
in O
a O
23 O
- O
year O
- O
old O
man O
with O
acute B-Disease
lymphocytic I-Disease
leukemia I-Disease
after O
10 O
months O
of O
maintenance O
therapy O
with O
6 O
- O
thioguanine O
. O

although O
this O
disease O
was O
clinically O
reversible O
, O
some O
subintimal O
fibrosis B-Disease
about O
the O
terminal O
hepatic O
veins O
persisted O
. O

this O
case O
presented O
a O
unique O
opportunity O
to O
observe O
the O
histologic O
features O
of O
clinically O
reversible O
hepatic B-Disease
veno I-Disease
- I-Disease
occlusive I-Disease
disease I-Disease
over O
time O
, O
and O
may O
be O
the O
first O
case O
of O
veno O
- O
occlusive O
related O
solely O
to O
6 O
- O
thioguanine O
. O

chlorpropamide O
- O
induced O
optic B-Disease
neuropathy I-Disease
. O

a O
65 O
- O
year O
- O
old O
woman O
with O
adult B-Disease
- I-Disease
onset I-Disease
diabetes I-Disease
treated O
with O
chlorpropamide O
( O
diabenese O
) O
had O
a O
toxic B-Disease
optic I-Disease
neuropathy I-Disease
that O
resolved O
with O
discontinuation O
of O
chlorpropamide O
therapy O
. O

visual B-Disease
loss I-Disease
occurs O
in O
diabetics B-Disease
for O
a O
variety O
of O
reasons O
, O
and O
accurate O
diagnosis O
is O
necessary O
to O
institute O
appropriate O
therapy O
. O

the O
possibility O
of O
a O
drug O
- O
induced O
optic B-Disease
neuropathy I-Disease
should O
be O
considered O
in O
the O
differential O
diagnosis O
of O
visual B-Disease
loss I-Disease
in O
diabetics B-Disease
. O

plasma O
and O
urinary O
lipids O
and O
lipoproteins O
during O
the O
development O
of O
nephrotic B-Disease
syndrome I-Disease
induced O
in O
the O
rat O
by O
puromycin O
aminonucleoside O
. O

this O
study O
was O
undertaken O
to O
ascertain O
whether O
the O
alterations O
of O
plasma O
lipoproteins O
found O
in O
nephrotic B-Disease
syndrome I-Disease
induced O
by O
puromycin O
aminonucleoside O
were O
due O
to O
nephrotic B-Disease
syndrome I-Disease
per O
se O
, O
or O
, O
at O
least O
in O
part O
, O
to O
the O
aminonucleoside O
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
the O
changes O
in O
plasma O
and O
urinary O
lipoproteins O
during O
the O
administration O
of O
puromycin O
aminonucleoside O
( O
20 O
mg O
/ O
kg O
for O
7 O
days O
) O
and O
the O
subsequent O
development O
of O
nephrotic B-Disease
syndrome I-Disease
. O

since O
massive O
albuminuria B-Disease
occurred O
after O
6 O
days O
of O
treatment O
, O
the O
time O
- O
course O
study O
was O
divided O
into O
two O
stages O
: O
pre O
- O
nephrotic B-Disease
stage O
( O
day O
1 O
- O
5 O
) O
and O
nephrotic B-Disease
stage O
( O
day O
6 O
- O
11 O
) O
. O

in O
pre O
- O
nephrotic B-Disease
stage O
the O
plasma O
level O
of O
fatty O
acids O
, O
triacylglycerol O
and O
vldl O
decreased O
while O
that O
of O
phospholipid O
, O
cholesteryl O
esters O
and O
hdl O
remained O
constant O
. O

at O
the O
beginning O
of O
nephrotic B-Disease
stage O
( O
day O
6 O
) O
the O
concentration O
of O
plasma O
albumin O
dropped O
to O
a O
very O
low O
level O
, O
while O
that O
of O
apolipoprotein O
a O
- O
i O
increased O
abruptly O
( O
4 O
- O
fold O
increase O
) O
and O
continued O
to O
rise O
, O
although O
less O
steeply O
, O
in O
the O
following O
days O
. O

in O
the O
pre O
- O
nephrotic B-Disease
stage O
lipoproteinuria O
was O
negligible O
, O
while O
in O
the O
early O
nephrotic B-Disease
stage O
the O
urinary O
loss O
of O
plasma O
lipoproteins O
consisted O
mainly O
of O
hdl O
. O

it O
is O
likely O
that O
the O
early O
and O
striking O
increase O
of O
plasma O
hdl O
found O
in O
nephrotic B-Disease
rats O
is O
related O
to O
a O
direct O
effect O
of O
the O
drug O
on O
hdl O
metabolism O
. O

fatal O
aplastic B-Disease
anemia I-Disease
following O
topical O
administration O
of O
ophthalmic O
chloramphenicol O
. O

a O
73 O
- O
year O
- O
old O
woman O
died O
of O
aplastic B-Disease
anemia I-Disease
less O
than O
two O
months O
after O
undergoing O
cataract B-Disease
extraction O
and O
beginning O
topical O
therapy O
with O
chloramphenicol O
. O

the O
first O
signs O
of O
pancytopenia B-Disease
began O
within O
one O
month O
of O
the O
surgery O
. O

the O
pattern O
of O
the O
aplastic B-Disease
anemia I-Disease
was O
associated O
with O
an O
idiosyncratic O
response O
to O
chloramphenicol O
. O

this O
was O
the O
second O
report O
of O
fatal O
aplastic B-Disease
anemia I-Disease
after O
topical O
treatment O
with O
chloramphenicol O
for O
ocular O
conditions O
, O
although O
two O
cases O
of O
reversible O
bone B-Disease
marrow I-Disease
hypoplasia I-Disease
have O
also O
been O
reported O
. O

any O
other O
suspected O
cases O
of O
ocular B-Disease
toxicity I-Disease
associated O
with O
topically O
applied O
chloramphenicol O
should O
be O
reported O
to O
the O
national O
registry O
of O
drug O
- O
induced O
ocular O
side O
effects O
, O
oregon O
health O
sciences O
university O
, O
portland O
, O
or O
97201 O
. O

in O
patients O
premedicated O
with O
scopolamine O
+ O
morphine O
( O
+ O
5 O
mg O
nitrazepam O
the O
evening O
before O
surgery O
) O
, O
the O
sleep O
- O
inducing O
effect O
of O
midazolam O
0 O
. O

15 O
mg O
/ O
kg O
i O
. O

v O
. O

was O
clearly O
slower O
in O
onset O
than O
that O
of O
thiopentone O
4 O
. O

67 O
mg O
/ O
kg O
i O
. O

v O
. O

somewhat O
fewer O
cardiovascular O
and O
local O
sequelae O
were O
found O
in O
the O
midazolam O
group O
, O
but O
, O
although O
apnoea B-Disease
occurred O
less O
often O
in O
the O
midazolam O
group O
it O
lasted O
longer O
. O

the O
incidence O
of O
parkinsonism B-Disease
was O
higher O
at O
higher O
doses O
of O
haloperidol O
and O
in O
younger O
patients O
. O

however O
, O
these O
medications O
were O
more O
effective O
in O
both O
young O
and O
old O
patients O
when O
given O
after O
parkinsonism B-Disease
developed O
. O

akathisia B-Disease
was O
controlled O
by O
the O
benzodiazepine O
lorazepam O
in O
14 O
out O
of O
16 O
patients O
, O
while O
prophylactic O
antiparkinsonians O
were O
ineffective O
. O

deaths O
from O
local O
anesthetic O
- O
induced O
convulsions B-Disease
in O
mice O
. O

median O
convulsant O
( O
cd50 O
) O
and O
median O
lethal O
( O
ld50 O
) O
doses O
of O
three O
representative O
local O
anesthetics O
were O
determined O
in O
adult O
mice O
to O
evaluate O
the O
threat O
to O
life O
of O
local O
anesthetic O
- O
induced O
convulsions B-Disease
. O

convulsions B-Disease
always O
preceded O
death O
, O
except O
after O
precipitous O
cardiopulmonary B-Disease
arrest I-Disease
from O
extreme O
doses O
. O

a O
cd50 O
dose O
of O
local O
anesthetic O
( O
causing O
convulsions B-Disease
in O
50 O
% O
of O
mice O
) O
was O
fatal O
in O
90 O
% O
of O
bupivacaine O
- O
induced O
seizures B-Disease
, O
in O
57 O
% O
of O
the O
chloroprocaine O
group O
, O
and O
in O
6 O
% O
of O
the O
lidocaine O
group O
. O

the O
narrow O
gap O
between O
convulsant O
and O
lethal O
doses O
of O
local O
anesthetics O
indicates O
that O
untreated O
convulsions B-Disease
present O
much O
more O
of O
a O
threat O
to O
life O
than O
heretofore O
appreciated O
. O

rem B-Disease
sleep I-Disease
deprivation I-Disease
changes O
behavioral O
response O
to O
catecholaminergic O
and O
serotonergic O
receptor O
activation O
in O
rats O
. O

the O
effects O
of O
rem B-Disease
sleep I-Disease
deprivation I-Disease
( O
remd B-Disease
) O
on O
apomorphine O
- O
induced O
aggressiveness B-Disease
and O
quipazine O
- O
induced O
head B-Disease
twitches I-Disease
in O
rats O
were O
determined O
. O

forty O
- O
eight O
hr O
of O
remd B-Disease
increased O
apomorphine O
- O
induced O
aggressiveness B-Disease
, O
and O
reduced O
( O
immediately O
after O
completing O
of O
remd B-Disease
) O
or O
increased O
( O
96 O
hr O
after O
completing O
of O
remd B-Disease
) O
quipazine O
- O
induced O
head B-Disease
twitches I-Disease
. O

fatal O
aplastic B-Disease
anemia I-Disease
due O
to O
indomethacin O
- O
- O
lymphocyte O
transformation O
tests O
in O
vitro O
. O

although O
indomethacin O
has O
been O
implicated O
as O
a O
possible O
cause O
of O
aplastic B-Disease
anemia I-Disease
on O
the O
basis O
of O
a O
few O
clinical O
observations O
, O
its O
role O
has O
not O
been O
definitely O
established O
. O

a O
case O
of O
fatal O
aplastic B-Disease
anemia I-Disease
is O
described O
in O
which O
no O
drugs O
other O
than O
allopurinol O
and O
indomethacin O
were O
given O
. O

a O
positive O
lymphocyte O
transformation O
test O
with O
indomethacin O
in O
vitro O
further O
substantiates O
the O
potential O
role O
of O
this O
drug O
in O
causing O
aplastic B-Disease
anemia I-Disease
in O
a O
susceptible O
patient O
. O

dose O
- O
effect O
and O
structure O
- O
function O
relationships O
in O
doxorubicin O
cardiomyopathy B-Disease
. O

the O
cardiomyopathy B-Disease
( O
cm B-Disease
) O
produced O
by O
the O
anticancer O
drug O
doxorubicin O
( O
dxr O
) O
( O
adriamycin O
) O
provides O
a O
unique O
opportunity O
to O
analyze O
dose O
- O
effect O
and O
structure O
- O
function O
relationships O
during O
development O
of O
myocardial B-Disease
disease I-Disease
. O

in O
dxr O
- O
cm B-Disease
myocardial B-Disease
damage I-Disease
is O
proportional O
to O
the O
degree O
of O
cytotoxic O
insult O
( O
dxr O
dose O
) O
while O
myocardial O
function O
is O
preserved O
until O
a O
critical O
dose O
or O
degree O
of O
damage O
is O
reached O
, O
after O
which O
myocardial O
performance O
deteriorates O
rapidly O
. O

massive O
cerebral B-Disease
edema I-Disease
associated O
with O
fulminant O
hepatic B-Disease
failure I-Disease
in O
acetaminophen O
overdose B-Disease
: O
possible O
role O
of O
cranial O
decompression O
. O

cerebral B-Disease
edema I-Disease
may O
complicate O
the O
course O
of O
fulminant B-Disease
hepatic I-Disease
failure I-Disease
. O

we O
present O
a O
patient O
with O
fatal O
acetaminophen O
- O
induced O
fulminant B-Disease
hepatic I-Disease
failure I-Disease
, O
with O
signs O
and O
symptoms O
of O
cerebral B-Disease
edema I-Disease
, O
unresponsive O
to O
conventional O
medical O
therapy O
. O

subjective O
assessment O
of O
sexual B-Disease
dysfunction I-Disease
of O
patients O
on O
long O
- O
term O
administration O
of O
digoxin O
. O

the O
patients O
of O
the O
study O
and O
control O
group O
( O
without O
digoxin O
) O
were O
of O
similar O
cardiac O
functional O
capacity O
and O
age O
( O
25 O
- O
40 O
years O
) O
and O
were O
randomly O
selected O
from O
the O
rheumatic B-Disease
heart I-Disease
disease I-Disease
patients O
. O

tests O
used O
to O
evaluate O
the O
changes O
in O
sexual O
behavior O
showed O
a O
significant O
decrease B-Disease
in I-Disease
sexual I-Disease
desire I-Disease
, O
sexual O
excitement O
phase O
( O
erection O
) O
, O
and O
frequency O
of O
sexual O
relations O
in O
the O
study O
group O
. O

endometrial B-Disease
carcinoma I-Disease
after O
hodgkin B-Disease
disease I-Disease
in O
childhood O
. O

a O
34 O
- O
year O
- O
old O
patient O
developed O
metastic O
endometrial B-Disease
carcinoma I-Disease
after O
hodgkin B-Disease
disease I-Disease
in O
childhood O
. O

she O
had O
ovarian B-Disease
failure I-Disease
after O
abdominal O
irradiation O
and O
chemotherapy O
for O
hodgkin B-Disease
disease I-Disease
, O
and O
received O
exogenous O
estrogens O
, O
a O
treatment O
implicated O
in O
the O
development O
of O
endometrial B-Disease
cancer I-Disease
in O
menopausal O
women O
. O

young O
women O
on O
replacement O
estrogens O
for O
ovarian B-Disease
failure I-Disease
after O
cancer B-Disease
therapy O
may O
also O
have O
increased O
risk O
of O
endometrial B-Disease
carcinoma I-Disease
and O
should O
be O
examined O
periodically O
. O

polyuria B-Disease
above O
3 O
litres O
/ O
24 O
hours O
was O
found O
in O
10 O
% O
of O
patients O
. O

nephrotoxicity B-Disease
of O
cyclosporin O
a O
and O
fk506 O
: O
inhibition O
of O
calcineurin O
phosphatase O
. O

cyclosporin O
a O
( O
csa O
; O
50 O
mg O
/ O
kg O
) O
and O
fujimycine O
( O
fk506 O
; O
5 O
mg O
/ O
kg O
) O
, O
but O
not O
the O
related O
macrolide O
immunosuppressant O
rapamycin O
( O
5 O
mg O
/ O
kg O
) O
, O
caused O
a O
reduction O
of O
glomerular O
filtration O
rate O
, O
degenerative O
changes O
of O
proximal O
tubular O
epithelium O
, O
and O
hypertrophy B-Disease
of O
the O
juxtaglomerular O
apparatus O
in O
male O
wistar O
rats O
when O
given O
for O
10 O
days O
. O

the O
molecular O
mechanisms O
of O
csa O
and O
fk506 O
toxicity B-Disease
were O
investigated O
. O

these O
results O
suggest O
that O
the O
nephrotoxic B-Disease
effects O
of O
csa O
and O
fk506 O
is O
likely O
mediated O
through O
binding O
to O
renal O
immunophilin O
and O
inhibiting O
calcineurin O
phosphatase O
. O

acute B-Disease
renal I-Disease
failure I-Disease
in O
high O
dose O
carboplatin O
chemotherapy O
. O

carboplatin O
has O
been O
reported O
to O
cause O
acute B-Disease
renal I-Disease
failure I-Disease
when O
administered O
in O
high O
doses O
to O
adult O
patients O
. O

we O
report O
a O
4 O
1 O
/ O
2 O
- O
year O
- O
old O
girl O
who O
was O
treated O
with O
high O
- O
dose O
carboplatin O
for O
metastatic O
parameningeal O
embryonal B-Disease
rhabdomyosarcoma I-Disease
. O

acute B-Disease
renal I-Disease
failure I-Disease
developed O
followed O
by O
a O
slow O
partial O
recovery O
of O
renal O
function O
. O

at O
various O
time O
intervals O
, O
physical O
examination O
and O
blood O
collection O
for O
ex O
vivo O
platelet B-Disease
aggregation I-Disease
and O
determination O
of O
intraplatelet O
camp O
were O
performed O
. O

seven O
out O
of O
12 O
subjects O
experienced O
headache B-Disease
of O
a O
short O
duration O
accompanying O
facial B-Disease
flush I-Disease
in O
one O
and O
nausea B-Disease
in O
one O
, O
especially O
after O
ingestion O
of O
clz O
. O

pravastatin O
- O
associated O
myopathy B-Disease
. O

a O
case O
of O
acute O
inflammatory B-Disease
myopathy I-Disease
associated O
with O
the O
use O
of O
pravastatin O
, O
a O
new O
hydrophilic O
3 O
- O
hydroxy O
- O
3 O
methylglutaril O
coenzyme O
a O
reductase O
inhibitor O
, O
is O
reported O
. O

the O
patient O
, O
a O
69 O
- O
year O
- O
old O
man O
was O
affected O
by O
non B-Disease
- I-Disease
insulin I-Disease
- I-Disease
dependent I-Disease
diabetes I-Disease
mellitus I-Disease
and O
hypertension B-Disease
. O

he O
assumed O
pravastatin O
( O
20 O
mg O
/ O
day O
) O
because O
of O
hypercholesterolemia B-Disease
. O

he O
was O
admitted O
with O
acute O
myopathy B-Disease
of O
the O
lower O
limbs O
which O
resolved O
in O
a O
few O
days O
after O
pravastatin O
discontinuation O
. O

a O
previously O
unknown O
hypothyroidism B-Disease
, O
probably O
due O
to O
chronic O
autoimmune B-Disease
thyroiditis I-Disease
, O
was O
evidenced O
. O

while O
lovastatin O
and O
simvastatin O
have O
been O
associated O
with O
toxic O
myopathy B-Disease
, O
pravastatin O
- O
associated O
myopathy B-Disease
could O
represent O
a O
distinct O
, O
inflammatory O
entity O
. O

reversal O
of O
ammonia O
coma B-Disease
in O
rats O
by O
l O
- O
dopa O
: O
a O
peripheral O
effect O
. O

ammonia O
coma B-Disease
was O
produced O
in O
rats O
within O
10 O
to O
15 O
minutes O
of O
an O
intraperitonealinjection O
of O
1 O
. O

7 O
mmol O
nh4cl O
. O

this O
coma B-Disease
was O
prevented O
with O
1 O
. O

68 O
mmol O
l O
- O
dopa O
given O
by O
gastric O
intubation O
15 O
minutes O
before O
the O
ammonium O
salt O
injection O
. O

intraventricular O
infusion O
of O
dopamine O
sufficient O
to O
raise O
the O
brain O
dopamine O
to O
the O
same O
extent O
did O
not O
prevent O
the O
ammonia O
coma B-Disease
nor O
affect O
the O
blood O
and O
brain O
ammonia O
concentrations O
. O

bilateral O
nephrectomy O
eliminated O
the O
beneficial O
effect O
of O
l O
- O
dopa O
on O
blood O
and O
brain O
ammonia O
and O
the O
ammonia O
coma B-Disease
was O
not O
prevented O
. O

thus O
, O
the O
reduction O
in O
blood O
and O
brain O
ammonia O
and O
the O
prevention O
of O
ammonia O
coma B-Disease
after O
l O
- O
dopa O
, O
can O
be O
accounted O
for O
by O
the O
peripheral O
effect O
of O
dopamine O
on O
renal O
function O
rather O
than O
its O
central O
action O
. O

these O
results O
provide O
a O
reasonable O
explanation O
for O
the O
beneficial O
effects O
observed O
in O
some O
encephalopathic B-Disease
patients O
receiving O
l O
- O
dopa O
. O

etoposide O
- O
related O
myocardial B-Disease
infarction I-Disease
. O

the O
occurrence O
of O
a O
myocardial B-Disease
infarction I-Disease
is O
reported O
after O
chemotherapy O
containing O
etoposide O
, O
in O
a O
man O
with O
no O
risk O
factors O
for O
coronary B-Disease
heart I-Disease
disease I-Disease
. O

two O
halogenated O
anesthetics O
, O
enflurane O
and O
isoflurane O
, O
have O
been O
associated O
with O
an O
allergic O
- O
type O
hepatic B-Disease
injury I-Disease
both O
alone O
and O
following O
previous O
exposure O
to O
halothane O
. O

halothane O
hepatitis B-Disease
appears O
to O
involve O
an O
aberrant O
immune O
response O
. O

an O
antibody O
response O
to O
a O
protein O
- O
bound O
biotransformation O
product O
( O
trifluoroacetyl O
adduct O
) O
has O
been O
detected O
on O
halothane O
hepatitis B-Disease
patients O
. O

this O
study O
was O
performed O
to O
determine O
cross O
- O
reactivity O
between O
enflurane O
and O
isoflurane O
with O
the O
hypersensitivity B-Disease
induced O
by O
halothane O
. O

this O
supports O
and O
extends O
previous O
evidence O
for O
a O
mechanism O
by O
which O
enflurane O
and O
/ O
or O
isoflurane O
could O
produce O
a O
hypersensitivity B-Disease
condition O
similar O
to O
that O
of O
halothane O
hepatitis B-Disease
either O
alone O
or O
subsequent O
to O
halothane O
administration O
. O

cholinergic O
toxicity B-Disease
resulting O
from O
ocular O
instillation O
of O
echothiophate O
iodide O
eye O
drops O
. O

a O
patient O
developed O
a O
severe O
cholinergic O
syndrome O
from O
the O
use O
of O
echothiophate O
iodide O
ophthalmic O
drops O
, O
presented O
with O
profound O
muscle B-Disease
weakness I-Disease
and O
was O
initially O
given O
the O
diagnosis O
of O
myasthenia B-Disease
gravis I-Disease
. O

seizure B-Disease
after O
flumazenil O
administration O
in O
a O
pediatric O
patient O
. O

flumazenil O
is O
a O
benzodiazepine O
receptor O
antagonist O
used O
to O
reverse O
sedation O
and O
respiratory B-Disease
depression I-Disease
induced O
by O
benzodiazepines O
. O

seizures B-Disease
and O
cardiac B-Disease
arrhythmias I-Disease
have O
complicated O
its O
use O
in O
adult O
patients O
. O

overdose B-Disease
patients O
who O
have O
coingested O
tricyclic O
antidepressants O
have O
a O
higher O
risk O
of O
these O
complications O
. O

we O
report O
the O
occurrence O
of O
a O
generalized O
tonic B-Disease
- I-Disease
clonic I-Disease
seizure I-Disease
in O
a O
pediatric O
patient O
following O
the O
administration O
of O
flumazenil O
. O

phase O
i O
trial O
of O
13 O
- O
cis O
- O
retinoic O
acid O
in O
children O
with O
neuroblastoma B-Disease
following O
bone O
marrow O
transplantation O
. O

purpose O
: O
treatment O
of O
neuroblastoma B-Disease
cell O
lines O
with O
13 O
- O
cis O
- O
retinoic O
acid O
( O
cis O
- O
ra O
) O
can O
cause O
sustained O
inhibition O
of O
proliferation O
. O

since O
cis O
- O
ra O
has O
demonstrated O
clinical O
responses O
in O
neuroblastoma B-Disease
patients O
, O
it O
may O
be O
effective O
in O
preventing O
relapse O
after O
cytotoxic O
therapy O
. O

this O
phase O
i O
trial O
was O
designed O
to O
determine O
the O
maximal O
- O
tolerated O
dosage O
( O
mtd O
) O
, O
toxicities B-Disease
, O
and O
pharmacokinetics O
of O
cis O
- O
ra O
administered O
on O
an O
intermittent O
schedule O
in O
children O
with O
neuroblastoma B-Disease
following O
bone O
marrow O
transplantation O
( O
bmt O
) O
. O

the O
dose O
was O
escalated O
from O
100 O
to O
200 O
mg O
/ O
m2 O
/ O
d O
until O
dose O
- O
limiting O
toxicity B-Disease
( O
dlt O
) O
was O
observed O
. O

dose O
- O
limiting O
toxicities B-Disease
in O
six O
of O
nine O
patients O
at O
200 O
mg O
/ O
m2 O
/ O
d O
included O
hypercalcemia B-Disease
( O
n O
= O
3 O
) O
, O
rash B-Disease
( O
n O
= O
2 O
) O
, O
and O
anemia B-Disease
/ O
thrombocytopenia B-Disease
/ O
emesis B-Disease
/ O
rash B-Disease
( O
n O
= O
1 O
) O
. O

all O
toxicities B-Disease
resolved O
after O
cis O
- O
ra O
was O
discontinued O
. O

three O
complete O
responses O
were O
observed O
in O
marrow O
metastases B-Disease
. O

serum O
levels O
known O
to O
be O
effective O
against O
neuroblastoma B-Disease
in O
vitro O
were O
achieved O
at O
this O
dose O
. O

the O
dlt O
included O
hypercalcemia B-Disease
, O
and O
may O
be O
predicted O
by O
serum O
cis O
- O
ra O
levels O
. O

time O
dependence O
of O
plasma O
malondialdehyde O
, O
oxypurines O
, O
and O
nucleosides O
during O
incomplete O
cerebral B-Disease
ischemia I-Disease
in O
the O
rat O
. O

incomplete O
cerebral B-Disease
ischemia I-Disease
( O
30 O
min O
) O
was O
induced O
in O
the O
rat O
by O
bilaterally O
clamping O
the O
common O
carotid O
arteries O
. O

peripheral O
venous O
blood O
samples O
were O
withdrawn O
from O
the O
femoral O
vein O
four O
times O
( O
once O
every O
5 O
min O
) O
before O
ischemia B-Disease
( O
0 O
time O
) O
and O
5 O
, O
15 O
, O
and O
30 O
min O
after O
ischemia B-Disease
. O

during O
ischemia B-Disease
, O
a O
time O
- O
dependent O
increase O
of O
plasma O
oxypurines O
and O
nucleosides O
was O
observed O
. O

plasma O
malondialdehyde O
, O
which O
was O
present O
in O
minimal O
amount O
at O
zero O
time O
( O
0 O
. O

58 O
mumol O
/ O
liter O
plasma O
; O
sd O
0 O
. O

15 O
) O
, O
increased O
after O
5 O
min O
of O
ischemia B-Disease
, O
resulting O
in O
a O
fivefold O
increase O
after O
30 O
min O
of O
carotid O
occlusion O
( O
0 O
. O

298 O
mumol O
/ O
liter O
plasma O
; O
sd O
0 O
. O

78 O
) O
. O

increased O
plasma O
malondialdehyde O
was O
also O
recorded O
in O
two O
other O
groups O
of O
animals O
subjected O
to O
the O
same O
experimental O
model O
, O
one O
receiving O
20 O
mg O
/ O
kg O
b O
. O

w O
. O

of O
the O
cyclooxygenase O
inhibitor O
acetylsalicylate O
intravenously O
immediately O
before O
ischemia B-Disease
, O
the O
other O
receiving O
650 O
micrograms O
/ O
kg O
b O
. O

w O
. O

of O
the O
hypotensive B-Disease
drug O
nitroprusside O
at O
a O
flow O
rate O
of O
103 O
microliters O
/ O
min O
intravenously O
during O
ischemia B-Disease
, O
although O
in O
this O
latter O
group O
malondialdehyde O
was O
significantly O
higher O
. O

the O
present O
data O
indicate O
that O
the O
determination O
of O
malondialdehyde O
, O
oxypurines O
, O
and O
nucleosides O
in O
peripheral O
blood O
, O
may O
be O
used O
to O
monitor O
the O
metabolic O
alterations O
of O
tissues O
occurring O
during O
ischemic B-Disease
phenomena O
. O

( O
abstract O
truncated O
at O
250 O
words O
) O
acute O
renal B-Disease
toxicity I-Disease
of O
doxorubicin O
( O
adriamycin O
) O
- O
loaded O
cyanoacrylate O
nanoparticles O
. O

acute O
doxorubicin O
- O
loaded O
nanoparticle O
( O
dxnp O
) O
renal B-Disease
toxicity I-Disease
was O
explored O
in O
both O
normal O
rats O
and O
rats O
with O
experimental O
glomerulonephritis B-Disease
. O

a O
3 O
times O
higher O
proteinuria B-Disease
appeared O
in O
animals O
treated O
with O
dxnp O
than O
in O
those O
treated O
with O
dx O
. O

free O
np O
did O
not O
provoke O
any O
proteinuria B-Disease
. O

in O
rats O
with O
immune O
experimental O
glomerulonephritis B-Disease
, O
5 O
/ O
6 O
rats O
given O
dx O
died O
within O
7 O
days O
, O
in O
contrast O
to O
animals O
treated O
by O
dxnp O
, O
np O
, O
or O
untreated O
, O
which O
all O
survived O
. O

proteinuria B-Disease
appeared O
in O
all O
series O
, O
but O
was O
2 O
- O
5 O
times O
more O
intense O
( O
p O
> O
0 O
. O

1 O
) O
and O
prolonged O
after O
doxorubicin O
treatment O
( O
400 O
- O
700 O
mg O
/ O
day O
) O
, O
without O
significant O
difference O
between O
dxnp O
and O
dx O
. O

these O
results O
demonstrate O
that O
, O
in O
these O
experimental O
conditions O
, O
dxnp O
killed O
less O
animals O
than O
free O
dx O
, O
despite O
of O
an O
enhanced O
renal B-Disease
toxicity I-Disease
of O
the O
former O
. O

both O
effects O
( O
better O
survival O
and O
nephrosis B-Disease
) O
are O
most O
probably O
related O
to O
an O
enhanced O
capture O
of O
dxnp O
by O
cells O
of O
the O
mononuclear O
phagocyte O
system O
, O
including O
mesangial O
cells O
. O

prostaglandin O
e2 O
- O
induced O
bladder B-Disease
hyperactivity I-Disease
in O
normal O
, O
conscious O
rats O
: O
involvement O
of O
tachykinins O
? O
prostanoids O
may O
, O
via O
release O
of O
tachykinins O
, O
contribute O
to O
both O
urge O
and O
bladder B-Disease
hyperactivity I-Disease
seen O
in O
inflammatory O
conditions O
of O
the O
lower O
urinary O
tract O
. O

refractory O
cardiogenic B-Disease
shock I-Disease
and O
complete O
heart B-Disease
block I-Disease
after O
verapamil O
sr O
and O
metoprolol O
treatment O
. O

a O
seventy O
- O
eight O
- O
year O
- O
old O
woman O
presented O
with O
complete O
heart B-Disease
block I-Disease
and O
refractory O
hypotension B-Disease
two O
days O
after O
a O
therapeutic O
dose O
of O
sustained O
- O
release O
verapamil O
with O
concomitant O
use O
of O
metoprolol O
. O

the O
patient O
continued O
to O
remain O
hypotensive B-Disease
with O
complete O
heart B-Disease
block I-Disease
, O
even O
with O
multiple O
uses O
of O
intravenous O
atropine O
as O
well O
as O
high O
doses O
of O
pressor O
agents O
such O
as O
dopamine O
and O
dobutamine O
. O

however O
, O
shortly O
after O
the O
use O
of O
intravenous O
calcium O
chloride O
, O
the O
refractory O
hypotension B-Disease
and O
complete O
heart B-Disease
block I-Disease
resolved O
. O

protective O
effect O
of O
misoprostol O
on O
indomethacin O
induced O
renal B-Disease
dysfunction I-Disease
in O
elderly O
patients O
. O

response O
to O
treatment O
was O
estimated O
by O
the O
visual O
analog O
scale O
for O
severity O
of O
pain B-Disease
. O

conclusion O
: O
hospitalized O
elderly O
patients O
are O
at O
risk O
for O
developing O
indomethacin O
related O
renal B-Disease
dysfunction I-Disease
. O

addition O
of O
misoprostol O
can O
minimize O
this O
renal B-Disease
impairment I-Disease
without O
affecting O
pain B-Disease
control O
. O

cognitive B-Disease
deterioration I-Disease
from O
long O
- O
term O
abuse O
of O
dextromethorphan O
: O
a O
case O
report O
. O

the O
drug O
is O
known O
to O
cause O
a O
variety O
of O
acute O
toxic O
effects O
, O
ranging O
from O
nausea B-Disease
, O
restlessness B-Disease
, O
insomnia B-Disease
, O
ataxia B-Disease
, O
slurred O
speech O
and O
nystagmus B-Disease
to O
mood O
changes O
, O
perceptual O
alterations O
, O
inattention O
, O
disorientation O
and O
aggressive B-Disease
behavior I-Disease
( O
rammer O
et O
al O
1988 O
; O
katona O
and O
watson O
1986 O
; O
isbell O
and O
fraser O
1953 O
; O
devlin O
et O
al O
1985 O
; O
mccarthy O
1971 O
; O
dodds O
and O
revai O
1967 O
; O
degkwitz O
1964 O
; O
hildebrand O
et O
al O
1989 O
) O
. O

this O
report O
describes O
a O
case O
of O
cognitive B-Disease
deterioration I-Disease
resulting O
from O
prolonged O
use O
of O
dm O
. O

effects O
of O
ouabain O
on O
myocardial O
oxygen O
supply O
and O
demand O
in O
patients O
with O
chronic O
coronary B-Disease
artery I-Disease
disease I-Disease
. O

a O
hemodynamic O
, O
volumetric O
, O
and O
metabolic O
study O
in O
patients O
without O
heart B-Disease
failure I-Disease
. O

the O
effects O
of O
digitalis O
glycosides O
on O
myocardial O
oxygen O
supply O
and O
demand O
are O
of O
particular O
interest O
in O
the O
presence O
of O
obstructive O
coronary B-Disease
artery I-Disease
disease I-Disease
, O
but O
have O
not O
been O
measured O
previously O
in O
man O
. O

we O
assessed O
the O
effects O
of O
ouabain O
( O
0 O
. O

15 O
mg O
/ O
kg O
body O
weight O
) O
on O
hemodynamic O
, O
volumetric O
, O
and O
metabolic O
parameters O
in O
11 O
patients O
with O
severe O
chronic O
coronary B-Disease
artery I-Disease
disease I-Disease
without O
clinical O
congestive B-Disease
heart I-Disease
failure I-Disease
. O

we O
conclude O
that O
in O
patients O
with O
chronic O
coronary B-Disease
artery I-Disease
disease I-Disease
who O
are O
not O
in O
clinical O
congestive B-Disease
heart I-Disease
failure I-Disease
left B-Disease
ventricular I-Disease
end I-Disease
- I-Disease
diastolic I-Disease
volume I-Disease
falls I-Disease
after O
ouabain O
administration O
even O
when O
it O
is O
initially O
normal O
. O

dexamethasone O
- O
induced O
ocular B-Disease
hypertension I-Disease
in O
perfusion O
- O
cultured O
human O
eyes O
. O

purpose O
: O
glucocorticoid O
administration O
can O
lead O
to O
the O
development O
of O
ocular B-Disease
hypertension I-Disease
and O
corticosteroid B-Disease
glaucoma I-Disease
in O
a O
subset O
of O
the O
population O
through O
a O
decrease O
in O
the O
aqueous O
humor O
outflow O
facility O
. O

in O
contrast O
, O
the O
dexamethasone O
- O
treated O
hypertensive B-Disease
eyes I-Disease
had O
thickened O
trabecular O
beams O
, O
decreased O
intertrabecular O
spaces O
, O
thickened O
juxtacanalicular O
tissue O
, O
activated O
trabecular O
meshwork O
cells O
, O
and O
increased O
amounts O
of O
amorphogranular O
extracellular O
material O
, O
especially O
in O
the O
juxtacanalicular O
tissue O
and O
beneath O
the O
endothelial O
lining O
of O
the O
canal O
of O
schlemm O
. O

conclusion O
: O
dexamethasone O
treatment O
of O
isolated O
, O
perfusion O
- O
cultured O
human O
eyes O
led O
to O
the O
generation O
of O
ocular B-Disease
hypertension I-Disease
in O
approximately O
30 O
% O
of O
the O
dexamethasone O
- O
treated O
eyes O
. O

steroid O
treatment O
resulted O
in O
morphologic O
changes O
in O
the O
trabecular O
meshwork O
similar O
to O
those O
reported O
for O
corticosteroid B-Disease
glaucoma I-Disease
and O
open B-Disease
angle I-Disease
glaucoma I-Disease
. O

this O
system O
may O
provide O
an O
acute O
model O
in O
which O
to O
study O
the O
pathogenic O
mechanisms O
involved O
in O
steroid B-Disease
glaucoma I-Disease
and O
primary B-Disease
open I-Disease
angle I-Disease
glaucoma I-Disease
. O

in O
four O
patients O
hearing B-Disease
impairment I-Disease
on O
the O
side O
of O
the O
block O
was O
demonstrated O
after O
operation O
, O
in O
three O
measurements O
on O
the O
day O
of O
surgery O
and O
in O
one O
on O
the O
following O
day O
. O

ibpb O
may O
cause O
transient O
auditory B-Disease
dysfunction I-Disease
in O
the O
ipsilateral O
ear O
, O
possibly O
via O
an O
effect O
on O
sympathetic O
innervation O
. O

the O
safety O
and O
efficacy O
of O
combination O
n O
- O
butyl O
- O
deoxynojirimycin O
( O
sc O
- O
48334 O
) O
and O
zidovudine O
in O
patients O
with O
hiv B-Disease
- I-Disease
1 I-Disease
infection I-Disease
and O
200 O
- O
500 O
cd4 O
cells O
/ O
mm3 O
. O

the O
mean O
sc O
- O
48334 O
steady O
- O
state O
trough O
level O
( O
4 O
. O

4 O
+ O
/ O
- O
0 O
. O

99 O
micrograms O
/ O
ml O
) O
was O
below O
the O
in O
vitro O
inhibitory O
concentration O
for O
human O
immunodeficiency B-Disease
virus O
( O
hiv O
) O
. O

diarrhea B-Disease
, O
flatulence B-Disease
, O
abdominal B-Disease
pain I-Disease
, O
and O
weight B-Disease
loss I-Disease
were O
common O
for O
combination O
recipients O
. O

( O
abstract O
truncated O
at O
250 O
words O
) O
prolonged O
paralysis B-Disease
due O
to O
nondepolarizing O
neuromuscular O
blocking O
agents O
and O
corticosteroids O
. O

the O
long O
- O
term O
use O
of O
nondepolarizing O
neuromuscular O
blocking O
agents O
( O
nd O
- O
nmba O
) O
has O
recently O
been O
implicated O
as O
a O
cause O
of O
prolonged O
muscle B-Disease
weakness I-Disease
, O
although O
the O
site O
of O
the O
lesion O
and O
the O
predisposing O
factors O
have O
been O
unclear O
. O

we O
report O
3 O
patients O
( O
age O
37 O
- O
52 O
years O
) O
with O
acute O
respiratory B-Disease
insufficiency I-Disease
who O
developed O
prolonged O
weakness B-Disease
following O
the O
discontinuation O
of O
nd O
- O
nmbas O
. O

renal O
function O
was O
normal O
but O
hepatic O
function O
was O
impaired O
in O
all O
patients O
, O
and O
all O
had O
acidosis B-Disease
. O

a O
muscle O
biopsy O
in O
this O
patient O
showed O
loss B-Disease
of I-Disease
thick I-Disease
, I-Disease
myosin I-Disease
filaments I-Disease
. O

the O
weakness B-Disease
in O
these O
patients O
is O
due O
to O
pathology B-Disease
at I-Disease
both I-Disease
the I-Disease
neuromuscular I-Disease
junction I-Disease
( O
most O
likely O
due O
to O
nd O
- O
nmba O
) O
and O
muscle O
( O
most O
likely O
due O
to O
corticosteroids O
) O
. O

hepatic B-Disease
dysfunction I-Disease
and O
acidosis B-Disease
are O
contributing O
risk O
factors O
. O

failure O
of O
ancrod O
in O
the O
treatment O
of O
heparin O
- O
induced O
arterial O
thrombosis B-Disease
. O

the O
morbidity O
and O
mortality O
associated O
with O
heparin O
- O
induced O
thrombosis B-Disease
remain O
high O
despite O
numerous O
empirical O
therapies O
. O

ancrod O
has O
been O
used O
successfully O
for O
prophylaxis O
against O
development O
of O
thrombosis B-Disease
in O
patients O
with O
heparin O
induced O
platelet B-Disease
aggregation I-Disease
who O
require O
brief O
reexposure O
to O
heparin O
, O
but O
its O
success O
in O
patients O
who O
have O
developed O
the O
thrombosis B-Disease
syndrome O
is O
not O
well O
defined O
. O

the O
authors O
present O
a O
case O
of O
failure O
of O
ancrod O
treatment O
in O
a O
patient O
with O
heparin O
- O
induced O
thrombosis B-Disease
. O

water B-Disease
intoxication I-Disease
associated O
with O
oxytocin O
administration O
during O
saline O
- O
induced O
abortion B-Disease
. O

four O
cases O
of O
water B-Disease
intoxication I-Disease
in O
connection O
with O
oxytocin O
administration O
during O
saline O
- O
induced O
abortions B-Disease
are O
described O
. O

the O
mechanism O
of O
water B-Disease
intoxication I-Disease
is O
discussed O
in O
regard O
to O
these O
cases O
. O

oxytocin O
administration O
during O
midtrimester O
- O
induced O
abortions B-Disease
is O
advocated O
only O
if O
it O
can O
be O
carried O
out O
under O
careful O
observations O
of O
an O
alert O
nursing O
staff O
, O
aware O
of O
the O
symptoms O
of O
water B-Disease
intoxication I-Disease
and O
instructed O
to O
watch O
the O
diuresis O
and O
report O
such O
early O
signs O
of O
the O
syndrome O
as O
asthenia B-Disease
, O
muscular O
irritability B-Disease
, O
or O
headaches B-Disease
. O

light O
chain O
proteinuria B-Disease
and O
cellular O
mediated O
immunity O
in O
rifampin O
treated O
patients O
with O
tuberculosis B-Disease
. O

light O
chain O
proteinuria B-Disease
was O
found O
in O
9 O
of O
17 O
tuberculosis B-Disease
patients O
treated O
with O
rifampin O
. O

response O
to O
varidase O
skin O
test O
antigen O
was O
negative O
for O
all O
eight O
tuberculosis B-Disease
patients O
tested O
, O
but O
there O
occurred O
a O
hyper O
- O
responsiveness O
of O
the O
lymphocytes O
of O
these O
eight O
patients O
to O
phytomitogen O
( O
pha O
- O
p O
) O
. O

as O
well O
as O
of O
those O
of O
seven O
other O
tuberculous B-Disease
patients O
. O

oral O
administration O
of O
kf17837 O
( O
2 O
. O

5 O
, O
10 O
. O

0 O
and O
30 O
. O

0 O
mg O
/ O
kg O
) O
significantly O
ameliorated O
the O
cataleptic B-Disease
responses O
induced O
by O
intracerebroventricular O
administration O
of O
an O
adenosine O
a2a O
receptor O
agonist O
, O
cgs O
21680 O
( O
10 O
micrograms O
) O
, O
in O
a O
dose O
- O
dependent O
manner O
. O

kf17837 O
also O
reduced O
the O
catalepsy B-Disease
induced O
by O
haloperidol O
( O
1 O
mg O
/ O
kg O
i O
. O

p O
. O

) O
and O
by O
reserpine O
( O
5 O
mg O
/ O
kg O
i O
. O

p O
. O

) O
. O

furthermore O
, O
kf17837 O
may O
be O
a O
useful O
drug O
in O
the O
treatment O
of O
parkinsonism B-Disease
. O

effect O
of O
nondopaminergic O
drugs O
on O
l O
- O
dopa O
- O
induced O
dyskinesias B-Disease
in O
mptp O
- O
treated O
monkeys O
. O

a O
group O
of O
four O
monkeys O
was O
rendered O
parkinsonian B-Disease
with O
the O
toxin O
mptp O
. O

this O
dose O
produced O
a O
striking O
antiparkinsonian O
effect O
, O
but O
all O
animals O
manifested O
dyskinesia B-Disease
. O

a O
series O
of O
agents O
acting O
primarily O
on O
neurotransmitters O
other O
than O
dopamine O
were O
then O
tested O
in O
combination O
with O
l O
- O
dopa O
to O
see O
if O
the O
dyskinetic B-Disease
movements O
would O
be O
modified O
. O

several O
drugs O
, O
including O
clonidine O
, O
physostigmine O
, O
methysergide O
, O
5 O
- O
mdot O
, O
propranolol O
, O
and O
mk O
- O
801 O
, O
markedly O
reduced O
the O
dyskinetic B-Disease
movements O
but O
at O
the O
cost O
of O
a O
return O
of O
parkinsonian B-Disease
symptomatology O
. O

however O
, O
yohimbine O
and O
meperidine O
reduced O
predominantly O
the O
dyskinetic B-Disease
movements O
. O

baclofen O
was O
also O
useful O
in O
one O
monkey O
against O
a O
more O
dystonic B-Disease
form O
of O
dyskinesia B-Disease
. O

atropine O
converted O
the O
dystonic B-Disease
movements O
into O
chorea B-Disease
. O

hallucinations B-Disease
and O
ifosfamide O
- O
induced O
neurotoxicity B-Disease
. O

background O
: O
hallucinations B-Disease
as O
a O
symptom O
of O
central O
neurotoxicity B-Disease
are O
a O
known O
but O
poorly O
described O
side O
effect O
of O
ifosfamide O
. O

most O
cases O
of O
ifosfamide O
- O
induced O
hallucinations B-Disease
have O
been O
reported O
with O
other O
mental O
status O
changes O
. O

methods O
: O
the O
authors O
interviewed O
six O
persons O
with O
ifosfamide O
- O
induced O
hallucinations B-Disease
in O
the O
presence O
of O
a O
clear O
sensorium O
. O

results O
: O
hallucinations B-Disease
occurred O
only O
when O
the O
patient O
' O
s O
eyes O
were O
closed O
and O
, O
in O
all O
but O
one O
case O
, O
were O
reported O
as O
disturbing O
or O
frightening O
. O

underreporting O
of O
these O
hallucinations B-Disease
by O
patients O
is O
likely O
. O

conclusions O
: O
hallucinations B-Disease
may O
be O
the O
sole O
or O
first O
manifestation O
of O
neurotoxicity B-Disease
. O

the O
clinician O
should O
be O
alerted O
for O
possible O
ifosfamide O
- O
induced O
hallucinations B-Disease
, O
which O
may O
occur O
without O
other O
signs O
of O
neurotoxicity B-Disease
. O

nan O
eyes O
- O
closed O
nan O
hallucinatory B-Disease
experiences O
appear O
to O
be O
an O
unusual O
feature O
of O
this O
presentation O
. O

if O
agitation B-Disease
becomes O
marked O
, O
high O
- O
potency O
neuroleptics O
( O
i O
. O

e O
. O

, O
haloperidol O
) O
may O
be O
effective O
. O

photodistributed O
nifedipine O
- O
induced O
facial O
telangiectasia B-Disease
. O

five O
months O
after O
starting O
nifedipine O
( O
adalat O
) O
, O
two O
patients O
developed O
photodistributed O
facial O
telangiectasia B-Disease
, O
which O
became O
more O
noticeable O
with O
time O
. O

neither O
patient O
complained O
of O
photosensitivity O
or O
flushing B-Disease
. O

one O
commenced O
the O
closely O
related O
drug O
amlodipine O
3 O
years O
later O
, O
with O
recurrence O
of O
telangiectasia B-Disease
. O

the O
photodistribution O
of O
the O
telangiectasia B-Disease
suggests O
a O
significant O
drug O
/ O
light O
interaction O
. O

penicillamine O
- O
induced O
rapidly O
progressive O
glomerulonephritis B-Disease
in O
a O
patient O
with O
rheumatoid B-Disease
arthritis I-Disease
. O

a O
67 O
- O
year O
- O
old O
woman O
with O
rheumatoid B-Disease
arthritis I-Disease
presented O
rapidly O
progressive O
glomerulonephritis B-Disease
( O
rpgn B-Disease
) O
after O
5 O
months O
of O
d O
- O
penicillamine O
( O
250 O
mg O
/ O
day O
) O
treatment O
. O

light O
microscopy O
study O
showed O
severe O
glomerulonephritis B-Disease
with O
crescent O
formation O
in O
60 O
% O
of O
the O
glomeruli O
and O
infiltration O
of O
inflammatory O
cells O
in O
the O
wall O
of O
an O
arteriole O
. O

this O
new O
case O
of O
rpgn B-Disease
in O
the O
course O
of O
d O
- O
penicillamine O
treatment O
emphasizes O
the O
need O
for O
frequent O
monitoring O
of O
renal O
function O
and O
evaluation O
of O
urinary O
sediment O
and O
proteinuria B-Disease
in O
these O
patients O
. O

a O
case O
of O
polymyositis B-Disease
in O
a O
patient O
with O
primary B-Disease
biliary I-Disease
cirrhosis I-Disease
treated O
with O
d O
- O
penicillamine O
. O

although O
d O
- O
penicillamine O
has O
been O
used O
for O
many O
rheumatologic B-Disease
diseases I-Disease
, O
toxicity B-Disease
limits O
its O
usefulness O
in O
many O
patients O
. O

polymyositis B-Disease
/ O
dermatomyositis B-Disease
can O
develop O
as O
one O
of O
the O
autoimmune O
complications O
of O
d O
- O
penicillamine O
treatment O
, O
but O
its O
exact O
pathogenesis O
remains O
unclear O
. O

we O
report O
a O
patient O
with O
primary B-Disease
biliary I-Disease
cirrhosis I-Disease
, O
who O
developed O
polymyositis B-Disease
while O
receiving O
d O
- O
penicillamine O
therapy O
. O

patients O
receiving O
d O
- O
penicillamine O
therapy O
should O
be O
followed O
carefully O
for O
the O
development O
of O
autoimmune O
complications O
like O
polymyositis B-Disease
/ O
dermatomyositis B-Disease
. O

hyperalgesia B-Disease
and O
myoclonus B-Disease
in O
terminal O
cancer B-Disease
patients O
treated O
with O
continuous O
intravenous O
morphine O
. O

eight O
cancer B-Disease
patients O
in O
the O
terminal O
stages O
of O
the O
disease O
treated O
with O
high O
doses O
of O
intravenous O
morphine O
developed O
hyperalgesia B-Disease
. O

five O
patients O
developed O
universal O
hyperalgesia B-Disease
and O
hyperesthesia B-Disease
which O
in O
2 O
cases O
were O
accompanied O
by O
myoclonus B-Disease
. O

in O
3 O
patients O
a O
pre O
- O
existing O
neuralgia B-Disease
increased O
to O
excruciating O
intensity O
and O
in O
2 O
of O
these O
cases O
myoclonus B-Disease
occurred O
simultaneously O
. O

although O
only O
few O
clinical O
descriptions O
of O
the O
relationship O
between O
hyperalgesia B-Disease
/ O
myoclonus B-Disease
and O
high O
doses O
of O
morphine O
are O
available O
, O
experimental O
support O
from O
animal O
studies O
indicates O
that O
morphine O
, O
or O
its O
metabolites O
, O
plays O
a O
causative O
role O
for O
the O
observed O
behavioural O
syndrome O
. O

liposomal O
daunorubicin O
in O
advanced O
kaposi B-Disease
' I-Disease
s I-Disease
sarcoma I-Disease
: O
a O
phase O
ii O
study O
. O

we O
report O
a O
non O
- O
randomized O
phase O
ii O
clinical O
trial O
to O
assess O
the O
efficacy O
and O
safety O
of O
liposomal O
daunorubicin O
( O
daunoxome O
) O
in O
the O
treatment O
of O
aids B-Disease
related O
kaposi B-Disease
' I-Disease
s I-Disease
sarcoma I-Disease
. O

eleven O
homosexual O
men O
with O
advanced O
kaposi B-Disease
' I-Disease
s I-Disease
sarcoma I-Disease
were O
entered O
in O
the O
trial O
. O

changes O
in O
size O
, O
colour O
and O
associated O
oedema B-Disease
of O
selected O
' O
target O
' O
lesions O
were O
measured O
. O

clinical O
, O
biochemical O
and O
haematological O
toxicities B-Disease
were O
assessed O
. O

stabilization O
of O
kaposi B-Disease
' I-Disease
s I-Disease
sarcoma I-Disease
occurred O
in O
the O
remaining O
six O
, O
maintained O
until O
the O
end O
of O
the O
trial O
period O
in O
four O
. O

the O
drug O
was O
generally O
well O
tolerated O
, O
with O
few O
mild O
symptoms O
of O
toxicity B-Disease
. O

the O
main O
problem O
encountered O
was O
haematological O
toxicity B-Disease
, O
with O
three O
subjects O
experiencing O
severe O
neutropenia B-Disease
( O
neutrophil O
count O
< O
0 O
. O

5 O
x O
10 O
( O
9 O
) O
/ O
l O
) O
. O

there O
was O
no O
evidence O
of O
cardiotoxicity B-Disease
. O

in O
this O
small O
patient O
sample O
, O
liposomal O
daunorubicin O
was O
an O
effective O
and O
well O
tolerated O
agent O
in O
the O
treatment O
of O
kaposi B-Disease
' I-Disease
s I-Disease
sarcoma I-Disease
. O

forty O
patients O
with O
non B-Disease
- I-Disease
hodgkin I-Disease
' I-Disease
s I-Disease
lymphoma I-Disease
treated O
with O
vincristine O
between O
1984 O
and O
1990 O
( O
cumulative O
dose O
12 O
mg O
in O
18 O
- O
24 O
weeks O
) O
were O
investigated O
in O
order O
to O
evaluate O
the O
long O
term O
effects O
of O
vincristine O
on O
the O
peripheral O
nervous O
system O
. O

the O
patients O
were O
interviewed O
with O
emphasis O
on O
neuropathic B-Disease
symptoms I-Disease
. O

twenty O
- O
seven O
patients O
reported O
neuropathic B-Disease
symptoms I-Disease
. O

it O
is O
concluded O
that O
with O
the O
above O
mentioned O
vincristine O
dose O
schedule O
signs O
and O
symptoms O
of O
vincristine O
neuropathy B-Disease
are O
reversible O
for O
a O
great O
deal O
and O
prognosis O
is O
fairly O
good O
. O

hepatic O
adenomas B-Disease
and O
focal B-Disease
nodular I-Disease
hyperplasia I-Disease
of O
the O
liver O
in O
young O
women O
on O
oral O
contraceptives O
: O
case O
reports O
. O

two O
cases O
of O
hepatic O
adenoma B-Disease
and O
one O
of O
focal B-Disease
nodular I-Disease
hyperplasia I-Disease
presumably O
associated O
with O
the O
use O
of O
oral O
contraceptives O
, O
are O
reported O
. O

histologic O
differences O
and O
clinical O
similarities O
between O
hepatic O
adenoma B-Disease
and O
focal B-Disease
nodular I-Disease
hyperplasia I-Disease
of O
the O
liver O
are O
discussed O
. O

loss O
of O
glutamate O
decarboxylase O
mrna O
- O
containing O
neurons O
in O
the O
rat O
dentate O
gyrus O
following O
pilocarpine O
- O
induced O
seizures B-Disease
. O

in O
situ O
hybridization O
methods O
were O
used O
to O
determine O
if O
glutamic O
acid O
decarboxylase O
( O
gad O
) O
mrna O
- O
containing O
neurons O
within O
the O
hilus O
of O
the O
dentate O
gyrus O
are O
vulnerable O
to O
seizure B-Disease
- O
induced O
damage O
in O
a O
model O
of O
chronic O
seizures B-Disease
. O

sprague O
- O
dawley O
rats O
were O
injected O
intraperitoneally O
with O
pilocarpine O
, O
and O
the O
hippocampal O
formation O
was O
studied O
histologically O
at O
1 O
, O
2 O
, O
4 O
, O
and O
8 O
week O
intervals O
after O
pilocarpine O
- O
induced O
seizures B-Disease
. O

additional O
neuronanatomical O
studies O
, O
including O
cresyl O
violet O
staining O
, O
neuronal B-Disease
degeneration I-Disease
methods O
, O
and O
histochemical O
localization O
of O
glial O
fibrillary O
acidic O
protein O
, O
suggested O
that O
the O
decrease O
in O
the O
number O
of O
gad O
mrna O
- O
containing O
neurons O
was O
related O
to O
neuronal B-Disease
loss I-Disease
rather O
than O
to O
a O
decrease O
in O
gad O
mrna O
levels O
. O

the O
results O
indicate O
that O
, O
in O
this O
model O
, O
a O
subpopulation O
of O
gad O
mrna O
- O
containing O
neurons O
within O
the O
dentate O
gyrus O
is O
selectively O
vulnerable O
to O
seizure B-Disease
- O
induced O
damage O
. O

effects O
of O
deliberate O
hypotension B-Disease
induced O
by O
labetalol O
with O
isoflurane O
on O
neuropsychological O
function O
. O

the O
effect O
of O
deliberate O
hypotension B-Disease
on O
brain O
function O
measured O
by O
neuropsychological O
tests O
was O
studied O
in O
41 O
adult O
patients O
. O

twenty O
- O
four O
patients O
were O
anaesthetized O
for O
middle O
- O
ear O
surgery O
with O
deliberate O
hypotension B-Disease
induced O
by O
labetalol O
with O
isoflurane O
( O
hypotensive B-Disease
group O
) O
. O

seventeen O
patients O
without O
hypotension B-Disease
served O
as O
a O
control O
group O
. O

the O
mean O
arterial O
pressure O
was O
77 O
+ O
/ O
- O
2 O
mmhg O
( O
10 O
. O

3 O
+ O
/ O
- O
0 O
. O

3 O
kpa O
) O
before O
hypotension B-Disease
and O
50 O
+ O
/ O
- O
0 O
mmhg O
( O
6 O
. O

7 O
+ O
/ O
- O
0 O
. O

0 O
kpa O
) O
during O
hypotension B-Disease
in O
the O
hypotensive B-Disease
group O
, O
and O
86 O
+ O
/ O
- O
2 O
mmhg O
( O
11 O
. O

5 O
+ O
/ O
- O
0 O
. O

3 O
kpa O
) O
during O
anaesthesia O
in O
the O
control O
group O
. O

the O
following O
psychological O
tests O
were O
performed O
: O
four O
subtests O
of O
the O
wechsler O
adult O
intelligence O
scale O
( O
similarities O
, O
digit O
span O
, O
vocabulary O
and O
digit O
symbol O
) O
, O
trail O
- O
making O
tests O
a O
and O
b O
, O
zung O
tests O
( O
self O
- O
rating O
anxiety B-Disease
scale O
and O
self O
- O
rating O
depression B-Disease
scale O
) O
and O
two O
- O
part O
memory O
test O
battery O
with O
immediate O
and O
delayed O
recall O
. O

the O
results O
indicate O
that O
hypotension B-Disease
induced O
by O
labetalol O
with O
isoflurane O
has O
no O
significant O
harmful O
effects O
on O
mental O
functions O
compared O
to O
normotensive O
anaesthesia O
. O

apparent O
cure O
of O
rheumatoid B-Disease
arthritis I-Disease
by O
bone O
marrow O
transplantation O
. O

we O
describe O
the O
induction O
of O
sustained O
remissions O
and O
possible O
cure O
of O
severe O
erosive O
rheumatoid B-Disease
arthritis I-Disease
( O
ra B-Disease
) O
by O
bone O
marrow O
transplantation O
( O
bmt O
) O
in O
2 O
patients O
. O

bmt O
was O
used O
to O
treat O
severe O
aplastic B-Disease
anemia I-Disease
which O
was O
caused O
by O
gold O
in O
one O
case O
and O
d O
- O
penicillamine O
in O
the O
other O
. O

in O
the O
8 O
and O
6 O
years O
since O
the O
transplants O
( O
representing O
8 O
and O
4 O
years O
since O
cessation O
of O
all O
immunosuppressive O
therapy O
, O
respectively O
) O
, O
the O
ra B-Disease
in O
each O
case O
has O
been O
completely O
quiescent O
. O

although O
short O
term O
remission O
of O
severe O
ra B-Disease
following O
bmt O
has O
been O
reported O
, O
these O
are O
the O
first O
cases O
for O
which O
prolonged O
followup O
has O
been O
available O
. O

this O
experience O
raises O
the O
question O
of O
the O
role O
of O
bmt O
itself O
as O
a O
therapeutic O
option O
for O
patients O
with O
uncontrolled O
destructive O
synovitis B-Disease
. O

seizures B-Disease
induced O
by O
combined O
levomepromazine O
- O
fluvoxamine O
treatment O
. O

we O
report O
a O
case O
of O
combined O
levomepromazine O
- O
fluvoxamine O
treatment O
- O
induced O
seizures B-Disease
. O

case O
report O
: O
pentamidine O
and O
polymorphic O
ventricular B-Disease
tachycardia I-Disease
revisited O
. O

pentamidine O
isethionate O
has O
been O
associated O
with O
ventricular B-Disease
tachyarrhythmias I-Disease
, O
including O
torsade B-Disease
de I-Disease
pointes I-Disease
. O

pentamidine O
- O
induced O
torsade B-Disease
de I-Disease
pointes I-Disease
may O
be O
related O
to O
serum O
magnesium O
levels O
and O
hypomagnesemia B-Disease
may O
synergistically O
induce O
torsade O
. O

torsade B-Disease
de I-Disease
pointes I-Disease
occurred O
after O
an O
average O
of O
10 O
days O
of O
treatment O
with O
pentamidine O
. O

torsade B-Disease
de I-Disease
pointes I-Disease
can O
be O
treated O
when O
recognized O
early O
, O
possibly O
without O
discontinuation O
of O
pentamidine O
. O

when O
qtc B-Disease
interval I-Disease
prolongation I-Disease
is O
observed O
, O
early O
magnesium O
supplementation O
is O
advocated O
. O

efficacy O
and O
tolerability O
of O
lovastatin O
in O
3390 O
women O
with O
moderate O
hypercholesterolemia B-Disease
. O

objective O
: O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
lovastatin O
in O
women O
with O
moderate O
hypercholesterolemia B-Disease
. O

myopathy B-Disease
, O
defined O
as O
muscle O
symptoms O
with O
creatine O
kinase O
elevations O
greater O
than O
10 O
times O
the O
upper O
limit O
of O
normal O
, O
was O
rare O
and O
associated O
with O
the O
highest O
recommended O
daily O
dose O
of O
lovastatin O
( O
80 O
mg O
) O
. O

conclusion O
: O
lovastatin O
is O
highly O
effective O
and O
generally O
well O
tolerated O
as O
therapy O
for O
primary O
hypercholesterolemia B-Disease
in O
women O
. O

tetany B-Disease
and O
rhabdomyolysis B-Disease
due O
to O
surreptitious O
furosemide O
- O
- O
importance O
of O
magnesium O
supplementation O
. O

diuretics O
may O
induce O
hypokalemia B-Disease
, O
hypocalcemia B-Disease
and O
hypomagnesemia B-Disease
. O

while O
severe O
hypokalemia B-Disease
may O
cause O
muscle B-Disease
weakness I-Disease
, O
severe O
hypomagnesemia B-Disease
is O
associated O
with O
muscle B-Disease
spasms I-Disease
and O
tetany B-Disease
which O
cannot O
be O
corrected O
by O
potassium O
and O
calcium O
supplementation O
alone O
( O
1 O
, O
2 O
) O
. O

surreptitious O
diuretic O
ingestion O
has O
been O
described O
, O
mainly O
in O
women O
who O
are O
concerned O
that O
they O
are O
obese B-Disease
or O
edematous B-Disease
. O

symptomatic O
hypokalemia B-Disease
has O
been O
reported O
in O
such O
patients O
( O
3 O
- O
7 O
) O
and O
in O
one O
case O
hypocalcemia B-Disease
was O
observed O
( O
8 O
) O
, O
but O
the O
effects O
of O
magnesium O
depletion O
were O
not O
noted O
in O
these O
patients O
. O

ciprofloxacin O
- O
induced O
nephrotoxicity B-Disease
in O
patients O
with O
cancer B-Disease
. O

nephrotoxicity B-Disease
associated O
with O
ciprofloxacin O
is O
uncommon O
. O

five O
patients O
with O
cancer B-Disease
who O
developed O
acute B-Disease
renal I-Disease
failure I-Disease
that O
followed O
treatment O
with O
ciprofloxacin O
are O
described O
and O
an O
additional O
15 O
cases O
reported O
in O
the O
literature O
are O
reviewed O
. O

allergic O
interstitial B-Disease
nephritis I-Disease
is O
believed O
to O
be O
the O
underlying O
pathological O
- O
process O
. O

an O
improvement O
in O
renal O
function O
that O
followed O
the O
discontinuation O
of O
the O
offending O
antibiotic O
supports O
the O
presumptive O
diagnosis O
of O
ciprofloxacin O
- O
induced O
acute B-Disease
renal I-Disease
failure I-Disease
. O

venous B-Disease
complications I-Disease
of O
midazolam O
versus O
diazepam O
. O

although O
some O
studies O
have O
suggested O
fewer O
venous B-Disease
complications I-Disease
are O
associated O
with O
midazolam O
than O
with O
diazepam O
for O
endoscopic O
procedures O
, O
this O
variable O
has O
not O
been O
well O
documented O
. O

we O
prospectively O
evaluated O
the O
incidence O
of O
venous B-Disease
complications I-Disease
after O
intravenous O
injection O
of O
diazepam O
or O
midazolam O
in O
122 O
consecutive O
patients O
undergoing O
colonoscopy O
and O
esophagogastroduodenoscopy O
. O

overall O
, O
venous B-Disease
complications I-Disease
were O
more O
frequent O
with O
diazepam O
( O
22 O
of O
62 O
patients O
) O
than O
with O
midazolam O
( O
4 O
of O
60 O
patients O
) O
( O
p O
< O
0 O
. O

1 O
) O
. O

pain B-Disease
at O
the O
injection O
site O
occurred O
in O
35 O
% O
( O
22 O
of O
62 O
) O
of O
patients O
in O
the O
diazepam O
group O
compared O
with O
7 O
% O
( O
4 O
of O
60 O
patients O
) O
in O
the O
midazolam O
group O
( O
p O
< O
0 O
. O

1 O
) O
. O

swelling B-Disease
and O
warmth O
at O
the O
injection O
site O
were O
not O
significantly O
different O
between O
the O
two O
groups O
. O

smoking O
, O
nonsteroidal O
anti O
- O
inflammatory O
drug O
use O
, O
intravenous O
catheter O
site O
, O
dwell O
time O
of O
the O
needle O
, O
alcohol O
use O
, O
and O
pain B-Disease
during O
the O
injection O
had O
no O
effect O
on O
the O
incidence O
of O
venous B-Disease
complications I-Disease
. O

clarithromycin O
- O
associated O
visual B-Disease
hallucinations I-Disease
in O
a O
patient O
with O
chronic B-Disease
renal I-Disease
failure I-Disease
on O
continuous O
ambulatory O
peritoneal O
dialysis O
. O

visual B-Disease
hallucinations I-Disease
are O
a O
rare O
event O
in O
chronic B-Disease
renal I-Disease
failure I-Disease
and O
not O
related O
to O
uremia B-Disease
per O
se O
. O

unreported O
in O
the O
literature O
is O
visual B-Disease
hallucinations I-Disease
occurring O
in O
association O
with O
the O
new O
macrolide O
antibiotic O
, O
clarithromycin O
. O

we O
describe O
such O
a O
case O
in O
a O
patient O
with O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
( O
esrd B-Disease
) O
maintained O
on O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
capd O
) O
. O

the O
combination O
of O
a O
relatively O
high O
dose O
of O
clarithromycin O
in O
face O
of O
chronic B-Disease
renal I-Disease
failure I-Disease
in O
a O
functionally O
anephric O
patient O
, O
with O
underlying O
aluminum O
intoxication O
, O
may O
have O
facilitated O
the O
appearance O
of O
this O
neurotoxic B-Disease
side O
effect O
. O

it O
is O
important O
to O
understand O
the O
pharmacokinetics O
of O
medications O
in O
face O
of O
chronic B-Disease
renal I-Disease
failure I-Disease
, O
the O
possibility O
of O
drug O
interactions O
, O
and O
how O
these O
factors O
should O
help O
guide O
medication O
therapy O
in O
the O
esrd B-Disease
patient O
. O

changes O
in O
peroxisomes O
in O
preneoplastic O
liver O
and O
hepatoma B-Disease
of O
mice O
induced O
by O
alpha O
- O
benzene O
hexachloride O
. O

peroxisomes O
in O
hepatomas B-Disease
and O
hyperplastic O
preneoplastic O
liver B-Disease
lesions I-Disease
induced O
in O
mice O
by O
500 O
ppm O
alpha O
- O
benzene O
hexachloride O
were O
examined O
histochemically O
and O
electron O
microscopically O
. O

although O
most O
of O
the O
hepatomas B-Disease
were O
well O
- O
differentiated O
tumors B-Disease
and O
contained O
a O
considerable O
number O
of O
peroxisomes O
, O
the O
tumor B-Disease
cells O
did O
not O
respond O
to O
ethyl O
- O
alpha O
- O
p O
- O
chlorophenoxyisobutyrate O
with O
proliferation O
of O
peroxisomes O
. O

these O
cells O
proliferated O
further O
, O
replacing O
the O
most O
part O
of O
the O
nodules O
, O
and O
with O
this O
process O
hepatomas B-Disease
appeared O
to O
have O
been O
formed O
. O

contribution O
of O
the O
sympathetic O
nervous O
system O
to O
salt O
- O
sensitivity O
in O
lifetime O
captopril O
- O
treated O
spontaneously O
hypertensive B-Disease
rats O
. O

objective O
: O
to O
test O
the O
hypothesis O
that O
, O
in O
lifetime O
captopril O
- O
treated O
spontaneously O
hypertensive B-Disease
rats O
( O
shr O
) O
, O
the O
sympathetic O
nervous O
system O
contributes O
importantly O
to O
the O
hypertensive B-Disease
effect O
of O
dietary O
sodium O
chloride O
supplementation O
. O

intravenous O
infusion O
of O
the O
ganglionic O
blocker O
hexamethonium O
resulted O
in O
a O
rapid O
decline O
in O
map O
that O
eliminated O
the O
dietary O
sodium O
chloride O
- O
induced O
increase B-Disease
in I-Disease
map I-Disease
in O
both O
groups O
. O

angioedema B-Disease
associated O
with O
droperidol O
administration O
. O

angioedema B-Disease
, O
also O
known O
as O
angioneurotic B-Disease
edema I-Disease
or O
quincke B-Disease
' I-Disease
s I-Disease
disease I-Disease
, O
is O
a O
well O
- O
demarcated O
, O
localized O
edema B-Disease
involving O
the O
subcutaneous O
tissues O
that O
may O
cause O
upper B-Disease
- I-Disease
airway I-Disease
obstruction I-Disease
. O

we O
report O
the O
case O
of O
a O
previously O
healthy O
19 O
- O
year O
- O
old O
man O
with O
no O
known O
drug B-Disease
allergies I-Disease
in O
whom O
angioedema B-Disease
with O
significant O
tongue B-Disease
swelling I-Disease
and O
protrusion O
developed O
within O
10 O
minutes O
of O
the O
administration O
of O
a O
single O
iv O
dose O
of O
droperidol O
. O

late O
cardiotoxicity B-Disease
after O
treatment O
for O
a O
malignant O
bone B-Disease
tumor I-Disease
. O

cardiac O
function O
was O
assessed O
in O
long O
- O
term O
survivors O
of O
malignant O
bone B-Disease
tumors I-Disease
who O
were O
treated O
according O
to O
rosen O
' O
s O
t5 O
or O
t10 O
protocol O
, O
both O
including O
doxorubicin O
. O

eighteen O
of O
31 O
( O
58 O
% O
) O
patients O
showed O
cardiac B-Disease
toxicity I-Disease
, O
defined O
as O
having O
one O
or O
more O
of O
the O
following O
abnormalities O
: O
late O
potentials O
, O
complex O
ventricular B-Disease
arrhythmias I-Disease
, O
left O
ventricular B-Disease
dilation I-Disease
, O
decreased O
shortening O
fraction O
, O
or O
decreased O
ejection O
fraction O
. O

the O
incidence O
of O
cardiac B-Disease
abnormalities I-Disease
increased O
with O
length O
of O
follow O
- O
up O
( O
p O
< O
or O
= O
. O

5 O
) O
. O

the O
incidence O
of O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
is O
high O
and O
increases O
with O
follow O
- O
up O
, O
irrespective O
of O
cumulative O
dose O
. O

the O
results O
of O
our O
study O
suggest O
that O
heart O
rate O
variability O
and O
lvpw O
index O
could O
be O
sensitive O
indicators O
for O
cardiotoxicity B-Disease
. O

acute O
blood O
pressure O
elevations O
with O
caffeine O
in O
men O
with O
borderline O
systemic O
hypertension B-Disease
. O

whether O
the O
vasoconstrictive O
actions O
of O
caffeine O
are O
enhanced O
in O
hypertensive B-Disease
persons O
has O
not O
been O
demonstrated O
. O

borderline O
hypertensive B-Disease
men O
( O
n O
= O
24 O
) O
were O
selected O
with O
screening O
systolic O
blood O
pressure O
( O
bp O
) O
of O
140 O
to O
160 O
mm O
hg O
and O
/ O
or O
diastolic O
bp O
90 O
to O
99 O
mm O
hg O
. O

low O
- O
risk O
controls O
( O
n O
= O
24 O
) O
reported O
no O
parental O
history O
of O
hypertension B-Disease
and O
had O
screening O
bp O
< O
130 O
/ O
85 O
mm O
hg O
. O

consequently O
, O
whereas O
all O
participants O
exhibited O
normotensive O
levels O
during O
the O
resting O
predrug O
baseline O
, O
33 O
% O
of O
borderline O
subjects O
achieved O
hypertensive B-Disease
bp O
levels O
after O
caffeine O
ingestion O
. O

thus O
, O
in O
borderline O
hypertensive B-Disease
men O
, O
exaggerated O
responses O
to O
caffeine O
were O
: O
selective O
for O
diastolic O
bp O
, O
consistent O
with O
greater O
vasoconstriction O
, O
replicated O
in O
2 O
protocols O
, O
and O
representative O
of O
nearly O
all O
borderline O
hypertensives B-Disease
. O

absence O
of O
effect O
of O
sertraline O
on O
time O
- O
based O
sensitization O
of O
cognitive B-Disease
impairment I-Disease
with O
haloperidol O
. O

results O
: O
impairment B-Disease
of I-Disease
cognitive I-Disease
function I-Disease
was O
observed O
6 O
to O
8 O
hours O
after O
administration O
of O
haloperidol O
on O
day O
2 O
but O
was O
not O
evident O
23 O
hours O
after O
dosing O
. O

conclusion O
: O
haloperidol O
produced O
a O
clear O
profile O
of O
cognitive B-Disease
impairment I-Disease
that O
was O
not O
worsened O
by O
concomitant O
sertraline O
administration O
. O

coexistence O
of O
cerebral B-Disease
venous I-Disease
sinus I-Disease
and I-Disease
internal I-Disease
carotid I-Disease
artery I-Disease
thrombosis I-Disease
associated O
with O
exogenous O
sex O
hormones O
. O

a O
forty O
- O
six O
year O
- O
old O
premenopausal O
woman O
developed O
headache B-Disease
, O
nausea B-Disease
and O
vomiting B-Disease
, O
left O
hemiparesis B-Disease
and O
seizure B-Disease
two O
days O
after O
parenteral O
use O
of O
progesterone O
and O
estradiol O
. O

diabetes B-Disease
mellitus I-Disease
( O
dm B-Disease
) O
was O
found O
during O
admission O
. O

computed O
tomography O
showed O
a O
hemorrhagic B-Disease
infarct I-Disease
in O
the O
right O
frontal O
lobe O
and O
increased O
density O
in O
the O
superior O
sagittal O
sinus O
( O
sss O
) O
. O

left O
carotid O
angiography O
found O
occlusion B-Disease
of I-Disease
the I-Disease
left I-Disease
internal I-Disease
carotid I-Disease
artery I-Disease
( O
ica O
) O
. O

right O
carotid O
angiograms O
failed O
to O
show O
the O
sss O
and O
inferior O
sagittal O
sinus O
, O
suggestive O
of O
venous B-Disease
sinus I-Disease
thrombosis I-Disease
. O

coexistence O
of O
the O
cerebral B-Disease
artery I-Disease
and I-Disease
the I-Disease
venous I-Disease
sinus I-Disease
occlusion I-Disease
has O
been O
described O
infrequently O
. O

in O
this O
case O
, O
the O
authors O
postulate O
that O
the O
use O
of O
estradiol O
and O
progesterone O
and O
the O
underlying O
dm B-Disease
increased O
vascular O
thrombogenicity O
, O
which O
provided O
a O
common O
denominator O
for O
thrombosis B-Disease
of I-Disease
both I-Disease
the I-Disease
ica I-Disease
and I-Disease
the I-Disease
venous I-Disease
sinus I-Disease
. O

chemotherapy O
of O
advanced O
inoperable O
non B-Disease
- I-Disease
small I-Disease
cell I-Disease
lung I-Disease
cancer I-Disease
with O
paclitaxel O
: O
a O
phase O
ii O
trial O
. O

paclitaxel O
( O
taxol O
; O
bristol O
- O
myers O
squibb O
company O
, O
princeton O
, O
nj O
) O
has O
demonstrated O
significant O
antineoplastic O
activity O
against O
different O
tumor B-Disease
types O
, O
notably O
ovarian B-Disease
and I-Disease
breast I-Disease
carcinoma I-Disease
. O

two O
phase O
ii O
trials O
of O
24 O
- O
hour O
paclitaxel O
infusions O
in O
chemotherapy O
- O
naive O
patients O
with O
stage O
iiib O
or O
iv O
non B-Disease
- I-Disease
small I-Disease
cell I-Disease
lung I-Disease
cancer I-Disease
( O
nsclc B-Disease
) O
reported O
response O
rates O
of O
21 O
% O
and O
24 O
% O
. O

leukopenia B-Disease
was O
dose O
limiting O
: O
as O
many O
as O
62 O
. O

5 O
% O
of O
patients O
experienced O
grade O
4 O
leukopenia B-Disease
. O

we O
investigated O
the O
efficacy O
and O
toxicity B-Disease
of O
a O
3 O
- O
hour O
paclitaxel O
infusion O
in O
a O
phase O
ii O
trial O
in O
patients O
with O
inoperable O
stage O
iiib O
or O
iv O
nsclc B-Disease
. O

most O
patients O
( O
72 O
. O

4 O
% O
) O
had O
stage O
iv O
nsclc B-Disease
. O

hematologic O
toxicities B-Disease
were O
mild O
: O
only O
one O
patient O
( O
2 O
% O
) O
developed O
grade O
3 O
or O
4 O
neutropenia B-Disease
, O
while O
29 O
% O
had O
grade O
1 O
or O
2 O
. O

grade O
1 O
or O
2 O
polyneuropathy B-Disease
affected O
56 O
% O
of O
patients O
while O
only O
one O
( O
2 O
% O
) O
experienced O
severe O
polyneuropathy B-Disease
. O

similarly O
, O
grade O
1 O
or O
2 O
myalgia B-Disease
/ O
arthralgia B-Disease
was O
observed O
in O
63 O
. O

2 O
% O
of O
patients O
, O
but O
only O
14 O
. O

3 O
% O
experienced O
grade O
3 O
or O
4 O
. O

nausea B-Disease
and O
vomiting B-Disease
were O
infrequent O
, O
with O
14 O
% O
of O
patients O
experiencing O
grade O
1 O
or O
2 O
and O
only O
2 O
% O
experiencing O
grade O
3 O
or O
4 O
. O

paclitaxel O
is O
thus O
an O
active O
single O
agent O
in O
this O
patient O
population O
, O
with O
a O
3 O
- O
hour O
infusion O
proving O
comparably O
effective O
to O
a O
24 O
- O
hour O
infusion O
and O
superior O
in O
terms O
of O
the O
incidence O
of O
hematologic O
and O
nonhematologic O
toxicity B-Disease
. O

further O
phase O
ii O
studies O
with O
paclitaxel O
combined O
with O
other O
drugs O
active O
against O
nsclc B-Disease
are O
indicated O
, O
and O
phase O
iii O
studies O
comparing O
paclitaxel O
with O
standard O
chemotherapy O
remain O
to O
be O
completed O
. O

paclitaxel O
combined O
with O
carboplatin O
in O
the O
first O
- O
line O
treatment O
of O
advanced O
ovarian B-Disease
cancer I-Disease
. O

in O
a O
phase O
i O
study O
to O
determine O
the O
maximum O
tolerated O
dose O
of O
paclitaxel O
( O
taxol O
; O
bristol O
- O
myers O
squibb O
company O
, O
princeton O
, O
nj O
) O
given O
as O
a O
3 O
- O
hour O
infusion O
in O
combination O
with O
carboplatin O
administered O
every O
21 O
days O
to O
women O
with O
advanced O
ovarian B-Disease
cancer I-Disease
, O
paclitaxel O
doses O
were O
escalated O
as O
follows O
: O
level O
1 O
, O
135 O
mg O
/ O
m2 O
; O
level O
2 O
, O
160 O
mg O
/ O
m2 O
; O
level O
3 O
, O
185 O
mg O
/ O
m2 O
; O
and O
level O
4 O
, O
210 O
mg O
/ O
m2 O
. O

the O
dose O
- O
limiting O
toxicity B-Disease
of O
the O
combination O
was O
myelosuppression B-Disease
( O
leukopenia B-Disease
, O
granulocytopenia B-Disease
, O
and O
thrombocytopenia B-Disease
) O
. O

neurotoxicity B-Disease
was O
largely O
moderate O
. O

occasional O
case O
reports O
have O
shown O
that O
acute O
myopathy B-Disease
may O
occur O
in O
patients O
treated O
with O
massive O
doses O
of O
corticosteroids O
. O

the O
mechanism O
of O
this O
myopathy B-Disease
is O
poorly O
understood O
. O

nutritional O
intake O
, O
measured O
daily O
in O
15 O
animals O
, O
showed O
a O
significant O
reduction B-Disease
of I-Disease
food I-Disease
intake I-Disease
in O
the O
steroid O
- O
treated O
groups O
( O
- O
50 O
and O
- O
79 O
% O
in O
m O
and O
t O
, O
respectively O
) O
. O

this O
was O
associated O
with O
a O
similar O
loss B-Disease
in I-Disease
body I-Disease
weight I-Disease
. O

half O
- O
relaxation O
time O
was O
prolonged O
in O
both O
steroid O
groups O
, O
and O
time O
to O
peak O
tension O
was O
longer O
with O
m O
, O
whereas O
tetanic B-Disease
tensions O
were O
similar O
. O

atpase O
staining O
of O
the O
diaphragm O
, O
scalenus O
medius O
, O
and O
gastrocnemius O
showed O
type O
iib O
fiber O
atrophy B-Disease
in O
the O
steroid O
groups O
and O
also O
diaphragmatic O
type O
iia O
atrophy B-Disease
with O
t O
, O
whereas O
histologic O
examinations O
revealed O
a O
normal O
muscular O
pattern O
with O
absence O
of O
necrosis B-Disease
. O

finally O
, O
a O
pair O
- O
fed O
( O
pf O
) O
study O
, O
performed O
in O
18 O
rats O
( O
c O
, O
t O
, O
and O
pf O
) O
, O
showed O
that O
muscle B-Disease
atrophy I-Disease
was O
considerably O
less O
pronounced O
in O
pf O
animals O
than O
in O
t O
- O
treated O
animals O
. O

we O
conclude O
that O
( O
1 O
) O
short O
- O
term O
treatment O
with O
massive O
doses O
of O
steroids O
induced O
severe O
respiratory O
and O
limb O
muscle O
wasting O
; O
( O
2 O
) O
both O
types O
of O
steroids O
induced O
predominantly O
type O
iib O
atrophy B-Disease
, O
resulting O
in O
the O
expected O
alterations O
in O
diaphragm O
contractile O
properties O
; O
( O
3 O
) O
neither O
steroid O
caused O
muscle O
necrosis B-Disease
; O
( O
4 O
) O
type O
iib O
atrophy B-Disease
was O
not O
caused O
by O
acute O
nutritional O
deprivation O
alone O
. O

continuous O
subcutaneous O
administration O
of O
mesna O
to O
prevent O
ifosfamide O
- O
induced O
hemorrhagic B-Disease
cystitis I-Disease
. O

hemorrhagic B-Disease
cystitis I-Disease
is O
a O
major O
potential O
toxicity B-Disease
of O
ifosfamide O
that O
can O
be O
prevented O
by O
administering O
mesna O
along O
with O
the O
cytotoxic O
agent O
. O

in O
addition O
, O
subcutaneous O
delivery O
of O
the O
neutralizing O
agent O
will O
not O
be O
associated O
with O
the O
risk O
of O
inadequate O
urinary O
mesna O
concentrations O
, O
such O
as O
in O
a O
patient O
taking O
oral O
mesna O
who O
experiences O
severe O
ifosfamide O
- O
induced O
emesis B-Disease
and O
is O
unable O
to O
absorb O
the O
drug O
. O

leg B-Disease
and I-Disease
back I-Disease
pain I-Disease
after O
spinal O
anaesthesia O
involving O
hyperbaric O
5 O
% O
lignocaine O
. O

thirteen O
of O
these O
patients O
experienced O
pain B-Disease
in I-Disease
the I-Disease
legs I-Disease
and I-Disease
/ I-Disease
or I-Disease
back I-Disease
after O
recovery O
from O
anaesthesia O
. O

the O
patients O
affected O
were O
younger O
( O
p O
< O
0 O
. O

5 O
) O
and O
the O
site O
of O
the O
dural O
puncture O
was O
higher O
( O
p O
< O
0 O
. O

1 O
) O
than O
those O
individuals O
without O
pain B-Disease
. O

five O
of O
the O
13 O
patients O
( O
38 O
% O
) O
with O
pain B-Disease
and O
seven O
of O
the O
41 O
patients O
( O
17 O
% O
) O
without O
pain B-Disease
admitted O
to O
a O
high O
alcohol O
intake O
, O
which O
might O
be O
a O
contributing O
factor O
. O

leg B-Disease
and I-Disease
/ I-Disease
or I-Disease
back I-Disease
pain I-Disease
is O
associated O
with O
the O
intrathecal O
use O
of O
hyperbaric O
5 O
% O
lignocaine O
. O

the O
use O
of O
serum O
cholinesterase O
in O
succinylcholine O
apnoea B-Disease
. O

fifteen O
patients O
demonstrating O
unexpected O
prolonged O
apnoea B-Disease
lasting O
several O
hours O
after O
succinylcholine O
have O
been O
treated O
by O
a O
new O
preparation O
of O
human O
serum O
cholinesterase O
. O

the O
use O
of O
serum O
cholinesterase O
in O
succinylcholine O
apnoea B-Disease
provided O
considerable O
relief O
to O
both O
patient O
and O
anaesthetist O
. O

increased O
sulfation O
and O
decreased O
7alpha O
- O
hydroxylation O
of O
deoxycholic O
acid O
in O
ethinyl O
estradiol O
- O
induced O
cholestasis B-Disease
in O
rats O
. O

influence O
of O
diet O
free O
of O
nad O
- O
precursors O
on O
acetaminophen O
hepatotoxicity B-Disease
in O
mice O
. O

recently O
, O
we O
demonstrated O
the O
hepatoprotective O
effects O
of O
nicotinic O
acid O
amide O
, O
a O
selective O
inhibitor O
of O
poly O
( O
adp O
- O
ribose O
) O
polymerase O
( O
parp O
; O
ec O
2 O
. O

4 O
. O

2 O
. O

30 O
) O
on O
mice O
suffering O
from O
acetaminophen O
( O
aap O
) O
- O
hepatitis B-Disease
, O
suggesting O
that O
the O
aap O
- O
induced O
liver B-Disease
injury I-Disease
involves O
a O
step O
which O
depends O
on O
adenoribosylation O
. O

the O
present O
study O
investigates O
the O
effects O
of O
a O
diet O
free O
of O
precursors O
of O
nad O
, O
the O
substrate O
on O
which O
parp O
acts O
, O
in O
female O
nmri O
mice O
with O
aap O
hepatitis B-Disease
and O
evaluates O
the O
influence O
of O
simultaneous O
ethanol O
consumption O
in O
these O
animals O
. O

liver B-Disease
injuries I-Disease
were O
quantified O
as O
serum O
activities O
of O
glutamate O
- O
oxaloacetate O
transaminase O
( O
got O
) O
and O
glutamate O
- O
pyruvate O
transaminase O
( O
gpt O
) O
. O

in O
these O
animals O
, O
only O
minor O
increases O
of O
serum O
transaminase O
activities O
were O
measured O
in O
the O
presence O
of O
aap O
, O
and O
unlike O
the O
exacerbation O
caused O
by O
ethanol O
in O
mice O
on O
a O
standard O
diet O
, O
the O
liver B-Disease
damage I-Disease
was O
inhibited O
by O
50 O
% O
by O
ethanol O
. O

a O
further O
64 O
% O
reduction O
of O
hepatitis B-Disease
was O
observed O
, O
when O
naa O
was O
given O
to O
ethanol O
/ O
aap O
- O
mice O
. O

our O
results O
provide O
evidence O
that O
the O
aap O
- O
induced O
hepatitis B-Disease
and O
its O
exacerbation O
by O
ethanol O
can O
either O
be O
reduced O
by O
end O
- O
product O
inhibition O
of O
parp O
by O
naa O
or O
by O
dietary O
depletion O
of O
the O
enzyme O
' O
s O
substrate O
nad O
. O

we O
see O
the O
main O
application O
of O
naa O
as O
for O
the O
combinational O
use O
in O
pharmaceutical O
preparations O
of O
acetaminophen O
in O
order O
to O
avoid O
hepatic B-Disease
damage I-Disease
in O
patients O
treated O
with O
this O
widely O
used O
analgesic O
. O

nightmares O
and O
hallucinations B-Disease
after O
long O
- O
term O
intake O
of O
tramadol O
combined O
with O
antidepressants O
. O

tramadol O
is O
a O
weak O
opioid O
with O
effects O
on O
adrenergic O
and O
serotonergic O
neurotransmission O
that O
is O
used O
to O
treat O
cancer B-Disease
pain B-Disease
and O
chronic O
non O
malignant O
pain B-Disease
. O

this O
drug O
was O
initiated O
in O
association O
with O
paroxetine O
and O
dosulepine O
hydrochloride O
in O
a O
tetraparetic B-Disease
patient O
with O
chronic B-Disease
pain I-Disease
. O

fifty O
- O
six O
days O
after O
initiation O
of O
the O
treatment O
the O
patient O
presented O
hallucinations B-Disease
that O
only O
stopped O
after O
the O
withdrawal O
of O
psycho O
- O
active O
drugs O
and O
tramadol O
. O

the O
case O
report O
questions O
the O
long O
term O
use O
of O
pain B-Disease
killers O
combined O
with O
psycho O
- O
active O
drugs O
in O
chronic O
non O
malignant O
pain B-Disease
, O
especially O
if O
pain B-Disease
is O
under O
control O
. O

effect O
of O
calcium O
chloride O
and O
4 O
- O
aminopyridine O
therapy O
on O
desipramine O
toxicity B-Disease
in O
rats O
. O

background O
: O
hypotension B-Disease
is O
a O
major O
contributor O
to O
mortality O
in O
tricyclic O
antidepressant O
overdose B-Disease
. O

this O
study O
addressed O
the O
potential O
role O
of O
calcium O
channel O
blockade O
in O
tricyclic O
antidepressant O
- O
induced O
hypotension B-Disease
. O

methods O
: O
two O
interventions O
were O
studied O
that O
have O
been O
shown O
previously O
to O
improve O
blood O
pressure O
with O
calcium O
channel O
blocker O
overdose B-Disease
. O

anesthetized O
rats O
received O
the O
tricyclic O
antidepressant O
desipramine O
ip O
to O
produce O
hypotension B-Disease
, O
qrs O
prolongation O
, O
and O
bradycardia B-Disease
. O

results O
: O
nahco3 O
briefly O
( O
5 O
min O
) O
reversed O
hypotension B-Disease
and O
qrs O
prolongation O
. O

the O
incidence O
of O
ventricular B-Disease
arrhythmias I-Disease
( O
p O
= O
0 O
. O

4 O
) O
and O
seizures B-Disease
( O
p O
= O
0 O
. O

3 O
) O
in O
the O
cacl2 O
group O
was O
higher O
than O
the O
other O
groups O
. O

conclusion O
: O
the O
administration O
of O
cacl2 O
or O
4 O
- O
aminopyridine O
did O
not O
reverse O
tricyclic O
antidepressant O
- O
induced O
hypotension B-Disease
in O
rats O
. O

cacl2 O
therapy O
may O
possibly O
worsen O
both O
cardiovascular B-Disease
and I-Disease
central I-Disease
nervous I-Disease
system I-Disease
toxicity I-Disease
. O

these O
findings O
do O
not O
support O
a O
role O
for O
calcium O
channel O
inhibition O
in O
the O
pathogenesis O
of O
tricyclic O
antidepressant O
- O
induced O
hypotension B-Disease
. O

valsartan O
, O
a O
new O
angiotensin O
ii O
antagonist O
for O
the O
treatment O
of O
essential O
hypertension B-Disease
: O
a O
comparative O
study O
of O
the O
efficacy O
and O
safety O
against O
amlodipine O
. O

methods O
: O
one O
hundred O
sixty O
- O
eight O
adult O
outpatients O
with O
mild O
to O
moderate O
hypertension B-Disease
were O
randomly O
allocated O
in O
double O
- O
blind O
fashion O
and O
equal O
number O
to O
receive O
80 O
mg O
valsartan O
or O
5 O
mg O
amlodipine O
for O
12 O
weeks O
. O

the O
incidence O
of O
drug O
- O
related O
dependent O
edema B-Disease
was O
somewhat O
higher O
in O
the O
amlodipine O
group O
, O
particularly O
at O
a O
dose O
of O
10 O
mg O
per O
day O
( O
2 O
. O

4 O
% O
for O
80 O
mg O
valsartan O
; O
3 O
. O

6 O
% O
for O
5 O
mg O
amlodipine O
; O
0 O
% O
for O
valsartan O
plus O
5 O
mg O
amlodipine O
; O
14 O
. O

3 O
% O
for O
10 O
mg O
amlodipine O
) O
. O

conclusions O
: O
the O
data O
show O
that O
valsartan O
is O
at O
least O
as O
effective O
as O
amlodipine O
in O
the O
treatment O
of O
mild O
to O
moderate O
hypertension B-Disease
. O

a O
measure O
of O
pupillary B-Disease
oscillation I-Disease
as O
a O
marker O
of O
cocaine O
- O
induced O
paranoia B-Disease
. O

cocaine O
- O
induced O
paranoia B-Disease
( O
cip B-Disease
) O
remains O
an O
important O
drug O
- O
induced O
model O
of O
idiopathic O
paranoia B-Disease
for O
which O
no O
psychophysiologic O
marker O
has O
yet O
emerged O
. O

measures O
of O
pupillary B-Disease
oscillation I-Disease
were O
able O
to O
significantly O
distinguish O
a O
group O
of O
abstinent O
crack O
cocaine O
abusers O
endorsing O
past O
cip B-Disease
( O
n O
= O
32 O
) O
from O
another O
group O
of O
crack O
addicts O
who O
denied O
past O
cip B-Disease
( O
n O
= O
29 O
) O
. O

serotonin B-Disease
syndrome I-Disease
from O
venlafaxine O
- O
tranylcypromine O
interaction O
. O

excessive O
stimulation O
of O
serotonin O
5ht1a O
receptors O
causes O
a O
syndrome O
of O
serotonin O
excess O
that O
consists O
of O
shivering O
, O
muscle B-Disease
rigidity I-Disease
, O
salivation B-Disease
, O
confusion B-Disease
, O
agitation B-Disease
and O
hyperthermia B-Disease
. O

we O
report O
a O
venlafaxine O
- O
maoi O
interaction O
that O
resulted O
in O
the O
serotonin B-Disease
syndrome I-Disease
in O
a O
23 O
- O
y O
- O
old O
male O
who O
was O
taking O
tranylcypromine O
for O
depression B-Disease
. O

within O
2 O
h O
he O
became O
confused O
with O
jerking O
movements O
of O
his O
extremities O
, O
tremors B-Disease
and O
rigidity B-Disease
. O

he O
was O
brought O
directly O
to O
a O
hospital O
where O
he O
was O
found O
to O
be O
agitated O
and O
confused O
with O
shivering O
, O
myoclonic B-Disease
jerks I-Disease
, O
rigidity B-Disease
, O
salivation B-Disease
and O
diaphoresis O
. O

after O
180 O
mg O
of O
diazepam O
i O
. O

v O
. O

he O
remained O
tremulous O
with O
muscle B-Disease
rigidity I-Disease
and O
clenched O
jaws O
. O

he O
was O
intubated O
for O
airway O
protection O
and O
because O
of O
hypoventilation B-Disease
, O
and O
was O
paralyzed B-Disease
to O
control O
muscle B-Disease
rigidity I-Disease
. O

his O
subsequent O
course O
was O
remarkable O
for O
non O
- O
immune O
thrombocytopenia B-Disease
which O
resolved O
. O

the O
patient O
' O
s O
maximal O
temperature O
was O
101 O
. O

2 O
f O
and O
his O
cpk O
remained O
< O
500 O
units O
/ O
l O
with O
no O
other O
evidence O
of O
rhabdomyolysis B-Disease
. O

this O
patient O
survived O
without O
sequelae O
due O
to O
the O
aggressive O
sedation O
and O
neuromuscular O
paralysis B-Disease
. O

cyclophosphamide O
associated O
bladder B-Disease
cancer I-Disease
- O
- O
a O
highly O
aggressive O
disease O
: O
analysis O
of O
12 O
cases O
. O

purpose O
: O
we O
gained O
knowledge O
of O
the O
etiology O
, O
treatment O
and O
prevention O
of O
cyclophosphamide O
associated O
urothelial B-Disease
cancer I-Disease
. O

materials O
and O
methods O
: O
the O
medical O
records O
of O
6 O
men O
and O
6 O
women O
( O
mean O
age O
55 O
years O
) O
with O
cyclophosphamide O
associated O
bladder B-Disease
cancer I-Disease
were O
reviewed O
. O

results O
: O
all O
tumors B-Disease
were O
grade O
3 O
or O
4 O
transitional O
cell O
carcinoma B-Disease
. O

the O
remaining O
patient O
with O
extensive O
cancer B-Disease
underwent O
partial O
cystectomy O
for O
palliation O
and O
died O
3 O
months O
later O
. O

conclusions O
: O
cyclophosphamide O
associated O
bladder B-Disease
tumor I-Disease
is O
an O
aggressive O
disease O
. O

however O
, O
long O
- O
term O
survival O
is O
possible O
when O
radical O
cystectomy O
is O
performed O
for O
bladder B-Disease
tumors I-Disease
with O
any O
sign O
of O
invasion O
and O
for O
recurrent O
high O
grade O
disease O
, O
even O
when O
noninvasive O
. O

extensive O
experimental O
and O
limited O
clinical O
data O
have O
shown O
that O
lometrexol O
has O
activity O
against O
tumours B-Disease
which O
are O
refractory O
to O
other O
drugs O
, O
notably O
methotrexate O
. O

however O
, O
the O
initial O
clinical O
development O
of O
lometrexol O
was O
curtailed O
because O
of O
severe O
and O
cumulative O
antiproliferative O
toxicities B-Disease
. O

preclinical O
murine O
studies O
demonstrated O
that O
the O
toxicity B-Disease
of O
lometrexol O
can O
be O
prevented O
by O
low O
dose O
folic O
acid O
administration O
, O
i O
. O

e O
. O

for O
7 O
days O
prior O
to O
and O
7 O
days O
following O
a O
single O
bolus O
dose O
. O

this O
observation O
prompted O
a O
phase O
i O
clinical O
study O
of O
lometrexol O
given O
with O
folic O
acid O
supplementation O
which O
has O
confirmed O
that O
the O
toxicity B-Disease
of O
lometrexol O
can O
be O
markedly O
reduced O
by O
folic O
acid O
supplementation O
. O

thrombocytopenia B-Disease
and O
mucositis B-Disease
were O
the O
major O
toxicities B-Disease
. O

there O
was O
no O
clear O
relationship O
between O
clinical O
toxicity B-Disease
and O
the O
extent O
of O
plasma O
folate O
elevation O
. O

associated O
studies O
demonstrated O
that O
lometrexol O
plasma O
pharmacokinetics O
were O
not O
altered O
by O
folic O
acid O
administration O
indicating O
that O
supplementation O
is O
unlikely O
to O
reduce O
toxicity B-Disease
by O
enhancing O
lometrexol O
plasma O
clearance O
. O

this O
information O
will O
facilitate O
the O
future O
evaluation O
of O
this O
class O
of O
compounds O
in O
cancer B-Disease
therapy O
. O

fatal O
excited O
delirium B-Disease
following O
cocaine O
use O
: O
epidemiologic O
findings O
provide O
new O
evidence O
for O
mechanisms O
of O
cocaine O
toxicity B-Disease
. O

we O
describe O
an O
outbreak O
of O
deaths O
from O
cocaine O
- O
induced O
excited O
delirium B-Disease
( O
edds B-Disease
) O
in O
dade O
county O
, O
florida O
between O
1979 O
and O
1990 O
. O

from O
a O
registry O
of O
all O
cocaine O
- O
related O
deaths O
in O
dade O
county O
, O
florida O
, O
from O
1969 O
- O
1990 O
, O
58 O
edds B-Disease
were O
compared O
with O
125 O
victims O
of O
accidental O
cocaine O
overdose B-Disease
without O
excited O
delirium B-Disease
. O

compared O
with O
controls O
, O
edds B-Disease
were O
more O
frequently O
black O
, O
male O
, O
and O
younger O
. O

they O
were O
less O
likely O
to O
have O
a O
low O
body O
mass O
index O
, O
and O
more O
likely O
to O
have O
died O
in O
police O
custody O
, O
to O
have O
received O
medical O
treatment O
immediately O
before O
death O
, O
to O
have O
survived O
for O
a O
longer O
period O
, O
to O
have O
developed O
hyperthermia B-Disease
, O
and O
to O
have O
died O
in O
summer O
months O
. O

edds B-Disease
had O
concentrations O
of O
cocaine O
and O
benzoylecgonine O
in O
autopsy O
blood O
that O
were O
similar O
to O
those O
for O
controls O
. O

the O
epidemiologic O
findings O
are O
most O
consistent O
with O
the O
hypothesis O
that O
chronic O
cocaine O
use O
disrupts O
dopaminergic O
function O
and O
, O
when O
coupled O
with O
recent O
cocaine O
use O
, O
may O
precipitate O
agitation B-Disease
, O
delirium B-Disease
, O
aberrant O
thermoregulation O
, O
rhabdomyolysis B-Disease
, O
and O
sudden B-Disease
death I-Disease
. O

pemoline O
induced O
acute O
choreoathetosis B-Disease
: O
case O
report O
and O
review O
of O
the O
literature O
. O

background O
: O
pemoline O
is O
an O
oxazolidine O
derivative O
that O
is O
structurally O
different O
from O
amphetamines O
and O
used O
in O
the O
treatment O
of O
attention B-Disease
deficit I-Disease
disorder I-Disease
. O

pemoline O
has O
not O
been O
commonly O
associated O
in O
the O
literature O
as O
a O
cause O
of O
acute O
movement B-Disease
disorders I-Disease
. O

the O
following O
case O
describes O
two O
children O
acutely O
poisoned O
with O
pemoline O
who O
experienced O
profound O
choreoathetosis B-Disease
. O

the O
children O
had O
a O
medical O
history O
significant O
for O
attention B-Disease
deficit I-Disease
disorder I-Disease
previously O
treated O
with O
methylphenidate O
without O
success O
. O

the O
choreoathetoid B-Disease
movements O
began O
45 O
min O
to O
1 O
h O
after O
ingestion O
. O

the O
children O
gave O
no O
history O
of O
prior O
movement B-Disease
disorders I-Disease
and O
there O
was O
no O
family O
history O
of O
movement B-Disease
disorders I-Disease
. O

the O
children O
received O
gastrointestinal O
decontamination O
and O
high O
doses O
of O
intravenous O
benzodiazepines O
in O
an O
attempt O
to O
control O
the O
choreoathetoid B-Disease
movements O
. O

despite O
treatment O
, O
the O
children O
continued O
to O
have O
choreoathetosis B-Disease
for O
approximately O
24 O
hours O
. O

conclusion O
: O
pemoline O
associated O
movement B-Disease
disorder I-Disease
has O
been O
rarely O
reported O
in O
the O
acute O
toxicology O
literature O
. O

the O
possibility O
of O
choreoathetoid B-Disease
movements O
should O
be O
considered O
in O
patients O
presenting O
after O
pemoline O
overdose B-Disease
. O

during O
the O
follow O
- O
up O
, O
3 O
patients O
( O
12 O
% O
) O
developed O
steroid O
- O
induced O
elevated B-Disease
intraocular I-Disease
pressure I-Disease
( O
iop O
) O
that O
resolved O
after O
corticosteroid O
therapy O
was O
discontinued O
. O

the O
transient O
steroid O
- O
induced O
iop B-Disease
rise I-Disease
did O
not O
seem O
to O
cause O
functional O
impairment O
. O

neutrophil O
superoxide O
and O
hydrogen O
peroxide O
production O
in O
patients O
with O
acute B-Disease
liver I-Disease
failure I-Disease
. O

defects O
in O
superoxide O
and O
hydrogen O
peroxide O
production O
may O
be O
implicated O
in O
the O
high O
incidence O
of O
bacterial B-Disease
infections I-Disease
in O
patients O
with O
acute B-Disease
liver I-Disease
failure I-Disease
( O
alf B-Disease
) O
. O

in O
the O
present O
study O
, O
oxygen O
radical O
production O
in O
patients O
with O
alf B-Disease
due O
to O
paracetamol O
overdose B-Disease
was O
compared O
with O
that O
of O
healthy O
volunteers O
. O

neutrophils O
from O
14 O
alf B-Disease
patients O
were O
stimulated O
via O
the O
complement O
receptors O
using O
zymosan O
opsonized O
with O
alf B-Disease
or O
control O
serum O
. O

superoxide O
and O
hydrogen O
peroxide O
production O
by O
alf B-Disease
neutrophils O
stimulated O
with O
zymosan O
opsonized O
with O
alf B-Disease
serum O
was O
significantly O
reduced O
compared O
with O
the O
control O
subjects O
( O
p O
< O
0 O
. O

1 O
) O
. O

superoxide O
and O
hydrogen O
peroxide O
production O
in O
neutrophils O
stimulated O
with O
formyl O
- O
methionyl O
- O
leucyl O
- O
phenylalanine O
( O
fmlp O
) O
from O
a O
further O
18 O
alf B-Disease
patients O
was O
unaffected O
compared O
with O
control O
neutrophils O
. O

serum O
c3 O
complement O
levels O
were O
significantly O
reduced O
in O
alf B-Disease
patients O
compared O
with O
control O
subjects O
( O
p O
< O
0 O
. O

5 O
) O
. O

these O
results O
demonstrate O
a O
neutrophil O
defect O
in O
alf B-Disease
due O
to O
paracetamol O
overdose B-Disease
, O
that O
is O
complement O
dependent O
but O
independent O
of O
serum O
complement O
, O
possibly O
connected O
to O
the O
complement O
receptor O
. O

in O
addition O
to O
its O
use O
as O
a O
stabilizer O
/ O
rigidifier O
of O
membranes O
, O
cholesteryl O
hemisuccinate O
, O
tris O
salt O
( O
cs O
) O
administration O
has O
also O
been O
shown O
to O
protect O
rats O
from O
the O
hepatotoxic B-Disease
effects O
of O
carbon O
tetrachloride O
( O
ccl4 O
) O
. O

to O
further O
our O
understanding O
of O
the O
mechanism O
of O
cs O
cytoprotection O
, O
we O
examined O
in O
rats O
and O
mice O
the O
protective O
abilities O
of O
cs O
and O
the O
non O
- O
hydrolyzable O
ether O
form O
of O
cs O
, O
gamma O
- O
cholesteryloxybutyric O
acid O
, O
tris O
salt O
( O
cse O
) O
against O
acetaminophen O
- O
, O
adriamycin O
- O
, O
carbon O
tetrachloride O
- O
, O
chloroform O
- O
and O
galactosamine O
- O
induced O
toxicity B-Disease
. O

a O
24 O
- O
h O
pretreatment O
of O
both O
rats O
and O
mice O
with O
a O
single O
dose O
of O
cs O
( O
100mg O
/ O
kg O
, O
i O
. O

p O
. O

) O
, O
resulted O
in O
significant O
protection O
against O
the O
hepatotoxic B-Disease
effects O
of O
ccl4 O
, O
chcl3 O
, O
acetaminophen O
and O
galactosamine O
and O
against O
the O
lethal O
( O
and O
presumably O
cardiotoxic B-Disease
) O
effect O
of O
adriamycin O
administration O
. O

the O
mechanism O
of O
cs O
protection O
does O
not O
appear O
to O
be O
dependent O
on O
the O
inhibition O
of O
chemical O
bioactivation O
to O
a O
toxic O
reactive O
intermediate O
( O
in O
light O
of O
the O
protection O
observed O
against O
galactosamine O
hepatotoxicity B-Disease
) O
. O

a O
murine O
model O
of O
adenomyosis B-Disease
: O
the O
effects O
of O
hyperprolactinemia B-Disease
induced O
by O
fluoxetine O
hydrochloride O
, O
a O
selective O
serotonin O
reuptake O
inhibitor O
, O
on O
adenomyosis B-Disease
induction O
in O
wistar O
albino O
rats O
. O

objective O
: O
the O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
fluoxetine O
given O
to O
castrated O
and O
noncastrated O
rats O
caused O
hyperprolactinemia B-Disease
and O
its O
effects O
with O
respect O
to O
adenomyosis B-Disease
. O

design O
: O
fluoxetine O
, O
a O
serotonin O
reuptake O
inhibitor O
, O
was O
given O
to O
wistar O
albino O
rats O
for O
98 O
days O
to O
produce O
hyperprolactinemia B-Disease
. O

histological O
studies O
revealed O
11 O
cases O
of O
adenomyosis B-Disease
, O
all O
within O
the O
noncastrated O
group O
receiving O
fluoxetine O
. O

this O
invasion O
eventually O
progresses O
to O
adenomyosis B-Disease
. O

postinfarction O
ventricular B-Disease
septal I-Disease
defect I-Disease
associated O
with O
long O
- O
term O
steroid O
therapy O
. O

two O
cases O
of O
postinfarction O
ventricular B-Disease
septal I-Disease
rupture I-Disease
in O
patients O
on O
long O
- O
term O
steroid O
therapy O
are O
presented O
and O
the O
favourable O
outcome O
in O
both O
cases O
described O
. O

a O
possible O
association O
between O
steroid O
therapy O
and O
subsequent O
postinfarction O
septal B-Disease
rupture I-Disease
is O
discussed O
. O

neuroactive O
steroids O
protect O
against O
pilocarpine O
- O
and O
kainic O
acid O
- O
induced O
limbic O
seizures B-Disease
and O
status B-Disease
epilepticus I-Disease
in O
mice O
. O

several O
structurally O
related O
metabolites O
of O
progesterone O
( O
3 O
alpha O
- O
hydroxy O
pregnane O
- O
20 O
- O
ones O
) O
and O
deoxycorticosterone O
( O
3 O
alpha O
- O
hydroxy O
pregnane O
- O
21 O
- O
diol O
- O
20 O
- O
ones O
) O
and O
their O
3 O
beta O
- O
epimers O
were O
evaluated O
for O
protective O
activity O
against O
pilocarpine O
- O
, O
kainic O
acid O
- O
and O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
) O
- O
induced O
seizures B-Disease
in O
mice O
. O

steroids O
with O
the O
3 O
- O
hydroxy O
group O
in O
the O
alpha O
- O
position O
and O
5 O
- O
h O
in O
the O
alpha O
- O
or O
beta O
- O
configurations O
were O
highly O
effective O
in O
protecting O
against O
pilocarpine O
( O
416 O
mg O
/ O
kg O
, O
s O
. O

c O
. O

) O
- O
induced O
limbic O
motor O
seizures B-Disease
and O
status B-Disease
epilepticus I-Disease
( O
ed50 O
values O
, O
7 O
. O

0 O
- O
18 O
. O

7 O
mg O
/ O
kg O
, O
i O
. O

p O
. O

) O
. O

although O
the O
neuroactive O
steroids O
were O
considerably O
less O
potent O
than O
the O
benzodiazepine O
clonazepam O
in O
protecting O
against O
pilocarpine O
seizures B-Disease
, O
steroids O
with O
the O
5 O
alpha O
, O
3 O
alpha O
- O
configuration O
had O
comparable O
or O
higher O
protective O
index O
values O
( O
td50 O
for O
motor O
impairment O
divided O
by O
ed50 O
for O
seizure B-Disease
protection O
) O
than O
clonazepam O
, O
indicating O
that O
some O
neuroactive O
steroids O
may O
have O
lower O
relative O
toxicity B-Disease
. O

steroids O
with O
the O
5 O
alpha O
, O
3 O
alpha O
- O
or O
5 O
beta O
, O
3 O
alpha O
- O
configurations O
also O
produced O
a O
dose O
- O
dependent O
delay O
in O
the O
onset O
of O
limbic O
seizures B-Disease
induced O
by O
kainic O
acid O
( O
32 O
mg O
/ O
kg O
, O
s O
. O

c O
. O

) O
, O
but O
did O
not O
completely O
protect O
against O
the O
seizures B-Disease
. O

however O
, O
when O
a O
second O
dose O
of O
the O
steroid O
was O
administered O
1 O
hr O
after O
the O
first O
dose O
, O
complete O
protection O
from O
the O
kainic O
acid O
- O
induced O
limbic O
seizures B-Disease
and O
status B-Disease
epilepticus I-Disease
was O
obtained O
. O

the O
steroids O
also O
caused O
a O
dose O
- O
dependent O
delay O
in O
nmda O
( O
257 O
mg O
/ O
kg O
, O
s O
. O

c O
. O

) O
- O
induced O
lethality O
, O
but O
did O
not O
completely O
protect O
against O
nmda O
seizures B-Disease
or O
lethality O
. O

we O
conclude O
that O
neuroactive O
steroids O
are O
highly O
effective O
in O
protecting O
against O
pilocarpine O
- O
and O
kainic O
acid O
- O
induced O
seizures B-Disease
and O
status B-Disease
epilepticus I-Disease
in O
mice O
, O
and O
may O
be O
of O
utility O
in O
the O
treatment O
of O
some O
forms O
of O
status B-Disease
epilepticus I-Disease
in O
humans O
. O

hepatic O
and O
extrahepatic O
angiotensinogen O
gene O
expression O
in O
rats O
with O
acute O
nephrotic B-Disease
syndrome I-Disease
. O

plasma O
concentration O
and O
urine O
excretion O
of O
the O
renin O
- O
angiotensin O
system O
proteins O
are O
altered O
in O
rats O
with O
nephrotic B-Disease
syndrome I-Disease
( O
ns B-Disease
) O
. O

in O
this O
work O
the O
messenger O
ribonucleic O
acid O
( O
mrna O
) O
levels O
of O
angiotensinogen O
( O
ao O
) O
were O
analyzed O
with O
the O
slot O
- O
blot O
hybridization O
technique O
in O
liver O
and O
other O
extrahepatic O
tissues O
: O
kidney O
, O
heart O
, O
brain O
, O
and O
adrenal O
gland O
from O
control O
, O
nephrotic B-Disease
, O
and O
pair O
- O
fed O
( O
pf O
) O
rats O
. O

ns B-Disease
was O
induced O
by O
a O
single O
injection O
of O
puromycin O
amino O
- O
nucleoside O
( O
pan O
) O
. O

although O
a O
great O
urinary O
excretion O
and O
half O
- O
normal O
plasma O
levels O
of O
ao O
were O
observed O
on O
day O
6 O
after O
pan O
injection O
, O
when O
ns B-Disease
was O
clearly O
established O
, O
hepatic O
ao O
mrna O
levels O
did O
not O
change O
. O

these O
data O
suggest O
that O
the O
hepatic O
and O
extrahepatic O
ao O
mrna O
levels O
are O
unaltered O
during O
the O
development O
of O
the O
acute O
ns B-Disease
induced O
by O
pan O
. O

neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
with O
risperidone O
. O

neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
is O
thought O
to O
be O
a O
result O
of O
dopamine O
d2 O
receptor O
blockade O
in O
the O
striatum O
of O
the O
basal O
ganglia O
. O

the O
high O
ratio O
is O
believed O
to O
impart O
the O
low O
frequency O
of O
extrapyramidal B-Disease
symptoms I-Disease
with O
risperidone O
at O
low O
dosages O
. O

with O
this O
low O
frequency O
of O
extrapyramidal B-Disease
symptoms I-Disease
, O
it O
was O
thought O
the O
frequency O
of O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
might O
also O
be O
lowered O
. O

a O
73 O
- O
year O
- O
old O
woman O
developed O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
after O
monotherapy O
with O
risperidone O
. O

it O
appears O
that O
the O
protection O
from O
extrapyramidal O
side O
effects O
observed O
with O
risperidone O
does O
not O
ensure O
protection O
from O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
. O

the O
attenuating O
effect O
of O
carteolol O
hydrochloride O
, O
a O
beta O
- O
adrenoceptor O
antagonist O
, O
on O
neuroleptic O
- O
induced O
catalepsy B-Disease
in O
rats O
. O

it O
is O
known O
that O
beta O
- O
adrenoceptor O
antagonists O
are O
effective O
in O
the O
treatment O
of O
akathisia B-Disease
, O
one O
of O
the O
extrapyramidal O
side O
effects O
that O
occur O
during O
neuroleptic O
treatment O
. O

neuroleptic O
- O
induced O
catalepsy B-Disease
, O
a O
model O
of O
neuroleptic O
- O
induced O
extrapyramidal O
side O
effects O
, O
was O
considered O
suitable O
as O
a O
model O
for O
predicting O
neuroleptic O
- O
induced O
akathisia B-Disease
in O
humans O
, O
although O
neuroleptic O
- O
induced O
catalepsy B-Disease
was O
not O
considered O
a O
specific O
test O
for O
neuroleptic O
- O
induced O
akathisia B-Disease
. O

therefore O
, O
the O
effects O
of O
carteolol O
, O
a O
beta O
- O
adrenoceptor O
antagonist O
, O
on O
haloperidol O
- O
induced O
catalepsy B-Disease
in O
rats O
were O
behaviorally O
studied O
and O
compared O
with O
those O
of O
propranolol O
and O
biperiden O
, O
a O
muscarinic O
receptor O
antagonist O
. O

carteolol O
, O
as O
well O
as O
propranolol O
and O
biperiden O
, O
inhibited O
the O
haloperidol O
- O
induced O
catalepsy B-Disease
. O

carteolol O
did O
not O
evoke O
postsynaptic O
dopamine O
receptor O
- O
stimulating O
behavioral O
signs O
such O
as O
stereotypy O
and O
hyperlocomotion B-Disease
in O
rats O
. O

these O
results O
strongly O
suggest O
that O
carteolol O
improves O
haloperidol O
- O
induced O
catalepsy B-Disease
via O
its O
beta O
- O
adrenoceptor O
antagonistic O
activity O
and O
is O
expected O
to O
be O
effective O
in O
the O
treatment O
of O
akathisia B-Disease
without O
attenuating O
neuroleptic O
- O
induced O
antipsychotic O
effects O
due O
to O
its O
postsynaptic O
dopamine O
receptor O
antagonistic O
activity O
. O

granulosa B-Disease
cell I-Disease
tumor I-Disease
of I-Disease
the I-Disease
ovary I-Disease
associated O
with O
antecedent O
tamoxifen O
use O
. O

review O
of O
the O
literature O
reveals O
an O
association O
between O
tamoxifen O
use O
and O
gynecologic O
tumors B-Disease
. O

case O
: O
a O
52 O
- O
year O
- O
old O
postmenopausal O
woman O
was O
treated O
with O
tamoxifen O
for O
stage O
ii O
estrogen O
receptor O
- O
positive O
breast B-Disease
carcinoma I-Disease
. O

after O
an O
additional O
17 O
months O
of O
elevated O
serum O
transaminases O
, O
the O
patient O
was O
found O
to O
have O
a O
stage O
ic O
granulosa B-Disease
cell I-Disease
tumor I-Disease
of I-Disease
the I-Disease
ovary I-Disease
. O

conclusion O
: O
patients O
with O
tamoxifen O
- O
induced O
liver B-Disease
dysfunction I-Disease
may O
be O
at O
increased O
risk O
for O
granulosa B-Disease
cell I-Disease
tumors I-Disease
because O
of O
alterations O
in O
tamoxifen O
metabolism O
. O

lifetime O
treatment O
of O
mice O
with O
azidothymidine O
( O
azt O
) O
produces O
myelodysplasia B-Disease
. O

azt O
has O
induced O
a O
macrocytic B-Disease
anemia I-Disease
in O
aids B-Disease
patients O
on O
long O
term O
azt O
therapy O
. O

histological O
examination O
on O
9 O
of O
10 O
mice O
with O
such O
thrombocytopenia B-Disease
showed O
changes O
compatible O
with O
myelodysplastic B-Disease
syndrome I-Disease
( O
mds B-Disease
) O
. O

there O
were O
two O
cases O
of O
hypocellular O
myelodysplasia B-Disease
, O
two O
cases O
of O
hypersegmented O
myelodysplastic B-Disease
granulocytosis O
, O
two O
cases O
of O
hypercellular O
marrow O
with O
abnormal O
megakaryocytes O
with O
bizarre O
nuclei O
, O
one O
case O
of O
megakaryocytic O
myelosis O
associated O
with O
a O
hyperplastic B-Disease
marrow I-Disease
, O
dysmyelopoiesis B-Disease
and O
a O
hypocellular B-Disease
marrow I-Disease
and O
two O
cases O
of O
myelodysplasia B-Disease
with O
dyserythropoiesis B-Disease
, O
hemosiderosis B-Disease
and O
a O
hypocellular B-Disease
marrow I-Disease
. O

above O
mentioned O
azt O
incorporation O
may O
have O
induced O
an O
ineffective O
hemopoiesis O
in O
the O
primitive O
hemopoietic O
progenitor O
cells O
, O
which O
is O
known O
to O
be O
seen O
commonly O
in O
the O
myelodysplastic B-Disease
syndrome I-Disease
. O

injections O
of O
ketamine O
in O
doses O
from O
100 O
microgram O
to O
3 O
mg O
into O
the O
artery O
produced O
a O
depression B-Disease
of O
the O
sa O
nodal O
activity O
by O
a O
direct O
action O
. O

this O
depression B-Disease
was O
followed O
by O
the O
sudden O
appearance O
of O
a O
stimulatory O
phase O
. O

bilateral O
vagotomy O
and O
sympathectomy O
or O
prior O
administration O
of O
a O
ganglion O
blocker O
failed O
to O
inhibit O
the O
occurrence O
of O
the O
ketamine O
- O
induced O
tachycardia B-Disease
, O
while O
it O
was O
completely O
abolished O
in O
the O
reserpinized O
dogs O
or O
by O
a O
prior O
injection O
of O
a O
beta O
- O
blocking O
agent O
into O
the O
sa O
node O
artery O
. O

over O
expression O
of O
vascular O
endothelial O
growth O
factor O
and O
its O
receptor O
during O
the O
development O
of O
estrogen O
- O
induced O
rat O
pituitary B-Disease
tumors I-Disease
may O
mediate O
estrogen O
- O
initiated O
tumor B-Disease
angiogenesis O
. O

estrogens O
, O
which O
have O
been O
associated O
with O
several O
types O
of O
human O
and O
animal O
cancers B-Disease
, O
can O
induce O
tumor B-Disease
angiogenesis O
in O
the O
pituitary O
of O
fischer O
344 O
rats O
. O

the O
mechanistic O
details O
of O
tumor B-Disease
angiogenesis O
induction O
, O
during O
estrogen O
carcinogenesis B-Disease
, O
are O
still O
unknown O
. O

to O
elucidate O
the O
role O
of O
estrogen O
in O
the O
regulation O
of O
tumor B-Disease
angiogenesis O
in O
the O
pituitary O
of O
female O
rats O
, O
the O
density O
of O
blood O
vessels O
was O
analysed O
using O
factor O
viii O
related O
antigen O
( O
fviiirag O
) O
immunohistochemistry O
and O
the O
expression O
of O
vascular O
endothelial O
growth O
factor O
/ O
vascular O
permeability O
factor O
( O
vegf O
/ O
vpf O
) O
was O
examined O
by O
western O
blot O
and O
immunohistochemical O
analysis O
. O

the O
high O
tumor B-Disease
angiogenic O
potential O
was O
associated O
with O
an O
elevated O
vegf O
/ O
vpf O
protein O
expression O
in O
the O
e2 O
exposed O
pituitary O
of O
ovariectomized O
( O
ovex O
) O
rats O
. O

these O
findings O
suggest O
that O
over O
expression O
of O
vegf O
and O
its O
receptor O
( O
vegfr O
- O
2 O
) O
may O
play O
an O
important O
role O
in O
the O
initial O
step O
of O
the O
regulation O
of O
estrogen O
induced O
tumor B-Disease
angiogenesis O
in O
the O
rat O
pituitary O
. O

persistent O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
following O
lithium O
therapy O
. O

we O
report O
the O
case O
of O
a O
patient O
who O
developed O
severe O
hypernatraemic O
dehydration B-Disease
following O
a O
head B-Disease
injury I-Disease
. O

ten O
years O
previously O
he O
had O
been O
diagnosed O
to O
have O
lithium O
- O
induced O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
, O
and O
lithium O
therapy O
had O
been O
discontinued O
. O

he O
remained O
thirsty O
and O
polyuric B-Disease
despite O
cessation O
of O
lithium O
and O
investigations O
on O
admission O
showed O
him O
to O
have O
normal O
osmoregulated O
thirst O
and O
vasopressin O
secretion O
, O
with O
clear O
evidence O
of O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
. O

lithium O
induced O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
is O
considered O
to O
be O
reversible O
on O
cessation O
of O
therapy O
but O
polyuria B-Disease
persisted O
in O
this O
patient O
for O
ten O
years O
after O
lithium O
was O
stopped O
. O

we O
discuss O
the O
possible O
renal O
mechanisms O
and O
the O
implications O
for O
management O
of O
patients O
with O
lithium O
- O
induced O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
. O

effects O
of O
nik O
- O
247 O
on O
cholinesterase O
and O
scopolamine O
- O
induced O
amnesia B-Disease
. O

the O
effects O
of O
nik O
- O
247 O
on O
cholinesterase O
, O
scopolamine O
- O
induced O
amnesia B-Disease
and O
spontaneous O
movement O
were O
examined O
and O
compared O
with O
those O
of O
the O
well O
- O
known O
cholinesterase O
inhibitors O
tacrine O
and O
e O
- O
2020 O
. O

all O
compounds O
at O
0 O
. O

1 O
- O
1 O
mg O
/ O
kg O
p O
. O

o O
. O

significantly O
improved O
the O
amnesia B-Disease
induced O
by O
scopolamine O
( O
0 O
. O

5 O
mg O
/ O
kg O
s O
. O

c O
. O

) O
in O
rats O
performing O
a O
passive O
avoidance O
task O
. O

these O
findings O
suggest O
that O
nik O
- O
247 O
at O
a O
low O
dose O
( O
0 O
. O

1 O
- O
1 O
mg O
/ O
kg O
p O
. O

o O
. O

) O
improves O
scopolamine O
- O
induced O
amnesia B-Disease
but O
does O
not O
affect O
spontaneous O
movement O
. O

the O
findings O
suggest O
that O
nik O
- O
247 O
may O
be O
a O
useful O
drug O
for O
the O
treatment O
of O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

potential O
therapeutic O
use O
of O
the O
selective O
dopamine O
d1 O
receptor O
agonist O
, O
a O
- O
86929 O
: O
an O
acute O
study O
in O
parkinsonian B-Disease
levodopa O
- O
primed O
monkeys O
. O

the O
clinical O
utility O
of O
dopamine O
( O
da O
) O
d1 O
receptor O
agonists O
in O
the O
treatment O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
is O
still O
unclear O
. O

we O
therefore O
conducted O
the O
present O
acute O
dose O
- O
response O
study O
in O
four O
1 O
- O
methyl O
- O
4 O
- O
phenyl O
- O
1 O
, O
2 O
, O
3 O
, O
6 O
- O
tetrahydropyridine O
( O
mptp O
) O
- O
exposed O
cynomolgus O
monkeys O
primed O
to O
exhibit O
levodopa O
- O
induced O
dyskinesias B-Disease
to O
evaluate O
the O
locomotor O
and O
dyskinetic B-Disease
effects O
on O
challenge O
with O
four O
doses O
( O
from O
0 O
. O

3 O
to O
1 O
. O

0 O
mg O
/ O
kg O
) O
of O
a O
- O
86929 O
( O
[ O
- O
] O
- O
[ O
5ar O
, O
11bs O
] O
- O
4 O
, O
5 O
, O
5a O
, O
6 O
, O
7 O
, O
11b O
- O
hexahydro O
- O
2 O
- O
propyl O
- O
3 O
- O
thia O
- O
5 O
- O
+ O
+ O
+ O
azacyclopent O
- O
1 O
- O
ena O
[ O
c O
] O
phenathrene O
- O
9 O
- O
10 O
- O
diol O
) O
, O
a O
selective O
and O
full O
da O
d1 O
- O
like O
receptor O
agonist O
with O
an O
intermediate O
duration O
of O
action O
. O

acute O
administration O
of O
a O
- O
86929 O
was O
as O
efficacious O
in O
alleviating O
mptp O
- O
induced O
parkinsonism B-Disease
as O
levodopa O
and O
ly O
- O
171555 O
, O
but O
was O
less O
likely O
to O
reproduce O
the O
levodopa O
- O
induced O
dyskinesias B-Disease
in O
these O
animals O
than O
with O
either O
ly O
- O
171555 O
or O
subsequent O
challenge O
of O
levodopa O
. O

potent O
da O
d1 O
receptor O
agents O
with O
an O
intermediate O
duration O
of O
efficacy O
such O
as O
a O
- O
86929 O
( O
approximately O
4 O
hr O
at O
higher O
doses O
tested O
) O
are O
potential O
therapeutic O
tools O
in O
pd B-Disease
and O
merit O
further O
attention O
. O

neuropeptide O
- O
y O
immunoreactivity O
in O
the O
pilocarpine O
model O
of O
temporal B-Disease
lobe I-Disease
epilepsy I-Disease
. O

neuropeptide O
- O
y O
( O
npy O
) O
is O
expressed O
by O
granule O
cells O
and O
mossy O
fibres O
of O
the O
hippocampal O
dentate O
gyrus O
during O
experimental O
temporal B-Disease
lobe I-Disease
epilepsy I-Disease
( O
tle B-Disease
) O
. O

this O
expression O
may O
represent O
an O
endogenous O
damping O
mechanism O
since O
npy O
has O
been O
shown O
to O
block O
seizure B-Disease
- O
like O
events O
following O
high O
- O
frequency O
stimulation O
in O
hippocampal O
slices O
. O

the O
pilocarpine O
( O
pilo O
) O
model O
of O
epilepsy B-Disease
is O
characterized O
by O
an O
acute O
period O
of O
status B-Disease
epilepticus I-Disease
followed O
by O
spontaneous O
recurrent O
seizures B-Disease
and O
related O
brain B-Disease
damage I-Disease
. O

the O
results O
demonstrate O
that O
changes O
in O
npy O
expression O
, O
including O
expression O
in O
the O
granule O
cells O
and O
mossy O
fibres O
and O
the O
loss O
of O
vulnerable O
npy O
neurons O
, O
are O
present O
in O
the O
pilo O
model O
of O
tle B-Disease
. O

posteroventral O
medial O
pallidotomy O
in O
advanced O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

background O
: O
posteroventral O
medial O
pallidotomy O
sometimes O
produces O
striking O
improvement O
in O
patients O
with O
advanced O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
, O
but O
the O
studies O
to O
date O
have O
involved O
small O
numbers O
of O
patients O
and O
short O
- O
term O
follow O
- O
up O
. O

methods O
: O
forty O
patients O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
underwent O
serial O
, O
detailed O
assessments O
both O
after O
drug O
withdrawal O
( O
nan O
off O
nan O
period O
) O
and O
while O
taking O
their O
optimal O
medical O
regimens O
( O
nan O
on O
nan O
period O
) O
. O

results O
: O
the O
percent O
improvements O
at O
six O
months O
were O
as O
follows O
: O
off O
- O
period O
score O
for O
overall O
motor O
function O
, O
28 O
percent O
( O
95 O
percent O
confidence O
interval O
, O
19 O
to O
38 O
percent O
) O
, O
with O
most O
of O
the O
improvement O
in O
the O
contralateral O
limbs O
; O
off O
- O
period O
score O
for O
activities O
of O
daily O
living O
, O
29 O
percent O
( O
95 O
percent O
confidence O
interval O
, O
19 O
to O
39 O
percent O
) O
; O
on O
- O
period O
score O
for O
contralateral O
dyskinesias B-Disease
, O
82 O
percent O
( O
95 O
percent O
confidence O
interval O
, O
72 O
to O
91 O
percent O
) O
; O
and O
on O
- O
period O
score O
for O
ipsilateral O
dyskinesias B-Disease
, O
44 O
percent O
( O
95 O
percent O
confidence O
interval O
, O
29 O
to O
59 O
percent O
) O
. O

the O
improvements O
in O
dyskinesias B-Disease
and O
the O
total O
scores O
for O
off O
- O
period O
parkinsonism B-Disease
, O
contralateral O
bradykinesia B-Disease
, O
and O
rigidity B-Disease
were O
sustained O
in O
the O
11 O
patients O
examined O
at O
two O
years O
. O

the O
improvement O
in O
ipsilateral O
dyskinesias B-Disease
was O
lost O
after O
one O
year O
, O
and O
the O
improvements O
in O
postural O
stability O
and O
gait O
lasted O
only O
three O
to O
six O
months O
. O

conclusions O
: O
in O
late O
- O
stage O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
, O
pallidotomy O
significantly O
reduces O
levodopa O
- O
induced O
dyskinesias B-Disease
and O
off O
- O
period O
disability O
. O

clarithromycin O
- O
induced O
ventricular B-Disease
tachycardia I-Disease
. O

although O
the O
side O
- O
effect O
profile O
of O
erythromycin O
is O
established O
, O
including O
gastroenteritis B-Disease
and O
interactions O
with O
other O
drugs O
subject O
to O
hepatic O
mixed O
- O
function O
oxidase O
metabolism O
, O
experience O
with O
the O
newer O
macrolides O
is O
still O
being O
recorded O
. O

cardiotoxicity B-Disease
has O
been O
demonstrated O
after O
both O
intravenous O
and O
oral O
administration O
of O
erythromycin O
but O
has O
never O
been O
reported O
with O
the O
newer O
macrolides O
. O

we O
report O
a O
case O
of O
ventricular B-Disease
dysrhythmias I-Disease
that O
occurred O
after O
six O
therapeutic O
doses O
of O
clarithromycin O
. O

the O
dysrhythmias B-Disease
resolved O
after O
discontinuation O
of O
the O
drug O
. O

effect O
of O
glyceryl O
trinitrate O
on O
the O
sphincter B-Disease
of I-Disease
oddi I-Disease
spasm I-Disease
evoked O
by O
prostigmine O
- O
morphine O
administration O
. O

objective O
: O
in O
this O
study O
the O
effect O
of O
glyceryl O
trinitrate O
on O
the O
prostigmine O
- O
morphine O
- O
induced O
sphincter B-Disease
of I-Disease
oddi I-Disease
spasm I-Disease
was O
evaluated O
in O
nine O
female O
patients O
with O
sphincter B-Disease
of I-Disease
oddi I-Disease
dyskinesia I-Disease
. O

method O
: O
sphincter B-Disease
of I-Disease
oddi I-Disease
spasm I-Disease
was O
induced O
by O
prostigmine O
- O
morphine O
administration O
( O
0 O
. O

5 O
mg O
prostigmine O
intramuscularly O
and O
10 O
mg O
morphine O
subcutaneously O
) O
and O
visualized O
by O
quantitative O
hepatobiliary O
scintigraphy O
. O

results O
: O
prostigmine O
- O
morphine O
provocation O
caused O
significant O
increases O
in O
the O
time O
to O
peak O
activity O
( O
tmax O
) O
over O
the O
hepatic O
hilum O
( O
hh O
: O
34 O
. O

33 O
+ O
/ O
- O
5 O
. O

5 O
vs O
. O

22 O
. O

77 O
+ O
/ O
- O
3 O
. O

26 O
) O
and O
the O
common O
bile O
duct O
( O
cbd O
: O
60 O
. O

44 O
+ O
/ O
- O
5 O
. O

99 O
vs O
. O

40 O
. O

0 O
+ O
/ O
- O
2 O
. O

88 O
) O
and O
in O
the O
half O
- O
time O
of O
excretion O
( O
t1 O
/ O
2 O
) O
over O
the O
liver O
parenchyma O
( O
lp O
: O
120 O
. O

4 O
+ O
/ O
- O
16 O
. O

1 O
vs O
. O

27 O
. O

37 O
+ O
/ O
- O
2 O
. O

19 O
) O
, O
hh O
( O
117 O
. O

61 O
+ O
/ O
- O
14 O
. O

71 O
vs O
. O

31 O
. O

85 O
+ O
/ O
- O
3 O
. O

99 O
) O
and O
cbd O
( O
158 O
. O

11 O
+ O
/ O
- O
9 O
. O

18 O
vs O
. O

40 O
. O

1 O
+ O
/ O
- O
6 O
. O

24 O
) O
, O
indicating O
a O
complete O
spasm B-Disease
at O
the O
level O
of O
the O
sphincter O
of O
oddi O
. O

conclusion O
: O
these O
results O
provide O
the O
first O
evidence O
of O
the O
effectiveness O
of O
glyceryl O
trinitrate O
on O
the O
morphine O
- O
induced O
sphincter B-Disease
of I-Disease
oddi I-Disease
spasm I-Disease
in O
humans O
. O

since O
glyceryl O
trinitrate O
is O
able O
to O
overcome O
even O
the O
drastic O
effect O
of O
morphine O
, O
it O
might O
be O
of O
relevance O
in O
the O
treatment O
of O
sphincter B-Disease
of I-Disease
oddi I-Disease
dyskinesia I-Disease
. O

immunopathology O
of O
penicillamine O
- O
induced O
glomerular B-Disease
disease I-Disease
. O

four O
patients O
with O
rheumatoid B-Disease
arthritis I-Disease
developed O
heavy O
proteinuria B-Disease
after O
five O
to O
12 O
months O
of O
treatment O
with O
d O
- O
penicillamine O
. O

the O
findings O
were O
similar O
to O
those O
in O
early O
membranous B-Disease
glomerulonephritis I-Disease
, O
differences O
being O
observed O
however O
in O
the O
results O
of O
staining O
for O
the O
early O
- O
acting O
complement O
components O
c1q O
and O
c4 O
. O

experimental O
cranial O
pain B-Disease
elicited O
by O
capsaicin O
: O
a O
pet O
study O
. O

using O
a O
positron O
emission O
tomography O
( O
pet O
) O
study O
it O
was O
shown O
recently O
that O
in O
migraine B-Disease
without O
aura O
certain O
areas O
in O
the O
brain O
stem O
were O
activated O
during O
the O
headache B-Disease
state O
, O
but O
not O
in O
the O
headache B-Disease
free O
interval O
. O

it O
was O
suggested O
that O
this O
brain O
stem O
activation O
is O
inherent O
to O
the O
migraine B-Disease
attack O
itself O
and O
represents O
the O
so O
called O
' O
migraine B-Disease
generator O
' O
. O

to O
test O
this O
hypothesis O
we O
performed O
an O
experimental O
pain B-Disease
study O
in O
seven O
healthy O
volunteers O
, O
using O
the O
same O
positioning O
in O
the O
pet O
scanner O
as O
in O
the O
migraine B-Disease
patients O
. O

a O
small O
amount O
of O
capsaicin O
was O
administered O
subcutaneously O
in O
the O
right O
forehead O
to O
evoke O
a O
burning O
painful B-Disease
sensation O
in O
the O
first O
division O
of O
the O
trigeminal O
nerve O
. O

using O
the O
same O
stereotactic O
space O
limits O
as O
in O
the O
above O
mentioned O
migraine B-Disease
study O
no O
brain O
stem O
activation O
was O
found O
in O
the O
acute O
pain B-Disease
state O
compared O
to O
the O
pain B-Disease
free O
state O
. O

the O
increase O
of O
activation O
in O
the O
region O
of O
the O
cavernous O
sinus O
however O
, O
suggests O
that O
this O
structure O
is O
more O
likely O
to O
be O
involved O
in O
trigeminal O
transmitted O
pain B-Disease
as O
such O
, O
rather O
than O
in O
a O
specific O
type O
of O
headache B-Disease
as O
was O
suggested O
for O
cluster B-Disease
headache I-Disease
. O

value O
of O
methylprednisolone O
in O
prevention O
of O
the O
arthralgia B-Disease
- O
myalgia B-Disease
syndrome O
associated O
with O
the O
total O
dose O
infusion O
of O
iron O
dextran O
: O
a O
double O
blind O
randomized O
trial O
. O

in O
40 O
% O
of O
treated O
patients O
, O
an O
arthralgia B-Disease
- O
myalgia B-Disease
syndrome O
develops O
. O

these O
data O
demonstrate O
that O
administration O
of O
mp O
before O
and O
after O
tdi O
reduces O
the O
frequency O
and O
severity O
of O
the O
arthralgia B-Disease
- O
myalgia B-Disease
syndrome O
. O

prolongation B-Disease
of I-Disease
the I-Disease
qt I-Disease
interval I-Disease
related O
to O
cisapride O
- O
diltiazem O
interaction O
. O

cisapride O
, O
a O
cytochrome O
p450 O
3a4 O
( O
cyp3a4 O
) O
substrate O
, O
is O
widely O
prescribed O
for O
the O
treatment O
of O
gastrointestinal B-Disease
motility I-Disease
disorders I-Disease
. O

prolongation B-Disease
of I-Disease
qt I-Disease
interval I-Disease
, O
torsades B-Disease
de I-Disease
pointes I-Disease
, O
and O
sudden B-Disease
cardiac I-Disease
death I-Disease
have O
been O
reported O
after O
concomitant O
administration O
with O
erythromycin O
or O
azole O
antifungal O
agents O
, O
but O
not O
with O
other O
cyp3a4 O
inhibitors O
. O

a O
possible O
drug O
interaction O
occurred O
in O
a O
45 O
- O
year O
- O
old O
woman O
who O
was O
taking O
cisapride O
for O
gastroesophageal B-Disease
reflux I-Disease
disorder I-Disease
and O
diltiazem O
, O
an O
agent O
that O
has O
inhibitory O
effect O
on O
cyp3a4 O
, O
for O
hypertension B-Disease
. O

the O
patient O
was O
in O
near O
syncope B-Disease
and O
had O
qt B-Disease
- I-Disease
interval I-Disease
prolongation I-Disease
. O

cortical O
motor O
overactivation O
in O
parkinsonian B-Disease
patients O
with O
l O
- O
dopa O
- O
induced O
peak O
- O
dose O
dyskinesia B-Disease
. O

we O
have O
studied O
the O
regional O
cerebral O
blood O
flow O
( O
rcbf O
) O
changes O
induced O
by O
the O
execution O
of O
a O
finger O
- O
to O
- O
thumb O
opposition O
motor O
task O
in O
the O
supplementary O
and O
primary O
motor O
cortex O
of O
two O
groups O
of O
parkinsonian B-Disease
patients O
on O
l O
- O
dopa O
medication O
, O
the O
first O
one O
without O
l O
- O
dopa O
induced O
dyskinesia B-Disease
( O
n O
= O
23 O
) O
and O
the O
other O
with O
moderate O
peak O
- O
dose O
dyskinesia B-Disease
( O
n O
= O
15 O
) O
, O
and O
of O
a O
group O
of O
14 O
normal O
subjects O
. O

the O
dyskinetic B-Disease
parkinsonian B-Disease
patients O
exhibited O
a O
pattern O
of O
response O
which O
was O
markedly O
different O
from O
those O
of O
the O
normal O
subjects O
and O
non O
- O
dyskinetic B-Disease
parkinsonian B-Disease
patients O
, O
with O
a O
significant O
overactivation O
in O
the O
supplementary O
motor O
area O
and O
the O
ipsi O
- O
and O
contralateral O
primary O
motor O
areas O
. O

these O
results O
are O
compatible O
with O
the O
hypothesis O
that O
an O
hyperkinetic B-Disease
abnormal B-Disease
involuntary I-Disease
movement I-Disease
, O
like O
l O
- O
dopa O
- O
induced O
peak O
dose O
dyskinesia B-Disease
, O
is O
due O
to O
a O
disinhibition O
of O
the O
primary O
and O
associated O
motor O
cortex O
secondary O
to O
an O
excessive O
outflow O
of O
the O
pallidothalamocortical O
motor O
loop O
. O

open O
- O
label O
assessment O
of O
levofloxacin O
for O
the O
treatment O
of O
acute O
bacterial O
sinusitis B-Disease
in O
adults O
. O

purpose O
: O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
levofloxacin O
( O
500 O
mg O
orally O
once O
daily O
for O
10 O
to O
14 O
days O
) O
in O
treating O
adult O
outpatients O
with O
acute O
bacterial O
sinusitis B-Disease
. O

the O
most O
common O
drug O
- O
related O
adverse O
events O
were O
diarrhea B-Disease
, O
flatulence B-Disease
, O
and O
nausea B-Disease
; O
most O
adverse O
events O
were O
mild O
to O
moderate O
in O
severity O
. O

conclusion O
: O
the O
results O
of O
this O
study O
indicate O
that O
levofloxacin O
500 O
mg O
once O
daily O
is O
an O
effective O
and O
safe O
treatment O
for O
acute O
bacterial O
sinusitis B-Disease
. O

iatrogenic O
risks O
of O
endometrial B-Disease
carcinoma I-Disease
after O
treatment O
for O
breast B-Disease
cancer I-Disease
in O
a O
large O
french O
case O
- O
control O
study O
. O

since O
tamoxifen O
is O
widely O
used O
in O
breast B-Disease
cancer I-Disease
treatment O
and O
has O
been O
proposed O
for O
the O
prevention O
of O
breast B-Disease
cancer I-Disease
, O
its O
endometrial O
iatrogenic O
effects O
must O
be O
carefully O
examined O
. O

we O
have O
investigated O
the O
association O
between O
endometrial B-Disease
cancer I-Disease
and O
tamoxifen O
use O
or O
other O
treatments O
in O
women O
treated O
for O
breast B-Disease
cancer I-Disease
in O
a O
case O
- O
control O
study O
. O

cases O
of O
endometrial B-Disease
cancer I-Disease
diagnosed O
after O
breast B-Disease
cancer I-Disease
( O
n O
= O
135 O
) O
and O
467 O
controls O
matched O
for O
age O
, O
year O
of O
diagnosis O
of O
breast B-Disease
cancer I-Disease
and O
hospital O
and O
survival O
time O
with O
an O
intact O
uterus O
were O
included O
. O

women O
who O
had O
received O
tamoxifen O
were O
significantly O
more O
likely O
to O
have O
endometrial B-Disease
cancer I-Disease
diagnosed O
than O
those O
who O
had O
not O
( O
crude O
relative O
risk O
= O
4 O
. O

9 O
, O
p O
= O
0 O
. O

1 O
) O
. O

women O
who O
had O
endometrial B-Disease
cancer I-Disease
and O
had O
received O
tamoxifen O
had O
more O
advanced B-Disease
disease I-Disease
and O
poorer O
prognosis O
than O
those O
with O
endometrial B-Disease
cancer I-Disease
who O
had O
not O
received O
this O
treatment O
. O

our O
results O
suggest O
a O
causal O
role O
of O
tamoxifen O
in O
endometrial B-Disease
cancer I-Disease
, O
particularly O
when O
used O
as O
currently O
proposed O
for O
breast B-Disease
cancer I-Disease
prevention O
. O

pelvic O
radiotherapy O
may O
be O
an O
additional O
iatrogenic O
factor O
for O
women O
with O
breast B-Disease
cancer I-Disease
. O

endometrial B-Disease
cancers I-Disease
diagnosed O
in O
women O
treated O
with O
tamoxifen O
have O
poorer O
prognosis O
. O

women O
who O
receive O
tamoxifen O
for O
breast B-Disease
cancer I-Disease
should O
be O
offered O
gynaecological O
surveillance O
during O
and O
after O
treatment O
. O

a O
long O
- O
term O
evaluation O
of O
the O
risk O
- O
benefit O
ratio O
of O
tamoxifen O
as O
a O
preventive O
treatment O
for O
breast B-Disease
cancer I-Disease
is O
clearly O
warranted O
. O

muscle B-Disease
rigidity I-Disease
was O
induced O
by O
haloperidol O
( O
2 O
. O

5 O
mg O
/ O
kg O
i O
. O

p O
. O

) O
. O

5 O
, O
7 O
- O
dichlorokynurenic O
acid O
( O
5 O
, O
7 O
- O
dcka O
) O
, O
a O
selective O
glycine O
site O
antagonist O
, O
injected O
in O
doses O
of O
2 O
. O

5 O
and O
4 O
. O

5 O
microg O
/ O
0 O
. O

5 O
microl O
bilaterally O
, O
into O
the O
rostral O
region O
of O
the O
striatum O
, O
decreased O
both O
the O
haloperidol O
- O
induced O
muscle B-Disease
rigidity I-Disease
( O
mmg O
) O
and O
the O
enhanced O
electromyographic O
activity O
( O
emg O
) O
. O

background O
: O
the O
most O
striking O
of O
carboplatin O
' O
s O
advantages O
( O
cbdca O
) O
over O
cisplatin O
( O
cddp O
) O
is O
its O
markedly O
reduced O
rate O
of O
neurotoxic B-Disease
effects O
. O

however O
, O
the O
use O
of O
cbdca O
higher O
- O
intensity O
schedules O
and O
the O
association O
with O
other O
neurotoxic B-Disease
drugs O
in O
polychemotherapy O
may O
cause O
some O
concern O
about O
its O
safety O
with O
respect O
to O
peripheral B-Disease
nervous I-Disease
system I-Disease
damage I-Disease
. O

neurotoxicity B-Disease
was O
assessed O
for O
behavioral O
( O
tail O
- O
flick O
test O
) O
, O
neurophysiological O
( O
nerve O
conduction O
velocity O
in O
the O
tail O
nerve O
) O
, O
morphological O
, O
morphometrical O
and O
analytical O
effects O
. O

results O
: O
cbdca O
administration O
induced O
dose O
- O
dependent O
peripheral B-Disease
neurotoxicity I-Disease
. O

pain B-Disease
perception O
and O
nerve O
conduction O
velocity O
in O
the O
tail O
were O
significantly O
impaired O
, O
particularly O
after O
the O
high O
- O
dose O
treatment O
. O

conclusions O
: O
cbdca O
is O
neurotoxic B-Disease
in O
our O
model O
, O
and O
the O
type O
of O
pathological O
changes O
it O
induces O
are O
so O
closely O
similar O
to O
those O
caused O
by O
cddp O
that O
it O
is O
probable O
that O
neurotoxicity B-Disease
is O
induced O
in O
the O
two O
drugs O
by O
the O
same O
mechanism O
. O

effects O
of O
cisapride O
on O
symptoms O
and O
postcibal O
small O
- O
bowel O
motor O
function O
in O
patients O
with O
irritable B-Disease
bowel I-Disease
syndrome I-Disease
. O

background O
: O
irritable B-Disease
bowel I-Disease
syndrome I-Disease
is O
a O
common O
cause O
of O
abdominal B-Disease
pain I-Disease
and O
discomfort O
and O
may O
be O
related O
to O
disordered B-Disease
gastrointestinal I-Disease
motility I-Disease
. O

our O
aim O
was O
to O
assess O
the O
effects O
of O
long O
- O
term O
treatment O
with O
a O
prokinetic O
agent O
, O
cisapride O
, O
on O
postprandial O
jejunal O
motility O
and O
symptoms O
in O
the O
irritable B-Disease
bowel I-Disease
syndrome I-Disease
( O
ibs B-Disease
) O
. O

methods O
: O
thirty O
- O
eight O
patients O
with O
ibs B-Disease
( O
constipation B-Disease
- O
predominant O
, O
n O
= O
17 O
; O
diarrhoea B-Disease
- O
predominant O
, O
n O
= O
21 O
) O
underwent O
24 O
- O
h O
ambulatory O
jejunal O
manometry O
before O
and O
after O
12 O
week O
' O
s O
treatment O
[ O
cisapride O
, O
5 O
mg O
three O
times O
daily O
( O
n O
= O
19 O
) O
or O
placebo O
( O
n O
= O
19 O
) O
] O
. O

results O
: O
in O
diarrhoea B-Disease
- O
predominant O
patients O
significant O
differences O
in O
contraction O
characteristics O
were O
observed O
between O
the O
cisapride O
and O
placebo O
groups O
. O

in O
cisapride O
- O
treated O
diarrhoea B-Disease
- O
predominant O
patients O
the O
mean O
contraction O
amplitude O
was O
higher O
( O
29 O
. O

3 O
+ O
/ O
- O
3 O
. O

2 O
versus O
24 O
. O

9 O
+ O
/ O
- O
2 O
. O

6 O
mm O
hg O
, O
cisapride O
versus O
placebo O
( O
p O
< O
0 O
. O

1 O
) O
; O
pretreatment O
, O
25 O
. O

7 O
+ O
/ O
- O
6 O
. O

0 O
mm O
hg O
) O
, O
the O
mean O
contraction O
duration O
longer O
( O
3 O
. O

4 O
+ O
/ O
- O
0 O
. O

2 O
versus O
3 O
. O

0 O
+ O
/ O
- O
0 O
. O

2 O
sec O
, O
cisapride O
versus O
placebo O
( O
p O
< O
0 O
. O

1 O
) O
; O
pretreatment O
, O
3 O
. O

1 O
+ O
/ O
- O
0 O
. O

5 O
sec O
) O
, O
and O
the O
mean O
contraction O
frequency O
lower O
( O
2 O
. O

0 O
+ O
/ O
- O
0 O
. O

2 O
versus O
2 O
. O

5 O
+ O
/ O
- O
0 O
. O

4 O
cont O
. O

/ O
min O
, O
cisapride O
versus O
placebo O
( O
p O
< O
0 O
. O

1 O
) O
; O
pretreatment O
, O
2 O
. O

5 O
+ O
/ O
- O
1 O
. O

1 O
cont O
. O

/ O
min O
] O
than O
patients O
treated O
with O
placebo O
. O

no O
significant O
differences O
in O
jejunal O
motility O
were O
found O
in O
the O
constipation B-Disease
- O
predominant O
ibs B-Disease
group O
. O

symptom O
scores O
relating O
to O
the O
severity O
of O
constipation B-Disease
were O
lower O
in O
cisapride O
- O
treated O
constipation B-Disease
- O
predominant O
ibs B-Disease
patients O
[ O
score O
, O
54 O
+ O
/ O
- O
5 O
versus O
67 O
+ O
/ O
- O
14 O
mm O
, O
cisapride O
versus O
placebo O
( O
p O
< O
0 O
. O

5 O
) O
; O
pretreatment O
, O
62 O
+ O
/ O
- O
19 O
mm O
] O
. O

diarrhoea B-Disease
- O
predominant O
ibs B-Disease
patients O
had O
a O
higher O
pain B-Disease
score O
after O
cisapride O
therapy O
[ O
score O
, O
55 O
+ O
/ O
- O
15 O
versus O
34 O
+ O
/ O
- O
12 O
mm O
, O
cisapride O
versus O
placebo O
( O
p O
< O
0 O
. O

5 O
) O
; O
pretreatment O
, O
67 O
+ O
/ O
- O
19 O
mm O
] O
. O

conclusion O
: O
cisapride O
affects O
jejunal O
contraction O
characteristics O
and O
some O
symptoms O
in O
ibs B-Disease
. O

prevention O
of O
breast B-Disease
cancer I-Disease
with O
tamoxifen O
: O
preliminary O
findings O
from O
the O
italian O
randomised O
trial O
among O
hysterectomised O
women O
. O

background O
: O
tamoxifen O
is O
a O
candidate O
chemopreventive O
agent O
in O
breast B-Disease
cancer I-Disease
, O
although O
the O
drug O
may O
be O
associated O
with O
the O
development O
of O
endometrial B-Disease
cancer I-Disease
. O

methods O
: O
in O
october O
, O
1992 O
, O
we O
started O
a O
double O
- O
blind O
placebo O
- O
controlled O
, O
randomised O
trial O
of O
tamoxifen O
in O
women O
( O
mainly O
in O
italy O
) O
who O
did O
not O
have O
breast B-Disease
cancer I-Disease
and O
who O
had O
had O
a O
hysterectomy O
. O

the O
primary O
endpoints O
are O
the O
occurrence O
of O
and O
deaths O
from O
breast B-Disease
cancer I-Disease
. O

41 O
cases O
of O
breast B-Disease
cancer I-Disease
occurred O
so O
far O
; O
there O
have O
been O
no O
deaths O
from O
breast B-Disease
cancer I-Disease
. O

there O
is O
no O
difference O
in O
breast B-Disease
- I-Disease
cancer I-Disease
frequency O
between O
the O
placebo O
( O
22 O
cases O
) O
and O
tamoxifen O
( O
19 O
) O
arms O
. O

there O
is O
a O
statistically O
significant O
reduction O
of O
breast B-Disease
cancer I-Disease
among O
women O
receiving O
tamoxifen O
who O
also O
used O
hormone O
- O
replacement O
therapy O
during O
the O
trial O
: O
among O
390 O
women O
on O
such O
therapy O
and O
allocated O
to O
placebo O
, O
we O
found O
eight O
cases O
of O
breast B-Disease
cancer I-Disease
compared O
with O
one O
case O
among O
362 O
women O
allocated O
to O
tamoxifen O
. O

compared O
with O
the O
placebo O
group O
, O
there O
was O
a O
significantly O
increased O
risk O
of O
vascular B-Disease
events I-Disease
and O
hypertriglyceridaemia B-Disease
among O
women O
on O
tamoxifen O
. O

interpretation O
: O
although O
this O
preliminary O
analysis O
has O
low O
power O
, O
in O
this O
cohort O
of O
women O
at O
low O
- O
to O
- O
normal O
risk O
of O
breast B-Disease
cancer I-Disease
, O
the O
postulated O
protective O
effects O
of O
tamoxifen O
are O
not O
yet O
apparent O
. O

there O
were O
no O
deaths O
from O
breast B-Disease
cancer I-Disease
recorded O
in O
women O
in O
the O
study O
. O

epileptogenic O
activity O
of O
folic O
acid O
after O
drug O
induces O
sle B-Disease
( O
folic O
acid O
and O
epilepsy B-Disease
) O
objective O
: O
to O
study O
the O
effect O
of O
folic O
acid O
- O
containing O
multivitamin O
supplementation O
in O
epileptic B-Disease
women O
before O
and O
during O
pregnancy O
in O
order O
to O
determine O
the O
rate O
of O
structural O
birth B-Disease
defects I-Disease
and O
epilepsy B-Disease
- O
related O
side O
effects O
. O

results O
: O
of O
60 O
epileptic B-Disease
women O
with O
periconceptional O
folic O
acid O
( O
0 O
. O

8 O
mg O
) O
- O
containing O
multivitamin O
supplementation O
, O
no O
one O
developed O
epilepsy B-Disease
- O
related O
side O
effects O
during O
the O
periconception O
period O
. O

one O
epileptic B-Disease
woman O
delivered O
a O
newborn O
with O
cleft B-Disease
lip I-Disease
and I-Disease
palate I-Disease
. O

another O
patient O
exhibited O
with O
a O
cluster O
of O
seizures B-Disease
after O
the O
periconception O
period O
using O
another O
multivitamin O
. O

this O
22 O
- O
year O
- O
old O
epileptic B-Disease
woman O
was O
treated O
continuously O
by O
carbamazepine O
and O
a O
folic O
acid O
( O
1 O
mg O
) O
- O
containing O
multivitamin O
from O
the O
20th O
week O
of O
gestation O
. O

she O
developed O
status B-Disease
epilepticus I-Disease
and O
later O
symptoms O
of O
systemic B-Disease
lupus I-Disease
erythematodes I-Disease
. O

her O
pregnancy O
ended O
with O
stillbirth B-Disease
. O

conclusions O
: O
the O
epileptic B-Disease
pregnant O
patient O
' O
s O
autoimmune B-Disease
disease I-Disease
( O
probably O
drug O
- O
induced O
lupus B-Disease
) O
could O
damage O
the O
blood O
- O
brain O
barrier O
, O
therefore O
the O
therapeutic O
dose O
( O
> O
or O
= O
1 O
mg O
) O
of O
folic O
acid O
triggered O
a O
cluster O
of O
seizures B-Disease
. O

physiological O
dose O
( O
< O
1 O
mg O
) O
of O
folic O
acid O
both O
in O
healthy O
and O
60 O
epileptic B-Disease
women O
, O
all O
without O
any O
autoimmune B-Disease
disease I-Disease
, O
did O
not O
increase O
the O
risk O
for O
epileptic B-Disease
seizures I-Disease
. O

stroke B-Disease
and O
cocaine O
or O
amphetamine O
use O
. O

the O
association O
of O
cocaine O
and O
amphetamine O
use O
with O
hemorrhagic O
and O
ischemic B-Disease
stroke B-Disease
is O
based O
almost O
solely O
on O
data O
from O
case O
series O
. O

the O
limited O
number O
of O
epidemiologic O
studies O
of O
stroke B-Disease
and O
use O
of O
cocaine O
and O
/ O
or O
amphetamine O
have O
been O
done O
in O
settings O
that O
serve O
mostly O
the O
poor O
and O
/ O
or O
minorities O
. O

we O
attempted O
to O
identify O
all O
incident O
strokes B-Disease
in O
women O
ages O
15 O
- O
44 O
years O
during O
a O
3 O
- O
year O
period O
using O
hospital O
admission O
and O
discharge O
records O
, O
emergency O
department O
logs O
, O
and O
payment O
requests O
for O
out O
- O
of O
- O
plan O
hospitalizations O
. O

there O
were O
347 O
confirmed O
stroke B-Disease
cases O
and O
1 O
, O
21 O
controls O
. O

the O
univariate O
matched O
odds O
ratio O
for O
stroke B-Disease
in O
women O
who O
admitted O
to O
using O
cocaine O
and O
/ O
or O
amphetamine O
was O
8 O
. O

5 O
( O
95 O
% O
confidence O
interval O
= O
3 O
. O

6 O
- O
20 O
. O

0 O
) O
. O

the O
use O
of O
cocaine O
and O
/ O
or O
amphetamine O
is O
a O
strong O
risk O
factor O
for O
stroke B-Disease
in O
this O
socioeconomically O
heterogeneous O
, O
insured O
urban O
population O
. O

acute B-Disease
renal I-Disease
failure I-Disease
subsequent O
to O
the O
administration O
of O
rifampicin O
. O

a O
clinical O
presentation O
is O
made O
of O
a O
2 O
- O
3 O
year O
follow O
- O
up O
of O
six O
cases O
of O
acute B-Disease
renal I-Disease
failure I-Disease
that O
have O
been O
reported O
earlier O
. O

the O
patients O
had O
developed O
transient O
renal B-Disease
failure I-Disease
after O
the O
intermittent O
administration O
of O
rifampicin O
. O

the O
stage O
of O
olig O
- O
anuria B-Disease
lasted O
for O
1 O
- O
3 O
weeks O
, O
and O
five O
of O
the O
patients O
were O
treated O
by O
hemodialysis O
. O

although O
in O
the O
acute O
stage O
the O
renal B-Disease
lesions I-Disease
histologically O
appeared O
toxic O
, O
evidence O
suggestive O
of O
an O
immunological O
mechanism O
cannot O
be O
excluded O
. O

chronic O
effects O
of O
a O
novel O
synthetic O
anthracycline O
derivative O
( O
sm O
- O
5887 O
) O
on O
normal O
heart O
and O
doxorubicin O
- O
induced O
cardiomyopathy B-Disease
in O
beagle O
dogs O
. O

this O
study O
was O
designed O
to O
investigate O
the O
chronic O
cardiotoxic B-Disease
potential O
of O
sm O
- O
5887 O
and O
a O
possible O
deteriorating O
effect O
of O
sm O
- O
5887 O
on O
low O
- O
grade O
cardiotoxicity B-Disease
pre O
- O
induced O
by O
doxorubicin O
in O
beagle O
dogs O
. O

animals O
which O
received O
over O
six O
courses O
of O
doxorubicin O
demonstrated O
the O
electrocardiogram O
( O
ecg O
) O
changes O
, O
decrease O
of O
blood O
pressure O
and O
high O
- O
grade O
histopathological O
cardiomyopathy B-Disease
, O
while O
animals O
which O
were O
terminally O
sacrificed O
after O
the O
sm O
- O
5887 O
administration O
did O
not O
show O
any O
changes O
in O
ecg O
, O
blood O
pressure O
and O
histopathological O
examinations O
. O

to O
examine O
a O
possibly O
deteriorating O
cardiotoxic B-Disease
effect O
of O
sm O
- O
5887 O
, O
low O
- O
grade O
cardiomyopathy B-Disease
was O
induced O
in O
dogs O
by O
four O
courses O
of O
doxorubicin O
( O
1 O
. O

5 O
mg O
/ O
kg O
) O
. O

the O
low O
- O
grade O
cardiotoxic B-Disease
changes O
were O
enhanced O
by O
the O
additional O
doxorubicin O
treatment O
. O

on O
the O
contrary O
, O
the O
sm O
- O
5887 O
treatment O
did O
not O
progress O
the O
grade O
of O
cardiomyopathy B-Disease
. O

in O
conclusion O
, O
sm O
- O
5887 O
does O
not O
have O
any O
potential O
of O
chronic O
cardiotoxicity B-Disease
and O
deteriorating O
effect O
on O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
in O
dogs O
. O

risk O
for O
valvular B-Disease
heart I-Disease
disease I-Disease
among O
users O
of O
fenfluramine O
and O
dexfenfluramine O
who O
underwent O
echocardiography O
before O
use O
of O
medication O
. O

background O
: O
because O
uncontrolled O
echocardiographic O
surveys O
suggested O
that O
up O
to O
30 O
% O
to O
38 O
% O
of O
users O
of O
fenfluramine O
and O
dexfenfluramine O
had O
valvular B-Disease
disease I-Disease
, O
these O
drugs O
were O
withdrawn O
from O
the O
market O
. O

objective O
: O
to O
determine O
the O
risk O
for O
new O
or O
worsening O
valvular B-Disease
abnormalities I-Disease
among O
users O
of O
fenfluramine O
or O
dexfenfluramine O
who O
underwent O
echocardiography O
before O
they O
began O
to O
take O
these O
medications O
. O

the O
primary O
outcome O
was O
new O
or O
worsening O
valvulopathy B-Disease
, O
defined O
as O
progression O
of O
either O
aortic B-Disease
or I-Disease
mitral I-Disease
regurgitation I-Disease
by O
at O
least O
one O
degree O
of O
severity O
and O
disease O
that O
met O
u O
. O

s O
. O

food O
and O
drug O
administration O
criteria O
( O
at O
least O
mild O
aortic B-Disease
regurgitation I-Disease
or O
moderate O
mitral B-Disease
regurgitation I-Disease
) O
. O

results O
: O
two O
patients O
( O
4 O
. O

3 O
% O
[ O
95 O
% O
ci O
, O
0 O
. O

6 O
% O
to O
14 O
. O

8 O
% O
] O
) O
receiving O
fenfluramine O
- O
phentermine O
developed O
valvular B-Disease
heart I-Disease
disease I-Disease
. O

one O
had O
baseline O
bicuspid B-Disease
aortic I-Disease
valve I-Disease
and O
mild O
aortic B-Disease
regurgitation I-Disease
that O
progressed O
to O
moderate O
regurgitation O
. O

the O
second O
patient O
developed O
new O
moderate O
aortic B-Disease
insufficiency I-Disease
. O

conclusion O
: O
users O
of O
diet O
medications O
are O
at O
risk O
for O
valvular B-Disease
heart I-Disease
disease I-Disease
. O

objective O
: O
to O
evaluate O
the O
effect O
of O
dosage O
regimen O
( O
once O
- O
daily O
vs O
. O

twice O
- O
daily O
) O
of O
tobramicyn O
on O
steady O
- O
state O
serum O
concentrations O
and O
toxicity B-Disease
. O

increased O
serum O
creatinine O
was O
observed O
in O
73 O
% O
of O
patients O
in O
od O
versus O
57 O
% O
of O
patients O
in O
td O
, O
without O
evidence O
of O
nephrotoxicity B-Disease
. O

in O
td O
group O
, O
three O
patients O
developed O
decreased B-Disease
auditory I-Disease
function I-Disease
, O
of O
which O
one O
presented O
with O
an O
auditory B-Disease
loss I-Disease
of O
- O
30 O
db O
, O
whereas O
in O
the O
od O
group O
only O
one O
patient O
presented O
decreased B-Disease
auditory I-Disease
function I-Disease
. O

enhanced O
bradycardia B-Disease
induced O
by O
beta O
- O
adrenoceptor O
antagonists O
in O
rats O
pretreated O
with O
isoniazid O
. O

high O
doses O
of O
isoniazid O
increase O
hypotension B-Disease
induced O
by O
vasodilators O
and O
change O
the O
accompanying O
reflex O
tachycardia B-Disease
to O
bradycardia B-Disease
, O
an O
interaction O
attributed O
to O
decreased O
synthesis O
of O
brain O
gamma O
- O
aminobutyric O
acid O
( O
gaba O
) O
. O

in O
the O
present O
study O
, O
the O
possible O
enhancement O
by O
isoniazid O
of O
bradycardia B-Disease
induced O
by O
beta O
- O
adrenoceptor O
antagonists O
was O
determined O
in O
rats O
anaesthetised O
with O
chloralose O
- O
urethane O
. O

isoniazid O
significantly O
increased O
bradycardia B-Disease
after O
propranolol O
, O
pindolol O
, O
labetalol O
and O
atenolol O
, O
as O
well O
as O
after O
clonidine O
, O
but O
not O
after O
hexamethonium O
or O
carbachol O
. O

structural B-Disease
and I-Disease
functional I-Disease
impairment I-Disease
of I-Disease
mitochondria I-Disease
in O
adriamycin O
- O
induced O
cardiomyopathy B-Disease
in O
mice O
: O
suppression O
of O
cytochrome O
c O
oxidase O
ii O
gene O
expression O
. O

the O
use O
of O
adriamycin O
( O
adr O
) O
in O
cancer B-Disease
chemotherapy O
has O
been O
limited O
due O
to O
its O
cumulative O
cardiovascular B-Disease
toxicity I-Disease
. O

our O
results O
indicated O
that O
1 O
) O
treatment O
of O
mice O
with O
adr O
caused O
cardiovascular B-Disease
arrhythmias I-Disease
characterized O
by O
bradycardia B-Disease
, O
extension O
of O
ventricular O
depolarization O
time O
( O
tqrs O
) O
, O
and O
failure O
of O
qrs O
at O
high O
concentrations O
( O
10 O
- O
14 O
mg O
/ O
kg O
body O
weight O
cumulative O
dose O
) O
; O
2 O
) O
the O
heart O
mitochondria O
underwent O
swelling B-Disease
, O
fusion O
, O
dissolution O
, O
and O
/ O
or O
disruption O
of O
mitochondrial O
cristae O
after O
several O
weeks O
of O
treatment O
. O

knowing O
that O
heart O
mitochondria O
represent O
almost O
40 O
% O
of O
heart O
muscle O
by O
weight O
, O
we O
conclude O
that O
the O
deteriorating O
effects O
of O
adr O
on O
cardiovascular O
function O
involve O
mitochondrial B-Disease
structural I-Disease
and I-Disease
functional I-Disease
impairment I-Disease
. O